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The rat pancreatic AR42J-B13 (B-13) cell line differentiates into non-replicative hepatocyte-
like (B-13/H) cells in response to glucocorticoid. As this response is dependent on the induction 
of serine/threonine protein kinase 1 (SGK1), this suggests a general essential role for SGK1 in 
hepatocyte maturation. To test this hypothesis, B-13 cells infected with AdV-SGK1F in the 
absence of glucocorticoid resulted in the expression of Flag-tagged SGK1F protein; increases 
in β-catenin phosphorylation; decreases in Tcf/Lef transcriptional activity; expression of 
hepatocyte marker genes and the conversion of B-13 cells to a cell phenotype near-similar to 
B-13/H cells. Given this demonstration of functionality, the effects of expressing adenoviral-
encoded flag-tagged human SGK1F (AdV-SGK1F) in induced pluripotent human stem cells 
(iPSCs) was investigated. iPSCs directed to differentiate to hepatocyte-like cells using the 
standard protocol for chemical inhibitors and mixtures of growth factors, were infected with 
AdV-SGK1F at different stages of their differentiation to hepatocytes, either at an early point 
during differentiation to endoderm; during endoderm differentiation to anterior definitive 
endoderm and hepatoblasts and once converted to hepatocyte-like cells.  SGK1F expression did 
not affect differentiation to endoderm, most possibly due to low levels of expression. However, 
expression of SGK1F in both iPSCs-derived endoderm and hepatocyte-like cells both resulted 
in the promotion of cells to an hepatoblast phenotype. These data demonstrate that the effect of 
expressing SGK1F in human iPSC-derived cells contrasts with its effects when expressed in B-
13 cells. Given that SGK1 expression promotes an hepatoblast phenotype rather than 
maturation of human iPSC towards a mature hepatocyte phenotype, these data suggest a 
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Ubiquitin ligase (Nedd4-2) 
α- fetoprotein (Afp)




1.1 Stem cells 
  A stem cell is a cell characterised by its ability for self-replication via cell division 
throughout the life of the organism. Stem cells can differentiate into diverse types of cells in 
the body of the organism. They are unspecialised cells which can be physiologically or 
experimentally induced to give rise to specialised cells. Embryonic stem cells (ESCs) and adult 
stem cells are the main types of stem cells in mammals. ESCs are isolated from the inner cell 
mass (ICM) of blastocysts and can differentiate all the specialised cells from the three germ 
layers (ectoderm, endoderm and mesoderm) 1,2. Adult stem cells are located in different tissues 
such as blood, skin or intestinal tissues. In adult organisms, stem cells work as a repair system 
replenishing damaged adult tissues. 
According to their differentiation potentiality into different sorts of cells, stem cells are 
categorised into totipotent, pluripotent, multipotent and unipotent stem cells. Totipotent stem 
cells are the stem cells that have the ability to differentiate into extraembryonic and embryonic 
cell types. Such cells can build a complete, viable organism. They are formed within the first 
few divisions of the egg being fertilised 3. Pluripotent stem cells are totipotent derived cells 
which can differentiate between every cell in an organism except for extraembryonic tissue 4. 
Multipotent stem cells are adult stem cells and only give rise to specific lineages of cells. 
Unipotent stem cells can differentiate into their cell type only; however, unipotent cells are able 
to self-renew, which distinguishes them from non-stem cells (e.g. progenitor cells, which 
cannot self-renew) 5 (Figure 1.1). Adult stem cells are frequently used for therapeutic purposes 
(e.g., bone marrow transplantation) 6. Stem cells can now be expanded in vitro and directed to 
differentiate into specific cell types with features which are consistent with the cells of different 
tissues, for instance, muscles or nerves. ESC lines and induced pluripotent stem cells (iPSCs) 
are promising candidates for regenerative medicine, disease modelling and drug discovery. 7 8 




Figure 1.1 Stem cells potency.  Totipotent cells or morula which are embryonic cells within 
the first couple of cell divisions after fertilisation, are the only cells that are totipotent and able 
to form all the cell types in a body in addition to the extraembryonic (placental) cells. ESCs are 
considered pluripotent and initiate within a blastocyst as ICM. These stem cells can differentiate 
all of the cell types that make up the body excluding the placenta. Unipotent cells can generate 
only their own type though they have the ability to self-renew. Figure adapted from 
https://vignette.wikia.nocookie.net/mmg-233-2014-genetics-genomics/images/f/f6/3D-Medical-Illustration-
Pluripotent-Stem-Cells.jpg/revision/latest?cb=201410130628329. 
1.1.1 Embryonic Stem Cells 
ESCs are pluripotent stem cells originating from the ICM of mammalian blastocysts. These 
cells exhibit a remarkable ability to proliferate indefinitely and maintain their pluripotent 
potential to differentiate into all cell lineages in the body 1,2. The discovery of mouse ESCs by 
Evans et al. (1981) and Martin et al. (1981) and the isolation of human embryonic stem cells 
(hESCs) in 1998 by Thomson et al., helped to realise the genuine potential of stem cells. 
Efficient differentiation of ESCs to any cells types suggests the ability to create new models of 
mammalian development and to establish additional supplies of cells for regenerative medicine. 
Embryological studies have offered valuable understandings into essential pathways controlling 
the differentiation of ESCs, which have resulted in improvements in gastrulation modelling in 
vitro and consequently, the effective induction of all germ layers; specifically, endoderm, 
mesoderm and ectoderm, in addition to arrays of their derivatives cells. Consequently, for 
culturing of particular types of specialised cells for example; blood, muscle, nerve or heart, the 
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researchers directed their efforts at controlling the differentiation of embryonic stem cells by 
amending the chemical composition of the culture medium, altering the surface of the culture 
dish or modifying the cultured cells by expressing certain genes. During years of investigations, 
these attempts have led to efficient protocols for the differentiation of a range of cell types from 
stem cells 10. 
Gastrulation is a critical process in embryogenesis in which all germ layers: ectoderm, 
mesoderm and endoderm are generated (Figure 1.2A). In the mouse, it begins with primitive 
streak (PS) structure formation in the region of the epiblast. During this process, uncommitted 
epiblast cells mobilise via the PS and leave either as the definitive endoderm (DE) or mesoderm 
11(Figure 1.2B). Lineage mapping and molecular analyses have described the zones of PS as 
posterior, mid and anterior, that vary in developmental potential and gene expression patterns. 
Numerous genes involving Mixl1 12 and Brachyury (T) 13 are found all through the PS, while 
other genes are expressed favourably in the anterior zone, such as forkhead box protein (Foxa2) 
14 or posterior zone (HoxB1, Evx1) 15,16. 
Mapping has demonstrated that the distinct subpopulations of mesoderm and endoderm are 
specified by both temporal and spatial control. The extraembryonic mesoderm is derived from 
the first mobilised epiblast cells that cross the posterior PS 17. When gastrulation continues, 
cells move through more parts of the anterior regions of the PS and produce cardiac and cranial 
mesoderm, then axial paraxial mesoderm. Epiblast cells passing most parts of the anterior zone 
of the PS give rise to DE. Unlike DE and mesoderm, ectoderm descends from the anterior region 
of the epiblast that does not cross the PS. The spatial and temporal separation of cell outcomes 
detected via gastrulation proposes that the various parts of the PS or the cell populations near 
the PS, comprise different signalling environments which control the initiation of certain 
lineages.  
The results of gene-targeting studies have revealed that members of the WNT family 18, as well 
as members of the transforming growth factor-β (TGFb) family compromising Bone 
morphogenic protein (BMP4)19 and Nodal  are vital for the germ layer development 20 21. 
Furthermore, the altered expression levels of the agonists of these pathways, in addition to the 
region-specific expression of inhibitors, combine to form signalling domains that regulate germ 
layer induction and specification 22. Therefore, germ layer formation is a dynamic process that 
is controlled, partly, by the organised activation and local inhibition of the signalling pathways: 
WNT, Nodal and BMP. 
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The differentiation of ESCs in vitro offers a powerful tool for developmental studies, drug 
screening and regenerative medicine. However, the ethical limitations regarding human embryo 
donation and destruction; immune system incompatibility and likelihood of cancer developing 
due to the challenges in determining the correct cues to direct differentiation in the specific 
desired cell types in vitro and in vivo and preventing teratoma formation 23 has resulted in the 
avoidance of ESC-based therapies. 
 
Figure 1.2 Germ layer formation during mouse gastrulation.    A: three primary germ layers 
generated during gastrulation: ectoderm, mesoderm and endoderm. B: gastrulation in the mouse 
embryo. The blue indicates the posterior region of the primitive streak that expresses the marker 
Brachyury, whilst the red demonstrates the anterior region of the primitive streak which 
expresses both Foxa2 and Brachyury. The thick black arrows at the top of the embryo indicate 
the entry of epiblast cells into the primitive streak. The orange/yellow region shows the new 
formation of the mesoderm and the thin black arrows present the movement of these cells away 
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from the primitive streak. The red arrow at the bottom depicts the movement of the earliest DE 
cells 10.  
1.1.2 Adult stem cells 
Adult stem cells are undifferentiated cells which exist in the postnatal organism; they are either 
multipotent or unipotent 24. They can make duplicate copies of themselves for extended periods 
and differentiate into some specialised cell types to preserve and repair the tissue in which they 
are found. Tissue homeostasis due to normal cell turnover and replacing cells that die because 
of injury or disease, are the primary functions of adult stem cells 25. Adult stem cells are 
hypothesised to exist in a stem cell niche which contains a specific micro-environment for the 
stem cells 26. Depending on their local environment, their development is restricted to the tissues 
or organs in which they reside, for example, in bone marrow; hematopoietic stem cells 
(HMSCs) differentiate into blood cells only 27.  
Adult stem cells have been identified in several tissues, such as brain, bone marrow, peripheral 
blood, dental pulp, spinal cord, blood vessels, skeletal muscle, epithelia of the skin and digestive 
system, cornea, retina, liver and pancreas 28,29,30,31,32. Adult stem cells show some advantages 
that overcome the drawbacks of working with ESCs. They are derived from adult tissue and 
therefore escape the ethical issues associated with ESCs. Additionally, they can also be patient-
specific and thus avoid immuno-rejection concerns, and in contrast to ESCs, adult stem cells 
do not form tumours when transplanted in vivo. However, the limited capacity of adult stem 
cells to divide in vitro, their scarcity in each tissue makes their use challenging. An additional 
disadvantage of adult stem cells is that they can only be induced to differentiate into only a few 
specialized cell types 
In several laboratories, researchers are attempting to discover reliable methods for adult stem 
cell expansion to large numbers followed by differentiation into specific cell types. Examples 
of potential treatments include bone regeneration using bone marrow stroma derived cells 
which has been reported to give rise to a variety of cell types: bone cells (osteoblasts and 
osteocytes), cartilage cells (chondrocytes), fat cells (adipocytes), and stromal cells that support 
blood formation. Generation of insulin-producing cells for type 1 diabetes; differentiation to 
insulin-producing cells can be achieved from adult stem cells, such as pancreatic stem cells can 
differentiate and be re-programmed to ensure the manifestation of a phenotype producing 
insulin. However, advanced strategies are needed to isolate and grow adult pancreatic stem 
cells, and to differentiate them into β cells. hepatic stem cells recent study demonstrated that 
small molecules could be used to differentiate rat hepatic stem-like cells into insulin-producing 
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cells that expressed distinct pancreatic-cell marker genes 33. and using cardiac muscle cells to 
restore damaged heart muscle after a heart attack as the evidence suggests that the heart contains 
a small population of endogenous stem cells that most likely facilitate the minor repair and 
turnover-mediated cell replacement.  The cells can be harvested in limited quantity from human 
endomyocardial biopsy specimens and can be injected into the site of infarction to promote 
cardiomyocyte formation and improvements in systolic function. 34,35.  In vivo, tissues can 
regenerate new cell populations upon damage or during normal tissue turnover by means of 
several mechanisms. A: transient de-differentiation of resident mature cells into precursor cells 
followed by re-differentiation to generate new cells 26. This mechanism has been reported to 
occur in pancreatitis 36, B: resident adult stem/progenitor cells can be signalled to expand and 
differentiate upon damage and injury to the tissue. This method of tissue regeneration is 
established in high turnover tissues such as the blood system and intestine.  
In recent years many studies have shown that adult stem cells can differentiate into cell types 
from different germ layers. For instance, mesoderm-derived stem cells in bone marrow can 
differentiate into endoderm-derived cells for instance liver or ectoderm-derived cells such as 
skin cells 37. In the scientific literature, as of yet, there is no correct name for this phenomenon; 
however, it is described as stem cell plasticity or transdifferentiation. In vivo, it can be induced 
by transplanting stem cells into an organ of the body which differs from the tissue they were 
originally isolated from or by amending the growth medium when they are cultured in vitro. 
The characteristics of stem cells that can regenerate the liver of adult mammals are uncertain. 
Typically, oval cells, initially derived from endoderm differentiate to either hepatocyte or the 
epithelium of the bile ducts. The well-known regenerative capacity of the liver is however, 
carried out by the hepatocyte mitoses themselves 38,39,40,41. Recent studies in rodents illustrate 
that mesoderm-derived HMSCs may be able to move to the damaged liver and showed plasticity 
in converting into hepatocytes 42. Adult stem cells identified in many tissues and organs show 
several advantages over working with ESCs, however, their limited capacity for renewal and 
the limited number of stem cells in each tissue make the generation of large quantities of stem 
cells difficult. 
1.1.3 Induced Pluripotent Stem Cells (iPSCs) 
Mouse ESCs were first generated in 1981 1 with culture conditions that allow the longstanding 
maintenance of pluripotency subsequently established 43. Advances in nuclear reprogramming 
resulted in the induction of differentiated somatic cells into the pluripotent state, the technique 
that subsequently produced the cloning of Dolly the sheep in 1997 44. The successful somatic 
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cloning demonstrated that differentiated cells have all the necessary genetic information 
required for the development of whole organisms and also confirmed that oocytes contain 
factors capable of somatic cell nuclei reprogramming. In 2001, Takashi Tada’s group 
demonstrated that ESCs also have factors that can reprogramme somatic cells 45. All these 
discoveries have produced the iPSCs technology established by Shinya Yamanaka and the 
reprogramming of mouse fibroblast in 2006 46. A year later, human somatic cells were 
reprogrammed into human iPSCs by the exogenous expression of 4 transcription factors; 
octamer-binding transcription factor 4 (Oct4), sex-determining region Y box-2 (Sox2), 
Krüppel-like transcription factor 4 (Klf4) and myelocytomatosis viral oncogene (c-Myc)47,48. 
As for ESCs, iPSCs are self-renewable and can differentiate into all cell types of the body, 
showing great hopes in the field of regenerative medicine (Figure 1.3). 
These days, the most common source for iPSCs are fibroblasts which are easily obtainable with 
a skin biopsy 49. Reprogrammed fibroblasts (iPSCs) have been converted to various somatic 
cells, for example, neural cells 50, hepatocytes 51,52, cardiac myocytes 53 and hematopoietic 
progenitor cells 54. However, iPSCs can be reprogrammed from a wide range of cells, such as 
circulating T cells, which are derived from the mesoderm; hepatocytes which have an endoderm 
origin and keratinocytes which are derived from the ectoderm. Each of these cells type have 
been successfully reprogrammed into iPSCs with 0.1% efficiency for circulating T cells and 
hepatocytes  55.  
Integrating vectors such as retroviruses and lentivirus have been used initially for 
reprogramming factor overexpression 46,47,56. Tumorigenicity is significant risk arising from the 
use of oncogenes (c-Myc and Klf4)57,58 in addition to the possible presence of undifferentiated 
cells 59. Moreover, the integrating vectors (retroviruses and lentivirus) might also cause 
insertional mutagenesis 60,61. The advances in iPSCs technology have led to the generation of 
iPSC in the absence of these factors either without c-Myc or both c-Myc and Klf4 62 decreasing 
liability to tumour formation in its chimaeras. Similarly, there is substantial progress regarding 
exogenous material exclusion by means of different methods. These methods include the 
plasmid 63, adenovirus 64 and Sendai virus 65 which are now routinely used in many laboratories. 
Moreover, it has recently been revealed that it is possible to reprogramme cells using messenger 
ribonucleic acid (mRNA) 66, besides microRNA (miRNA) 67 at higher efficiencies.  
Currently, the study of several human diseases is performed through the use of animal models 
and cell lines that approximate to specific cell types. However, robust  disease models are 
difficult to achieve because animal models inescapably involve inter-species variabilities and 
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primary human cells are difficult to retain in culture for an extended period 68. An advantage of 
human iPSCs is that they can provide more accurate human disease models. 
As mentioned, iPSCs were differentiated to various somatic cells in addition to patient-specific 
iPSC lines. Consequently, disease modelling has been reported, such as motor neurons from an 
82-year-old amyotrophic lateral sclerosis (ALS) patient 69, motor neurons from spinal muscular 
atrophy 70,71 and familial dysautonomia 72. 
Applying iPSC technology to drug screening is something that is widely used. iPSC-derived 
models of disease deliver both a practical and functional assessment of how an individual will 
respond to a specific therapeutic agent 73. The utilisation of iPSC-derived disease modelling 
tools in high-throughput screening assays could permit better prognosis of drug-induced 
toxicity, for instance, hepatotoxicity and cardiotoxicity 72  
 
Figure 1.3 A schematic diagram shows the potential applications of induced pluripotent 
stem cell (iPSC).  Fibroblasts or other cell types can be reprogrammed into iPSC. Afterwards, 
this iPSC can be used for generation of specialised cells which can be used for cell replacement 
therapies; otherwise, iPSC can be used for common disease modelling, drug and toxicology 
screening or basic biology studies 74. 
 
1.2 The adult Liver: Anatomy and physiology 
The liver is considered the largest internal organ in the body, weighing nearly 1,500 g. It is 
situated below the diaphragm in the right upper abdominal cavity and is protected by the rib 
cage. The liver is reddish-brown and is enclosed by a delicate connective tissue capsule 
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recognised as Glisson’s capsule. It is divided into the right and left lobes by the falciform tendon 
that runs beside the umbilical fissure and attaches the liver to the anterior wall of the abdominal 
wall. The right lobe can be subdivided into anterior and posterior parts, whereas the left lobe is 
divided into a medial segment (quadrate lobe) and a lateral segment (caudate lobe) by the 
falciform ligament. Additionally, 60–70% of the liver mass is taken up by the right lobe, while 
the left lobe and caudate lobe make up the rest (Figure 1.4). The location of the liver interfacing 
with the digestive system facilitates its vital function in the processing of absorbed nutrients via 
the metabolism of proteins, carbohydrates and lipids. The liver is supplied by blood via a dual 
supply comprising the hepatic artery and the portal vein. The hepatic artery branches from the 
celiac artery (trunk) which also gives rise to the left gastric, splenic and common hepatic 
arteries. The hepatic artery delivers approximately 25% of the blood supply, while the portal 
vein delivers the rest of the blood supply. Portal veins deliver nutrients absorbed by the 
intestinal system to the liver, except the complex lipids which are transported primarily by 
lymphatics.  
 
Figure 1.4 Liver location and anatomy diagram.  A. The liver is the largest internal organ 
weighing approximately 1,500 g in the adult. It lies behind the rib cage in the upper right 
abdomen under the diaphragm and extends from the 5th rib to the bottom of the rib cage. B, 
The liver is multi-lobed in most mammalian species. In humans, the liver is mainly divided by 
falciform ligaments into two lobes, the right and left; the ligaments attach the liver to the 
abdominal wall and diaphragm. Two smaller lobes, the quadrate and caudate lobe are situated 
on the bottom side of the liver. 75
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1.2.1 Liver architecture  
The liver consists of epithelial and mesenchymal elements arranged in microscopic functional 
unit near point(s) of blood entry through the portal tract and blood exit via the central veins. 
These structural and functional units are the lobules (first described by Kiernan) or the acinus 
(first described by Rappaport) 76,77(Figure 1.5). The human liver contains about one million 
lobules. Each lobule is about 1-2.5 mm in size, has a hexagonal shape consisting of hepatocyte 
plates which radiate outward from a central vein (a branch of hepatic vein) in the centre. 
Hepatocytes account for 78% of liver volume and constitute the dominant parenchymal cell 
type of the liver. They are typically arranged in cords that are one or two cells thick separated 
by sinusoids 78(Figure 1.5). The portal triads are regularly distributed at the apices of the lobule 
comprising an artery, a vein and a bile duct bundled all together by connective tissue. The blood 
flows from the hepatic artery, and portal vein into central veins among capillaries called the 
sinusoids (Figure 1.5) They are padded by endothelial cells in addition to Kupffer cells which 
are a specific population of cells belonging to the macrophage phagocytic system. The sinusoid 
endothelial lining is fenestrated to permit secure exchanging between the blood and hepatocytes 
via the space of Disse which is a compartment between the endothelial cells and hepatocytes 
that contains the blood plasma for exchange between blood and hepatocytes (Figure 1.6). In 
addition to the plasma, the space contains connective tissue and hepatic stellate cells (HSCs). 
The function of the HSCs is to control the sinusoidal blood flow and fibrogenesis, besides a 
prominent role for vitamin A storage 79. The canaliculi surround each hepatocyte are generated 
by the tight junctions formed between neighbouring hepatocytes and are responsible for the 
gathering of bile salts and bile acids which are transported across the hepatocyte’s apical surface 
(Figure 1.5). Bile assembled by the canaliculi is transported to the bile ducts in the portal triad 
and consequently carried to the gallbladder for storage. The lining of the bile ducts are cuboidal 
to columnar epithelium cells connected to a basement membrane 80 (Figure 1.5). 
 
 




Figure 1.5 A schematic diagram of the hepatic lobule.  The liver tissue made up of small 
lobules 1-2.5 mm in size. Each lobule consists of the central vein (a branch of the hepatic vein) 
surrounded by six pairs of vessels (branches of the portal the hepatic artery). A small bile duct 
accompanies each pair of blood vessels. The blood enters to the lobule through the portal vein 
and hepatic artery in the portal triad. The blood flows through the capillaries 
called the sinusoids into central veins. The bile is collected from the hepatic cells and carried 
out of the liver through bile ducts 81.





Figure 1.6The sinusoids.   Electron microscopy image showing fenestrated sinusoids 
endothelial lining cells (grey), the hepatic plate (cyan) and connective tissue (red) 81.
 
1.2.2 Liver zonation 
Jungermann et al. demonstrated that hepatocytes, although being histologically identical, were 
specialised, and perform a different function according to their site along the porto-central axis 
of the liver acinus, which is divided into zones corresponding to remoteness from the arterial 
blood supply 76. The closest hepatocytes to the arterioles in zone 1 have an abundant supply of 
oxygen, whereas those in zone 3 are the farthest from the arterioles and have the most 
impoverished supply of oxygen. Zone 2 is presumed to be an intermediate environment. This 
arrangement also means that cells in zone one are the first cells exposed to blood-borne toxins 
absorbed into the portal blood from the small intestine 82,83. Consequently, different pathologic 
processes lead to lesions that reflect acinar structure; for instance, necrotic hepatocytes at the 
periphery of the acinus. Acinar zones 1, 2 and 3 are parallel to the periportal, mid- and 
pericentral zones of the lobule, respectively. A distinctive gene expression profile exhibited by 
hepatocytes within each zone matches their metabolic compartmentalisation. For example, 
hepatocytes in zone-1 specialise in ammonia detoxification and gluconeogenesis, whereas the 
Chapter 1. Introduction 
13 
 
zone-3 cells are committed to lipogenesis and glycolysis 84. This zone-related heterogeneity of 
hepatocytes has been hypothesised as a consequence of the differential degree of exposure to 
oxygen, nutrition and gut-derived toxins 85. For example, zone 3 hepatocytes mainly express 
cytochrome P450s, which allow xenobiotic metabolism (Figure 1.7). Xenobiotics require 
metabolism by Cytochrome P450 (CYP) which cause injury for most of the centrilobular area 
(zone three).  
Even though, hepatocytes in the periportal (zone 1) are exposed first to xenobiotics absorbed 
by the gut, the ingestion of protoxins represents the majority of exposure to toxins and protoxins 
require enzyme-mediated conversion into a cytotoxic product. According to this fact, pro-toxin 
damage is found in the regions where the activating enzyme is expressed in addition to the 
lowest levels of oxygen in the centrilobular regions (zone 3), which may have an impact on the 
capability of cells to respond to and resist the injury. Therefore, hepatocytes are the more likely 
cell type damaged by hepatotoxins 86. The evidence indicates that the gradient of WNT 
signalling that increases towards the central vein is thought to play a crucial role in modelling 
zonation. Consequently, WNT up-regulated genes are high in centrilobular regions and low in 
periportal regions (Figure 1.8) 87. More recent studies on mice revealed that liver zonation is 
dependent on a β-catenin mechanism 88. Thus, the upregulation of canonical WNT signalling 
in zone 3 might be critical for homeostatic renewal of hepatocytes in this zone 89. 
 
Figure 1.7 Liver cell plate acinus is divided into three zones.  Zone 1 (periportal zone) 
surrounds the afferent vessels and the portal triad where hepatocytes are first exposed to the 
nutrient and oxygen-rich blood entering from the portal vein and hepatic artery. Zone 2 
(intermediate zone) lies between zone 1 and zone 3. Zone 3 (centrilobular zone) where CYP450 
expression is highest in hepatocytes surrounding the central vein 90. 
 





Figure 1.8 Liver zonated functions.  The different  metabolic functions located in  different 
zones of the acinus include ammonia detoxification, glucose and energy metabolism, and 
xenobiotic metabolism. The proteins required for  each type of zonal metabolism are 
demonstrated. The PV  gene upregulated by WNT signalling are indicated in orange, while the 
PP genes down regulated by WNT signalling  are shown in blue. Adapted from Colont 
et.al.(2011) 91. 
1.2.3 Functions of the liver 
The liver is a vital organ of the body, accountable for lots of chemical actions required by the 
body to survive. It is a gland because it produces chemicals which are used by other organs of 
the body. Therefore, the liver is considered both an organ and a gland. The human liver is 
believed to perform approximately 500 separate functions, most of these functions are 
performed in combination with other organs and systems. Most functions of the liver are carried 
out by the hepatocytes. These functions primarily include; metabolism of glucose, lipid, 
bilirubin, urea, detoxification of drugs and xenobiotics, production of serum proteins (such as 
albumin and clotting factors), storage of minerals and vitamins and secretion of bile, besides 
immunologic functions, as the liver contains cells involved in adaptive and innate immunity.  
Gluconeogenesis or the synthesis of glucose from amino acids (alanine from muscle), pyruvate, 
and lactate is primarily carried out by the liver. Similarly, the liver performs glycogenesis which 
is glycogen synthesis from excess glucose for storage of glucose. In addition, glucose can be 
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produced from glycogen by glycogenolysis when the body requires it. Hence, the liver plays a 
crucial role in the maintenance of blood glucose levels which prevent hypoglycaemia 
maintaining glucose supply to the brain and other tissues for energy demands 92 The liver is the 
only organ capable of converting cholesterol to bile acids, which are necessary for the efficient 
absorption and transport of dietary lipid nutrients 93,94. 
A further critical metabolic role of the liver is its active involvement in the detoxification and 
metabolism of xenobiotics and drugs due to the expression of drug metabolising enzymes 
(DMEs) in hepatocytes. These DMEs primarily act to modify lipophilic xenobiotics, absorbed 
from the gut, to create more excretable (through bile or urine) compounds by way of a three 
phase process — phase I xenobiotics modification, phase II xenobiotics conjugation and phase 
III further modification and excretion. In phase I, liver enzymes are accountable for the 
metabolism of xenobiotics by first activating them via oxidation, reduction, hydrolysis or 
hydration reactions. These chemical reactions add or expose functional groups such as -OH, -
SH, -NH2 or –COOH on the substance 95, which facilitate the subsequent conjugation of 
hydrophilic groups by phase II conjugation enzymes. In humans, the majority of the drug 
oxidation in phase I reactions involves flavin-containing monooxygenases and the superfamily 
of CYP monooxygenases. Hepatic microsomal cytochrome P450 is a paradigm of a group of 
enzymes required for xenobiotic metabolism 96. The primary drug metabolising P450 in the 
human liver is CYP3A4; it constitutes up to 60% of P450 enzymes in the liver and metabolises 
up to 75% of drugs metabolism 97. The conjugation reactions in phase II include sulphation, 
methylation and glucuronidation for an additional increase in the solubility of oxidised 
metabolites. In phase III, the xenobiotic conjugates may be further metabolised in addition to 
the induction of the drug transporters in the membranes of hepatocytes, kidney, intestine cells 
and other tissues for excretion out of the body 98  
The liver also plays one more vital function in purifying the body from toxic substances by 
converting ammonia into a water-soluble compound known as urea. Ammonia is a toxic weak 
basic compound derived from the metabolism of amino acids. Severe liver injury results in the 
accumulation of ammonia which is toxic to the brain and other parts of the central nervous 
system (CNS). The ammonia detoxification process takes place primarily in the liver. This 
process is carried out through a cycle of biochemical reactions known as the urea cycle which 
consists of four enzymatic reactions: one in the mitochondria and three in the cytosol 99.  
Liver cells 
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The hepatocyte is polygonal in shape. It measures approximately 25 to 40 µm and comprises 
a large amount of smooth endoplasmic reticulum in the cytoplasm, while most cells in the body 
have only small amounts. The cytoplasm contains abundant glycogen and is eosinophilic 
reflecting numerous mitochondria and a central nucleus (binucleate cells are also typical). The 
nucleus is round or oval, with dispersed chromatin and prominent basophilic nucleoli 
containing abundant rough endoplasmic reticulum 100. All these features allow the hepatocytes 
to perform its crucial metabolic and synthetic functions, for instance protein synthesis and 
storage, synthesis of bile salts, detoxification of cholesterol and phospholipids, elimination of 
exogenous and endogenous substances, as well as induction of bile formation and secretion. 
Typically, hepatocytes are arranged in one or two cells thick cords separated by sinusoids. They 
form a critically important cell layer to separate the sinusoidal blood from canaliculus bile. The 
cell membrane of the hepatocyte faces the sinusoids basolateral and forms the biliary 
canaliculus with the next hepatocyte. Moreover, it has a portion next to the canaliculus that 
attaches laterally to the next hepatocyte. This position of hepatocyte between the blood plasma 
flow in the sinusoid and the bile in the canaliculus contributes to their proper organised polarity 
101 (Figure 1.9). 
 
Figure 1.9Microscopic micrograph of H & E stained hepatocyte cords.  Arrowheads show 
the accumulation of brown coarse granules of iron. Arrows illustrate the bile (greenish-brown) 
within biliary canaliculi that are situated between hepatocytes (H & E stain, magnification 
x500) 100. 
Cholangiocytes or biliary epithelial cells (BECs) are epithelial cells lining the biliary tree 
which is a three-dimensional network of bile ducts. Cholangiocytes participate in the 
modification of the hepatic bile when it is conveyed through the biliary tree. They contribute to 
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bile modification by managed transportation of several ions, solutes and water via the 
cholangiocyte apical and basolateral plasma membranes. Several locally acting hormones 
mediate cholangiocyte fluid and electrolyte secretion 102. Cholangiocytes also have a role in 
inflammatory responses; they interact with other liver cell types through the production of many 
growth factors, peptides and pro-inflammatory and chemotactic cytokines. 103. 
Hepatic stellate cells (HSCs) are also known as vitamin A-storing cells, interstitial cells, fat-
storing cells, lipocytes and Ito cells. HSCs are located in the space of Dissè between the 
hepatocytes and liver sinusoidal endothelial cells. They primarily function to store the majority 
of vitamin A in the body in lipid droplets as retinyl ester in the cytoplasm. Physiologically, 
these cells are quiescent and play important roles in the regulation of retinoid homeostasis. In 
pathological conditions such as in acute liver injury, the population of HSCs expand and 
increase their expression of alpha-smooth muscle actin. In chronic liver injury, HSCs lose 
vitamin A and synthesise an abundant extracellular matrix (ECM) elements like proteoglycan, 
glycosaminoglycan, collagen and adhesive glycoproteins, besides morphological changes from 
the HSCs star-like shape to that of fibroblasts or myofibroblasts shape 104 
Kupffer cells are liver-resident macrophages. They adhere to the sinusoidal side of endothelial 
cells and are found primarily in the periportal region of the liver 105. This localisation allows 
them to act as the first line of protection against immunoreactive material transferred from the 
gut by the portal circulation. They stop the movement of these gut-derived immune-reactive 
substances from travelling beyond the hepatic sinusoid. Likewise, they maintain blood 
homeostasis through the phagocytosis of large particles and dead erythrocytes and 
microorganisms. While in many conditions such as toxin-induced fibrosis 106 and drug-induced 
liver injury 107, the Kupffer cells are protective. Additionally, the direct or indirect activation of 
Kupffer cells by toxic agents leads to the release of a group of inflammation mediators, reactive 
oxygen species and growth factors. This activation appears to account for the modulation of 
acute hepatocyte injury as well as chronic liver reactions such as hepatic cancer 108.  
Liver sinusoidal endothelial cells (LSECs) form the walls of the hepatic sinusoids and 
comprise the highest proportion of non-parenchymal cells in the liver. They exhibit distinctive 
phenotypic and structural characteristics which discriminate them from the capillary 
endothelium found in other organs. LSECs are fenestrated by many pores of 100 to 150 nm 
diameters. This fenestration provides channels between the sinusoidal blood and the 
subendothelial space of Disse 79, as described previously in Section 1.2.1. Under normal 
physiological conditions, the fenestrations mediate the exchange of plasma, nutrients, lipids and 
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lipoproteins between hepatic sinusoids and hepatocytes 109,110. LSECs show a high endocytic 
capacity in comparison to other endothelial cells mediated via distinct endocytosis receptors, 
giving them importance as the most efficient scavengers of blood‐borne waste macromolecules 
and nanoparticles in the body 111. 
 
1.3 Overview of liver development 
1.3.1 Endoderm formation  
In the early stages of development, the epiblast is differentiated from the ICM of the 
preimplantation blastocyst.  The epiblast represents the source of the gastrula, i.e. the three germ 
layers; ectoderm, mesoderm and definitive endoderm (DE) 112. When the pluripotent epiblast 
cells travel through the PS, DE is developed 113,114. Subsequently, the multipotent endoderm 
gives rise to the epithelium of the gastrointestinal and the respiratory systems, as well as the 
glandular and ductal cells of the liver, pancreas, thyroid and thymus. In the earliest stages, 
studies discovered the requirement for high doses of the TGF-β family member Nodal for DE 
induction during gastrulation 113,115,116. Nodal signalling motivates the expression of an array of 
endoderm transcription factors comprising the forkhead domain proteins Foxa1–3 and the 
HMG domain DNA-binding factor (Sox17). These transcription factors consecutively control 
a cascade of genes that direct cells to the endoderm lineage 117.  
1.3.2  Endoderm patterning: making the foregut  
Higher levels of nodal signalling are demanded by anterior endoderm fate than posterior 
endoderm cells. The expression of Foxa2 is also essential to make anterior definitive endoderm 
(ADE)117,118. After gastrulation, naive endoderm cells remain plastic and not yet dedicated to 
specific organ fates. After 48 hours, the endoderm germ layer develops a primitive gut tube. It 
is from this tube that the organ buds arise. During this time, the endoderm along the A-P axis 
gradually subdivides into foregut, midgut and hindgut domains by the action of a sequence of 
overlying growth factor signals from the adjacent mesoderm119. These domains which can give 
rise to several organs are distinguished by the expression of transcription factors, for example 
Hhex in the foregut, pancreatic and duodenal homeobox gene 1(Pdx1) in the midgut and Cdx 
in the posterior endoderm, distinguishing these domains which then give rise to several organs 
120. 
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1.3.3 Foregut development requires repression of WNT/β-catenin and FGF4  
Due to dynamic tissue movements during gastrula and early somite stages, the endoderm 
becomes proximal to various mesodermal tissues which produce the patterning factors. These 
factors comprise FGF, WNT and BMP ligands, and moreover, all of them appear to retain 
hindgut identity and block the foregut fate in the posterior 121,122 Experiments in Xenopus and 
chick propose that FGF4 and WNTs secreted from the posterior mesoderm prevent foregut fate 
and encourage hindgut development 123 (Figure 1.10). Experiments in Xenopus exhibited that 
preventing the activity of the canonical WNT effector β-catenin in posterior endoderm resulted 
in activation of Hhex expression and liver bud formation in the intestine 124. Surprisingly a few 
hours after development, FGF and WNT signalling have contrasting effects and encourage 
hepatic development 125. 
 
 
Figure 1.10 An outline of endoderm patterning by WNT and FGF 
In the first gastrulation and somite phases: different WNT and FGF signalling through the A-P 
axis divides the primitive endoderm into foregut, midgut and hindgut progenitor areas  
expressing the different transcription factors Hhex, Pdx1 and Cdx as indicated. The data from 
the available literature suggest that WNT and FGF ligands are expressed progressively in the 
mesoderm (indicated in red) next to the endoderm (depicted by yellow) to prevent foregut 
formation and stimulate hindgut fate. Canonical WNT/β-catenin activity is expected to be 
repressed by WNT-antagonists expressed in the anterior endoderm 126.
 
1.3.4 Hepatic competence  
In vivo, the foregut endoderm only can develop into the liver 127,128. Initial foregut 
organogenesis is significantly impacted by the expression of transcription factors, such as Hhex, 
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GATA-binding proteins (Gata4–6) and Foxa2 129. This expression could explain the intrinsic 
hepatic competence. The liver-specific serum albumin gene expression has been identified to 
develop via three developmental stages. During the first stage, the nucleosomes appear tightly 
packed and the gene is in closed chromatin and transcriptionally inactive. In the second stage, 
the enhancer element of the gene is bound to Foxa and Gata transcription factors. One 
biochemical studies has shown that this binding is adequate to enhance chromatin accessibility 
by creating a locally open domain of nucleosomes 130, although it is insufficient to trigger the 
transcription of the gene 131. In endoderm cells, this open chromatin domain encourages the 
competence of these hepatic genes to be transcribed. In the third stage, liver genes become 
activated in the hepatic endoderm due to the stimulus of different signals from the mesoderm, 
more transcription-factor-binding sites at the enhancer become occupied (C/EBP, 
CCAAT/enhancer binding protein, nuclear factor 1), as well as at the promoter which activates 
the albumin gene 114.  
1.3.5 Hepatic induction by FGF and BMP  
As mentioned previously, mesodermal signalling is crucial for endoderm patterning into 
discrete tissue areas. The organogenesis of the embryonic gut tube is affected by FGF signalling 
in different ways. Studies on mice propose different thresholds of FGF signalling released from 
the cardiac mesoderm resulting in the production of liver, pancreas and lung lineages from the 
progenitor cells of the ventral foregut. In vitro experiments performed on mice showed that 
applying the recombinant FGF signalling in moderate doses, induced liver-specific gene 
expression 132. In other studies using mice, the cells of the septum transversum mesenchyme, 
which are a distinctive mesoderm cell type, are found close to the ventral endoderm and 
influence the hepatic induction. Using an inhibitor of BMPs and a mouse Bmp4 null mutation, 
it was realised that BMP signalling triggered by the septum transversum mesenchyme is 
essential to exclude pancreatic fate and to stimulate liver genes in the endoderm 133. BMPs 
influence the levels of the GATA4 transcription factor and act similarly to FGF signalling 
produced from the cardiac mesoderm. This information indicates that the specification of the 
endodermal domain for the liver is controlled by coincident signalling from specific 
mesodermal suppliers 133 (Figure 1.11). Signal transduction analysis revealed that FGF signals 
induce hepatic gene expression by means of MAP kinase, whereas the hepatic growth is 
regulated by PI3 kinase 134.  




Figure 1.11 Hepatic induction.  The figure demonstrates the anterior segment of an e8.25 of 
the mouse embryo in the 2–4 somite phase (lateral view). The grey indicates the growing head. 
The yellow demonstrates the DE which is forming a foregut pocket. The liver (lv) in a part of 
the ventral foregut is triggered by BMP signals produced from the septum transversum 
mesenchyme (orange) and the FGF from cardiogenic mesoderm (red). Hepatic fate is specified, 
while foregut endoderm will express liver genes, such as Albumin after the 5–7 somite stage. 
Different doses of FGF appear to provoke ventral pancreas (pa) and lung (lu) from the 
progenitors of the foregut. In the dorsal endoderm, FGF4 and WNT signals from the axial 
mesoderm block hepatic fate 126.
 
1.3.6 Liver bud morphogenesis and growth  
After FGF and BMP signals have specified the hepatic endoderm from the septum transversum 
and cardiac mesenchyme, the hepatic epithelium begins to express liver-specific genes, for 
instance  α- fetoprotein (Afp), Hnf4α , albumin and  becomes columnar in shape, the contiguous 
basement membrane ruptures and the hepatoblasts (hepatic precursors) proliferate and move to 
the nearby stroma and develop the liver bud. Transcription factors (such as Hhex, 
Hnf6/Onecut1, Onecut2, Prox1 and Gata4/6) are essential to stimulate the morphogenesis of 
the liver bud. Hepatoblast migration, proliferation and survival are regulated by paracrine 
signals from hepatic mesenchyme and endothelial cells including FGF, BMP, WNT, HGF, 
TGF-β and retinoic acid (RA) in addition to the  transcription factor such as by hepatocyte 
nuclear factor 4 (Hnf4α), T-box transcription factor (Tbx3) and Hlx 135.  
1.3.7 Hepatocytes and biliary epithelial cells differentiation  
Hepatoblasts are bi-potential, expressing genes related to both adult hepatocytes which marked 
by albumin and Hnf4α and cholangiocytes which marked by cytokeratin-19, in addition to 
foetal liver genes like Afp. Their differentiation into hepatocytes or cholangiocytes depends on 
their sites. Those cells located adjacent to the portal vein mesenchyme are encouraged to 
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differentiate into cholangiocytes by a Notch-mediated process, while the cells located more in-
depth in the parenchyma produce hepatocytes 135. In response to the mesenchyme signals 
(possibly TGFβ and WNTs), hepatoblasts adjacent to the portal mesenchyme down regulate 
pro-hepatic factors HNF4α, Tbx3 and C/EBP and increase expression of BEC transcription 
factors OC1/HNF6, OC2 and HNF1β. Continued signalling from the periportal mesenchyme 
(Notch, EGF and HGF) are essential for ductal plate remodelling. In comparison, hepatoblasts 
in the parenchyma not exposed to periportal mesenchyme signals, activate the expression of 
hepatogenic factors. Subsequently, factors such as oncostatin M (OSM), glucocorticoids, 
hepatocyte growth factor (HGF) and WNT promote hepatocyte maturation 126
 
1.4 Liver disease and regeneration  
1.4.1  Liver disease and cirrhosis 
 Liver disease causes around 2 million mortalities each year worldwide; specifically, 1 million 
caused by viral hepatitis and hepatocellular carcinoma HCC and 1 million owing to 
complications with cirrhosis. At present, cirrhosis is the 11th most frequent reason for fatality 
worldwide, whilst liver cancer is the 16th most common cause of fatality; together, they account 
for 3.5% of all deaths internationally. Worldwide, approximately 2 billion people drink alcohol, 
and more than 75 million suffering from alcohol-use disorders and are endangered by alcohol-
related liver disease. Roughly 2 billion adult people are overweight or obese, and more than 
400 million are diabetics; which places them at risk of non-alcoholic fatty liver disease as well 
as hepatocellular carcinoma. The global predominance of viral hepatitis remains elevated; 
however, drug-induced liver injury keeps increasing as a leading trigger of acute hepatitis. Liver 
transplantation is the second most common solid organ transplantation and just less than 10% 
of global transplantation requests are met at existing rates (Table 1.1) 136.  
Liver cirrhosis is characterised by replacement of liver tissue by dense fibrous scar tissue as 
well as a continued stimulus for regeneration, which results in widespread distortion of standard 
hepatic architecture and a transformation to a nodular architecture 137. Hepatocytes primarily in 
zone 3 are more likely to be exposed to hepatic pro-toxins which results in necrosis. Signals 
from damaged cells generate Kupffer cell activation which in turn release a range of 
chemokines and cytokines that result in activation of both resident and circulating leucocytes 
138,139. In response to the injury, several alterations in the liver architecture along with changes 
in the expression of adhesion proteins in sinusoidal endothelial cells that results in loss of 
fenestrae take place. This injury results in a conversion of hepatic stellate cells into 
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myofibroblasts, which proliferate and secrete extracellular matrix proteins and fibrosis. In the 
acute conditions and under some chronic conditions, fibrosis may be reversible. However, if 
the liver damage continues to re-occur through repeated acute incidents within a particular 
period of time, the resolution, myofibroblast increase in numbers leading to a distorted hepatic 
architecture and vascular structure by the formation of fibrous scar tissue, eventually 
developing into cirrhosis and liver failure 140.  
Unfortunately, the treatment options for most of the hepatic diseases are limited. Up to now, 
the majority of the treatments for chronic liver disease have been directed at the causing agent: 
for instance, there are several active antiviral agents as therapies for hepatitis B and C. Likewise, 
there are many immunosuppressive agents which are given for immune-driven disease, such as 
autoimmune hepatitis. Even though these agents regularly have a beneficial effect on the degree 
of fibrosis, researchers are currently focusing on the development of drugs that are precisely 
developed to interfere with fibrosis. As the disease is only associated with general symptoms 
like malaise and fatigue, the risk of developing liver cirrhosis or hepatocellular carcinoma, 
consequently liver failure is increased. For end-stage liver disease, the only available option for 
treatment is orthotopic transplantation. Hepatocyte transplantation is the alternative to whole 
organ transplantation for patients with hepatic failure or hereditary liver disease. 





% of total 
mortalities 




World 11 1,162 2.1 15.8 788 
Pacific & East Asia 13 328 2.0 14.4 547 
Central Asia & 
Europe  
17 115 1.2 12.7 78 
Caribbean & Latin 
America 
9 98 2.7 15.6 33 
North Africa & 
Middle East 
8 77 3.5 18.2 24 
North America 12 50 1.7 14.0 27 
South Asia 10 314 2.5 18.0 38 
Sub-Saharan Africa 16 179 1.9 17.9 42 
Table 1.1 Worldwide deaths related to liver cirrhosis and liver cancer 2015.  
Adapted from Asrani (2019)136.  
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1.4.2 Liver regeneration  
The liver performs crucial physiological functions and the malfunctions of the liver directly 
threaten life. Hence, the liver retains an exceptional regeneration capacity after injury. The 
organ can maintain homeostasis via either the replication of mature cells or the differentiation 
of stem cells. The synthetic and metabolic functions of the liver are predominantly performed 
by hepatocytes. Therefore, the default pathway in response to mild-to-moderate acute liver 
injury is for hepatocyte-mediated liver regeneration. In conditions such as massive hepatocyte 
loss or severe viral hepatitis which result in mature hepatocytes replication impairment, the 
response to these severe injuries is associated with activation and expansion of adult hepatic 
progenitor cells (HPCs) 141,142,143. HPCs existence in normal liver are characterised by 
expression of surface markers involving epithelial cell adhesion molecule (EpCAM), CD13 and 
CD133 144. HPCs also express markers of both biliary epithelial cells (K7, K19 and K14) and 
hepatocytes lineages (K8, K18, C-met and albumin) 145,146.  
The origin of HPCs has been much debated; traditionally they are thought to be small epithelial 
cells of the bile duct situated in the canal of Hering, the structures that reside between the 
intrahepatic bile ducts and hepatocyte-lined canaliculi 147(Figure 1.12). Similarly, early 
investigations suggested an extrahepatic origin such as bone marrow 148. It has been suggested 
that HPCs may originate from HSCs, as they express the same genes as undifferentiated cells 
in rats and contain many similar signalling pathways 149. More recent studies suggest that HPCs 
may originate from the dedifferentiation of mature hepatocytes or bile ductular epithelial cells 
in response to liver damage, proposing that the conversion from hepatocytes or bile ductular 
epithelial cells to HPCs is a reversible process after recovery from injury 150. Moreover, in 
addition to the canal of Hering at least three more discrete niches have been determined: 
intralobular bile ducts, periductal cells and peribiliary hepatocytes. 
Due to the lack of expression of a unique HPCs specific marker, the understanding of 
mechanisms originating bidirectional differentiation capacity of HPCs is inadequate. It is 
expected that the interaction between different constituents of HPCs niche is the vital factor 
controlling the self-renewal, activation, maintenance and differentiation capacity of the HPCs. 
Therefore, the potential of HPCs to contribute to liver regeneration could be related to the type 
and the severity of liver injury 151,152,153.  
 




Figure 1.12 Schematic overview of liver lobule demonstrating the site of the canal of 
Hering.  The Canal of Hering is located in the junctional region between the hepatocytes and 
bile ducts 154.
 
1.5 Transdifferentiation of pancreas to liver 
1.5.1  Pancreas anatomy and physiology  
The pancreas is a tapered 6-inch long gland that is located behind the stomach across the back 
of the abdomen. It extends through the abdomen from the curved part of the duodenum to the 
spleen. The pancreas’ head is connecting to the duodenum and it is the broadest region of the 
organ. The organ extends laterally to the left and slightly narrowing forming the body of the 
pancreas. The narrow, tapered region extends from the body of the organ into the left side of 
the abdominal cavity close to the spleen is called the tail of the pancreas 155(Figure 1.13). 
The pancreas consists of exocrine and endocrine glandular tissue. Therefore, it is categorised 
as a heterocrine gland. The exocrine tissue forms approximately 99% of the pancreas mass. It 
is organised into several small groups recognised as acini, which are small collections of 
exocrine cells surrounding tiny ducts to form a raspberry-like structure. The acini exocrine cells 
secrete digestive enzymes which are excreted to the acini ducts. The products of many acini run 
into the largest pancreatic duct formed by joining the ducts of numerous acini 156 (Figure 1.13). 
The exocrine part of the pancreas performs a significant role in food digestion. The partially 
digested food is discharged slowly from the stomach into the duodenum in the form of a chyme, 
which is a thick, acidic liquid. 
Acini of the pancreas secrete pancreatic juice to be released into the duodenum to accomplish 
the chyme’s digestion. Pancreatic juice is a blend of salts, water, bicarbonate, as well as several 
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digestive enzymes. The pancreatic juice contains bicarbonate ions which act to neutralise the 
acidity of chyme to protect the wall of the intestine in addition to the generation of a proper 
environment for the pancreatic enzymes to function 157. The pancreatic enzymes specialise in 
digesting certain compounds that exist in chyme; such enzymes include amylase, trypsin, 
chymotrypsin, carboxypeptidase, lipase and nucleases 158.  
The endocrine tissue makes up 1% of the weight of the pancreas and it secretes hormones into 
the bloodstream. It consists of small collections of cells known as islets of Langerhans.  
Numerous capillaries flow through each islet to convey hormones to the other parts of the body.  
Alpha and beta cells are the main types of endocrine cells which make up the islets (Figure 
1.13). The endocrine portion of the pancreas act to regulate the glucose homeostasis in the 
bloodstream. The glucose levels in the blood must be maintained within specific borders to 
secure a steady source of glucose nourishing the cells of the body, although not to excess, as 
glucose could damage organs such as the kidney. The pancreas produces glucagon and insulin 
hormones in order to control blood sugar. The glucagon is secreted by the alpha cells. It 
increases blood glucose concentrations by motivating the liver and adipose tissue to breakdown 
the glycogen and triglycerides respectively into glucose to be released into the blood 159. 
Moreover, insulin is secreted by the beta cells which reduces blood glucose concentrations 
following a meal by increasing the taking of glucose by the liver, muscle and adipose tissues. 
Insulin promotes the storage of absorbed glucose in the forms of the glycogen in the muscles 
and liver and triglycerides in adipose tissue 160.  
 




Figure 1.13 An illustration of the anatomy of the pancreas.  The pancreas crosses the 
abdomen laterally and superiorly toward the left side. The most broad part of the organ lies in 
the bend of the duodenum is called the head (right side). The body of the pancreas is the tapered 
part extending up slightly (left side). The end close to the spleen is the organ, the tail. It consists 
of two types of glands: the exocrine gland made of small clusters of acinar cells and secretes 
digestive enzymes which are released via a network of ducts joined to form the main pancreatic 
duct. Additionally, the endocrine gland, made up of the islets of Langerhans, secretes hormones 
into the bloodstream 161. 
1.5.2 Overview of signals defining hepatic and pancreatic progenitors 
Many genetic approaches have revealed that the pancreas and liver cells are derived from the 
endoderm germ layer after hours of endoderm development. The endodermal epithelium folds 
to the anterior of the gut tube to create the foregut and to the posterior to create the hindgut. 
Primarily, general suppression of fibroblast growth factor 4 (FGF4) and mesodermal WNT 
signalling in the foregut permits liver and pancreas induction. In the ventral foregut, bone 
morphogenetic protein (BMP) from septum transversum mesenchyme cells and FGF from the 
cardiac mesoderm promote the liver programme and suppress the pancreas programme 114. 
Subsequent morphogenetic movements assist in foregut closure. During this process, the 
undifferentiated cells of lateral ventral endoderm avoid the pancreas inhibitory FGF because 
they move caudal to the cardiac domain and can initiate ventral pancreatic development. The 
liver and ventral pancreas bud are characterised by the expression of Hex 162,163. Activin and 
FGF signals from the notochord block sonic hedgehog (Shh) signalling within the dorsal foregut 
endoderm allowing the pancreatic programme 164.  
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After activation of gene expression for the liver or pancreas, the epithelium of the endoderm 
changes to a columnar appearance. The cells of hepatic and pancreatic endoderm then migrate 
to the adjacent mesenchyme making tissue buds which become vascularised and proliferate 162. 
Therefore, the embryonic development of the liver and pancreas are similar and may explain 
the observed transdifferentiation of cell types in adulthood. 
1.5.3 The trans-differentiation  
Throughout embryogenesis, neighbouring tissues that develop in a shared cell layer will possess 
similar combinations of transcription factors specifying their fate. Tissues develop by varying 
the expression of a small number of transcription factors 165,166. This close developmental 
relationship is giving the cells of these tissues the ability to interconvert in some cases of chronic 
tissue damage and regeneration 167  
The term metaplasia is used to describe the conversion of cells or tissue from one phenotype to 
another and can comprise the direct transformations of differentiated cells as well as stem cells 
165,166. In human pathology, the term metaplasia has been extensively used to define the 
unpredicted exhibition of unrelated tissues in ectopic sites 168, for instance, the appearance of 
patches of intestinal epithelium in the stomach 169. In contrast, transdifferentiation is described 
as an irreversible switching of the cells that already differentiated to another phenotype, which 
signifies the loss of one phenotype and the acquisition of another 170. The term 
‘transdifferentiation’ was first proposed by Selman and Kafatos to explain a change in cell 
differentiation when they observed a switch in cell type during metamorphosis in the silk moth 
171. 
1.5.4 Transdifferentiation of pancreatic cells into hepatocytes in vivo 
Several pathological and experimental conditions lead to the transdifferentiation of pancreatic 
cells to hepatocytes. In 1981, Scarpelli and Rao used a methionine-deficient diet protocol to 
stimulate pancreas injury and regeneration in a Syrian golden hamster and observed hepatocytes 
in the regenerating pancreas, their observation was confirmed by detecting a variety of 
morphological features in addition to the expression of albumin and peroxisomes 172. Since 
then, various protocols have been used for the in vivo induction of hepatocyte in the pancreas, 
for example, the use of peroxisome proliferators treatment (e.g. ciprofibrate) 173,174 or particular 
carcinogens 175 and epithelial cells transplantation 176. The copper-depletion protocol is perhaps 
the most widely examined in vivo model of the hepatic metaplasia of the pancreas 175,177,178. 
Such a model is extremely reproducible in vivo. For example, hepatocytes may be induced in 
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the pancreas of adult rats kept for 7–9 weeks on a copper-deficient diet supplemented with a 
copper-chelating agent.  This results in a near total loss of pancreatic acinar cells and formation 
of numerous foci of hepatocytes during the recovery stage. Moreover, the liver cells in some 
animals occupied more than 60% of pancreatic volume within weeks  6–8 of recovery 177. The 
copper-deficient protocol results in the expression of HNF-1, HNF-3a, HNF-3b, HNF-4, 
C/EBPa and C/EBPβ in the pancreas of copper-depletion rat 178,179. 
Several of these transcription factors are mutual to both pancreas and liver 180 and it appears 
doubtful that factors typically found in both pancreas and liver tissues would be responsible for 
the transdifferentiation. However, the liver-enriched transcription factors LETFs (C/EBPβ) is 
not naturally expressed in the pancreas. Utilising in vitro model (treatment of organ cultures of 
mouse embryonic pancreas with DEX), show that it DEX is associated with an elevation of 
expression of the transcription factor C/EBPβ (CCAAT/ enhancer-binding protein β) and a 
reduction of the transcription factor Pdx-1. DEX also induces the appearance of hepatocyte-like 
cells in organ cultures of the pancreas, based on the expression of liver markers, albumin, α1-
antitrypsin and transthyretin. These findings suggested that C/EBPβ is a crucial component that 
discriminates between the liver and pancreatic differentiation programme 181. Several different 
cell origins for pancreatic hepatocytes have been suggested by using in vivo model systems ; 
specifically,  the suggested origins include acinar, endocrine or ductular cells 174,176,182. For 
example, using peroxisome proliferators induced hepatocytes in the pancreas of an adult male 
when added to their diet. Uricase-containing crystalloid nucleoids, specific for rat hepatocyte 
peroxisomes, existed in pancreatic hepatocytes. These structures assisted the detection of cells 
with hybrid cytoplasmic characteristics of pancreatic acinar and endocrine cells and 
hepatocytes. Such cells are assumed to represent a transitional stage in which pancreas-specific 
genes are being repressed while liver-specific ones are simultaneously expressed. The presence 
of exocrine and/or endocrine secretory granules in transitional cells suggests that 
acinar/intermediate cells represent the precursor cell from which pancreatic hepatocytes are 
derived 174. 
 since the embryonic development of the liver and pancreas are induced from the adjacent area 
in the foregut endoderm 183. This suggests that the difference in developmental specification of 
the liver and pancreas refers to the expression of only a few genes which also means the 
possibility to induce the conversion of liver into the pancreas (reverse transdifferentiation).  
The transdifferentiation of liver into the pancreatic exocrine tissue has been observed in animal 
experiments and certain human pathologies. It has been demonstrated in the livers of rats after 
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treatment with polychlorinated biphenyls 184, in the liver of fish treated with chemical 
carcinogens 185 or in the human liver of a patient with hepatic carcinoma 186. Moreover, the 
hepatocytes have been reversely transdifferentiated into pancreatic cells by adenoviral-
mediated expression of PDX1 which induced the conversion of hepatocytes into insulin-
producing pancreatic β-like cells in mice with budding β-cells to ameliorate Type 1 diabetes 
mellitus 187,188. 
These finding offered evidence regarding the origin of pancreatic hepatocytes. However, the 
difficulties in using the whole-animal experiments such as the ethical concern in addition to the 
requirement of time-consuming protocols and very high cost involved in breeding and housing 
has pushed the experts to use the pancreatic AR42J-B13 cells to establish the cell lineage 
experiment and to investigate the molecular and cellular basis of the transdifferentiation of 
pancreas to liver. In contrast to whole animal studies, cell lines offer several advantages, such 
as they are cost-effective, easy to use, provide an unlimited supply of material and bypass 
ethical concerns associated with the use of animal tissue. More advantages of using the 
pancreatic AR42J-B13 cells to establish the cell lineage experiment instead of the whole animal 
are ensuring that the starting populations are clearly defined and markers used to mark the cells 
remain exclusively in the original cells and their progeny and will not diffuse to the 
neighbouring cells. 
1.5.5 Trans-differentiation of B-13 cells to hepatocyte (B-13/H cells) 
The AR42J is a cell line isolated from adenocarcinoma of an azaserine-treated Wistar/Lewis rat 
189. Azaserine is a natural antibiotic initially isolated from Streptomyces fragilis 190 that causes 
cytotoxicity in cells. Only one intraperitoneal inoculation of 30 mg azaserine per kg body 
weight is efficient to induce adenoma and consequently carcinoma in rats several months after 
exposure, primarily in the pancreas 191. The AR42J is an exocrine pancreatic adenocarcinoma 
cell line used currently in basic exocrine pancreas research 192. They were isolated from tumour 
cells produced from the rat azaserine studies and were re-transplanted into untreated rats of the 
same species by intraperitoneal and subcutaneous injections up to five times 189 (Figure 1.14). 
The generated AR42J cell line was observed to express high levels of pancreatic exocrine 
enzymes such as amylase 193. The AR42J-B-13 (B-13 ) cell line is a sub-clone of the AR42J 
cell line which was subcloned by the Kojima lab in 1996 and stimulated to produce insulin-
secreting β-like cells after treatment with activin A and HGF 194,195.  
In 2000, Shen and colleagues observed that the B-13 cells go through an overwhelming 
alteration in the phenotype from the pancreatic exocrine-like cell to an hepatocyte-like-
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cells(B13/H cells) in response to the glucocorticoid dexamethasone (DEX) treatment 196. A 
sequence of reports after this discovery conclusively verify this information and reveal that B-
13/H cells express a diversity of hepatocyte-specific genes or hepatocyte enriched, comprising 
glucose-6-phosphatase, albumin, transferrin, transthyretin 197 and cytochrome P450 198. The 
expression of many hepatocyte-specific genes can be observed within ~3 days of DEX 
treatment including UGT, transferrin and CYP2E1, whereas albumin expression is not detected 
until later, at around day 9, showing the full transdifferentiation event takes time 199. A distinct 
characteristic of B-13/H cells is that they are exhibiting afunctional capacity that is 
quantitatively similar to freshly isolated rat hepatocytes (Figure 1.15). This feature is essential 
for in vitro cell models for studying toxicity mechanisms and possibly using the model to screen 
for drug and chemical toxicity 200.  
To date, the data propose that the B-13 may be corresponding to a pancreatic or liver progenitor 
cell based on it trans-differentiation from the phenotype of B-13 acinar cells straight to the 
hepatocyte-like B-13/H phenotype. Utilising a B-13 cell line stably transfected with a green 
fluorescent protein (GFP) gene controlled by a promoter (trans-activated in exocrine pancreas 
cells), data demonstrated that following treatment with glucocorticoid, B-13/H cells were 
detected expressing both GFP and hepatocyte markers. This observation suggests that the 
mechanism of altered differentiation is likely a direct conversion from “differentiated” 
pancreatic exocrine cell type into a hepatocyte and excludes the reversion to a plastic 
progenitor-like intermediate. However, more recent limited evidence suggests that B-13 cells 
may be turned to form a ductal phenotype in response to glucocorticoid and EGF 201. This 
conversion suggests that B-13 cells have a potency similar to hepatoblasts or may possess an 
endodermal progenitor phenotype, although a variety of cells in vitro are reflecting apparent 
response like epithelial-mesenchymal transition (EMT), to which the apparent plastic nature of 
B-13 could refer 202, even if B-13 cells entering (or are able under certain circumstances to 
enter) a transient plastic state prior to conversion to B-13/H cells remains ambiguous.  
Despite the fact that many liver-enriched transcription factors have been involved in trans-
differentiation to B-13/H, as mentioned previously (C/EBPß), which were expressed in the 
pancreas of copper-depletion rats has been identified as the critical component in trans-
differentiation 203. More importantly, Shen et al. (2000) found that transfection of C/EBPβ into 
B-13 cells can trigger the trans-differentiation into B13/H cells, while the dominant-negative 
form of C/EBPβ can inhibit this process. This observation suggests that C/EBPβ is an essential 
candidate for switching the pancreatic phenotype to the liver 181. The data from literature 
demonstrated that DEX treatment results in suppression of WNT signalling and subsequent 
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expression of C/EBPβ 204. Therefore, the role of WNT signalling in trans-differentiation has 
been examined.  
 
Figure 1.14 Origin and isolation of the AR42J and AR42J-B13 (B-13) cell lines.  Light 
micrographs of AR42J cell line and b-13 as indicated (Upper panels), fluorescence 
immunocytochemical staining showing cytoplasmic staining of the CYP2E1, DNA stained with 
DAPI DNA to identify the nucleus in B-13/H cells (lower panel)200. 





Figure 1.15 Western blotting analysis of the indicated proteins after induction of  hepatic 
phenotype.  In vitro induction of cytochrome P450s in B-13, B-13/H and rat hepatocytes. B-
13, B-13/H and rat hepatocytes in culture were treated daily for 3 days with cytochrome P450 
inducers (androstenol, 5 μM; β-naphthoflavone [β-NF], 20 μM; phenobarbitone [PB], 1 mM; 
1,4-Bis-[2-(3,5dichloropyridyloxy)]benzene,3,3’,5,5’-Tetrachloro-1,4-bis(pyridyloxy)benzene 
[TCPOBOP], 1.5 μM DEX, 10 μM; pregnenolone 16α carbonitrile [PCN], 2 μM or bezafibrate 
250 Μm. 200




1.5.6 Role of the WNT/β-catenin pathway in the transdifferentiation of B-13 cells into B-
13/H cells 
The WNT signalling pathway is a highly conserved signalling pathway across multiple species 
from Drosophila to humans 205. Initially, discovered for its role in carcinogenesis, then for its 
function in early development controls including cell fate defining, proliferation, migration and 
body axis patterning. Additionally, the WNT signalling pathway also controls tissue 
regeneration in the adult. The pathways of WNT signalling are a set of signal transduction 
pathways which start with proteins that deliver signals into a cell through cell surface receptors 
via specific proteins. The pathways involve a diverse family of secreted lipid-modified 
signalling glycoproteins which work as ligands to trigger the discrete WNT pathways via 
paracrine and autocrine routes 206. WNT signalling launches when a WNT protein combines 
into a frizzled (Fz) family receptor 207 co-receptors like lipoprotein receptor-related protein 
(LRP)-5/6 and receptor tyrosine kinase (RTK) may be involved besides the interaction between 
the Fz receptor and the WNT protein 208. As soon as the receptor is activated, a signal is 
conveyed to Dishevelled (Dsh), which is a phosphoprotein found in the cytoplasm. The 
conduction of this signal is via a direct interaction between Fz and Dsh. Subsequently, the WNT 
signal can turn-off into several pathways. The three most studied WNT signalling pathways are 
the noncanonical planar cell polarity pathway, the noncanonical WNT/calcium pathway and 
the canonical WNT pathway. As their names indicate, these pathways belong to one of two 
groups: canonical or noncanonical. The canonical pathway implies the protein β-catenin while 
the noncanonical pathway works independently 209. 
It has been documented that the canonical pathway plays a role in B-13 cells transdifferentiation 
into B-13/H cells. It is mediated by ligand binding to Frizzled and LRP (5/6) receptors resulting 
in the cytoplasmic gathering of β-catenin and β-catenin pass on to the nucleus. In the nucleus,  
it interacts with T cell factor (TCF)/lymphatic enhancement factor (LEF) for regulation of 
different target genes expression 205,210 In the absence of WNT, β-catenin would not accumulate 
in the cytoplasm as it would be degraded by the destruction complex which is composed of the 
following proteins: adenomatosis polyposis Coli (APC), Axin, protein phosphatase 2A (PP2A), 
casein kinase 1α (CK1α) and glycogen synthase kinase 3(GSK3)211,212. It degrades β-catenin 
by directing it for ubiquitination. Then, the degraded β-catenin are sent to the proteasome to be 
digested 213. In contrast, in the presence of the WNT ligand, it binds the Frizzled (Fz) receptor 
and its co-receptor (LRP6) or its close relative LRP5. As a consequence, the destruction 
complex function is disturbed. This function disturbance is attributable to the formation of a 
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WNT-Fz-LRP6 complex together with the recruitment of the scaffolding protein Dishevelled 
(Dsh) outcomes in the phosphorylation and activation of LRP6 and the recruitment of the Axin 
complex to the receptors. These actions inhibit Axin-facilitated β-catenin phosphorylation. 
Moreover, this permits β-catenin to accumulate, stabilise and travel to the nucleus to act as 
transcription cofactor beside the TCF/LEF (T-cell factor/lymphoid enhancing factor) 
transcription factors to induce WNT target gene expression 213 (Figure 1.16).  
 
Figure 1.16 The canonical WNT/β-catenin pathway.  WNT proteins are binding to frizzled 
receptors and the LRP co-receptor (WNT ON state) forming WNT-frizzled-LRP5/6 complex 
act to suppress the activity of glycogen synthase kinase-3β (GSK-3β). This prevents 
phosphorylation of downstream molecules allowing β-catenin to stabilise and accumulate 
within the cytoplasm prior to translocating to the nucleus and activating gene expression of the 
target genes. In the absence of the WNT ligand (WNT OFF state), the destruction complex of 
β-catenin (axin, APC, CK1α and GSK 3β) will phosphorylate β-catenin targeting it for 
ubiquitination subsequent proteasomal degradation 210. 
 
As mentioned previously in this section, WNT signalling is essential in organ development 214. 
Moreover, the WNT/β-catenin pathway is predicted to play a role in liver development in 
addition to hepatocyte zonation in the adult liver 215,216 as discussed in Section 1.2.2. Focusing 
on canonical WNT signalling pathway, the expression analysis of its elements presented that 
AR42J B-13 cells are expressing the WNT ligands (WNT1, WNT2b, WNT3a and WNT5a ) 
mRNAs and that the levels were repressed by DEX treatment. Furthermore, it has been 
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demonstrated that DEX treatment in AR42J B-13 cells results in down-regulation of frizzled 
receptors (Fzd) and up-regulation of both DKK (Dickkopf-related protein 1) and sFRP (secreted 
Frizzled-related protein)217. This finding predicts that B-13 cells conversion into B-13/H cells 
by DEX may be induced by the suppression of the WNT signalling pathway.  
Moreover, in 2010, Wallace et al. found that DEX treatment induced a transient loss of 
constitutive WNT3a expression, resulting in an activation of GSK3β (glycogen synthase kinase 
3β) and consequent beta-catenin phosphorylation and loss of its nuclear localisation 218. 
Similarly, it is indicated that Tcf/Lef transcriptional activity was high in B-13 cells and 
furthermore, that this activity decreases with DEX treatment. Twenty-four hours of treatment 
with DEX was adequate to inhibit Tcf/Lef activity to a level parallel to that after treatment with 
the Tcf/Lef inhibitor quercetin (Figure 1.17) 218. Additionally, siRNA knockdown of beta-
catenin in B13 cells was sufficient to enhance DEX dependent transdifferentiation, whereas 
transfection with a mutant beta-catenin protein  (a non-degradable version of β-catenin) 
prevented dexamethasone-mediated transdifferentiation 218. β-Catenin acts as an activator for 
the transcription factors Tcf (T-cell factor)/Lef (lymphoid enhancer factor) and loss of cellular 
β-catenin is followed by a reduction in Tcf/Lef transcriptional activity. Although treatment of 
B13 cells with the Tcf/Lef inhibitor (Quercetin) resulted in induction of C/EBPβ, indicating 
that C/EBPβ is repressed by Tcf/Lef activity, the Tcf/Lef inhibitor did not promote 
transdifferentiation into B-13/H cells but did potentiate glucocorticoid-mediated 
transdifferentiation. Thus, inhibition of Tcf/Lef alone was not adequate to induce 
transdifferentiation of B13 cells into B13/H cells218. This data suggests that although it was 
evident that DEX treatment results in suppression of WNT signalling and subsequent 
expression of C/EBPβ, the connection between DEX and the WNT/β-catenin pathway needs to 
be identified. 




Figure 1.17 B-13 cells into B-13/H cells transdifferentiation is linked with suppression of 
Tcf/Lef transcriptional activity.  B-13 cells were treated with DEX and transfected with the 
demonstrated constructs. After 24 hours of DEX treatment, the medium was changed and the 
cells were treated with 100 nMWNT agonists, 50µM quercetin and 10nMDEX. The cells were 
harvested 24 hours later. 0.1% (v/v) DMSO treatment was used as a vehicle control. Normalised 
luciferase activity versus cells transfected with TK$or TCF6-TK* during the same treatment. 
Significantly different with a p-value <0.05 using ANOVA (two-tailed) and ANOVA (two-
tailed)218.
 
1.5.7 Glucocorticoids in transdifferentiation of pancreas to liver 
Glucocorticoids are endogenous adrenal hormones. They were discovered in the 1940s as 
extracts of the adrenal cortex. Their levels in the blood are controlled by the hypothalamus-
pituitary-adrenal (HPA) axis 219,220. The primary physiological function of glucocorticoids is 
the regulation of general metabolism. In response to stress, high levels of glucocorticoids 
promote gluconeogenesis, lipolysis and protein and amino acid degradation 220. Glucocorticoids 
also regulate fluid and electrolyte homeostasis as they promote diuresis. Besides, they have a 
general anti-inflammatory effect, which allows them to be used as therapeutic agents 221. 
Although glucocorticoids also have multiple effects on foetal development, their circulating 
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levels are low in the embryo and foetus because the placental enzymes, such as 11β-
hydroxysteroid dehydrogenase [HSD2] inactivate glucocorticoids by metabolising them into 
inactive yields. Consequently, foetal levels only rise as the foetal HPA axis develops 222,223. 
This increase in circulating foetal glucocorticoid perhaps significantly participates in cell 
differentiation and tissue maturation, most particularly stimulating maturation of the lung as 
well as the production of the surfactant essential for extrauterine lung function 224. The effects 
of glucocorticoid are mediated by glucocorticoid Receptors (GR) and mineralcorticoid 
receptors (MR)225. It has been reported that the GR facilitates the response to glucocorticoid in 
B-13 cells and induces the process of transdifferentiation 226.  DEX which is a synthetic 
glucocorticoid has been commonly employed in generating B-13/H cells 166. It is more specific 
for GR than lots of natural glucocorticoids and less rapidly metabolised. Additionally, GR 
antagonists inhibit B-13 cells transdifferentiation into B-13/H cells 226. Other classes of steroids 
(e.g. oestrogens) are not able to stimulate the trans-differentiation of B-13 cells into B-13/H 
cells 200,227. Although glucocorticoids also activate the MR 228, glucocorticoid-dependent trans-
differentiation to the B-13/H cell is not blocked by MR antagonists. Besides, B-13 trans-
differentiation does not occur in response to mineralocorticoids 226. 
As mentioned in a previous section (1.5.4), several observations over the years have stated in 
vivo manifestation of hepatocyte-like tissue in pancreatic exocrine, in response to a range of 
pathological conditions. Later reports have been directed to study the effects of glucocorticoid 
on pancreatic exocrine tissue differentiation. In vitro studies have demonstrated that 
glucocorticoid treatment results in the conversion of both rodent and human embryonic acinar 
cells into hepatocyte-like cells 181,229. Although the functionality of these pancreatic hepatocyte-
like cells needs to be quantitatively compared to liver hepatocyte, then it would be arguable 
whether such cells could be defined as hepatocytes. However, the in-vitro environment in which 
the cells were cultured could influence this quantitative comparability which means that the 
cells could have the potentiality to form functional hepatocytes in the appropriate environment 
(such as in vivo). Moreover, studies in both rodents and humans verify this 217,227. In a study 
conducted by Wallace et al. (2009), using in vivo models, they demonstrated that pancreatic 
acinar cells of adult rats had been converted into cells that express liver-levels of CYP2E1 after 
treatment with high dose glucocorticoid for just a few weeks 217. 
In a transgenic mouse with high circulating endogenous glucocorticoids, many of the clinical 
features of Cushing’s disease are evident. Cushing's disease results from an adrenocorticotropic 
hormone-secreting pituitary tumour that leads to excess secretion of adrenocorticotropic 
hormone (ACTH). This excess secretion of ACTH stimulates secretion of cortisol by the 
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adrenal glands, resulting in supraphysiological levels of circulating cortisol. The 
pathophysiological levels of cortisol are associated with hypertension, diabetes, obesity, and 
early death 230. In the pancreas of many mice at 21 weeks of age there was significant liver-
levels of hepatocyte gene expression 231. This observation demonstrates that in vivo 
pathologically high levels of glucocorticoids alters the healthy pancreas to a hepatocyte-like 
phenotype showing equivalent levels of hepatocyte gene expression. Later analyses also 
indicate that the pancreas of adult patients maintained at high levels of systemic glucocorticoid 
treatment expressed hepatocyte levels of hepatocyte expressed genes 227.  
1.5.8 The role of Serine/threonine protein kinase (SGK1) in glucocorticoid-dependent 
transdifferentiation of B-13 cells  to B-13/H cells 
Serum and glucocorticoid-regulated kinases (SGKs) are also known as Serine/threonine protein 
kinases. SGK1 is a member of the Protein kinase superfamily; AGC kinases which include 
protein kinase A, protein kinase G and protein kinase C. Multiple isoform variants exist of most 
AGC kinases, adding to the complexity of this family 232. Physiologically, SGK1 functions to 
regulate sodium salt re-absorption by the kidney 233. Sgk1 exhibits a broad distribution in the 
tissues.  
In situ hybridisation studies localised Sgk1 mRNA in several epithelial and nonepithelial cells 
in the brain 234, eye 235 lung 234, liver 236, ovary 237, pancreas 238 and kidney 239. Little is known 
concerning the distribution of the Sgk isoforms at the protein level which may refer (at least in 
part) to the fact that the existing antibodies are not isoform-specific and thus, may detect 
different Sgk isoforms. Moreover, Sgk1 is an unstable protein with a rapid turnover/half-life of 
approximately 30 minutes 240. Rapid degradation of Sgk1 occurs through its ubiquitination and 
degradation by the proteasome 240. Although Sgk isoforms are expressed in numerous tissues 
and cell types, the function of Sgk1 in aldosterone-dependent control of sodium ion (Na+) 
homeostasis is the most-studied role of these kinases concerning the transportation of epithelial 
ions 241. The kidneys perform a vital role in keeping Na+ homeostasis. Excretion of Na+ in 
urine requires strict regulation to retain a constant extracellular volume during different dietary 
Na+ consumption and extrarenal Na+ losses 241. In the kidney, the expression of Sgk1 is induced 
by aldosterone which binds to the MR. Sgk1 then translocates into the nucleus and becomes 
phosphorylated via the PI-3K pathway, leaving SGK1 functionally active as a kinase which 
results in phosphorylation of the ubiquitin ligase Nedd4-2. Consequently, there is inhibition of 
epithelial Na+ channel (ENaC) ubiquitylation, internalisation and degradation in the 
endosomal/lysosomal system 241. In addition to this indirect action of Sgk1 on the ENaC cells 
abundant availability, it was suggested that Sgk1 could increase the activity of the ENaC 
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channel by direct interaction with the ENaC channel 242 and phosphorylation of α-ENaC 
subunits 243. In the kidney, HSD11B2 rapidly oxidises the glucocorticoid to the inactive 
metabolite, thus preventing illicit activation of the mineral corticoid receptor by glucocorticoids 
which ensures that the main activation of MR is in response to mineralocorticoid and not 
glucocorticoid levels 244.  
Despite a clear functional role for SGK1 in the kidney, Sgk1 is induced by a vast spectrum of 
stimuli in addition to glucocorticoids, mineralocorticoids 245 and serum. These  stimuli include 
cell shrinkage and swelling 246, TGF-β247, chronic viral hepatitis 236, vitamin D3 248, glucose 249, 
fibroblast growth factor (FGF)250, platelet-derived growth factor (PDGF) 250, heat shock 251 and 
oxidative stress 251. As SGK1 provokes stress in response to low salt levels to promote salt re-
absorption, the effect of Sgk1 gene knockout in mice has only been noticed when the mice are 
forced onto a low salt intake 252,253. Recently, SGK1 has been shown to play a role in cell 
differentiation 254,255; however, there is no apparent phenotype – developmental identified. In 
comparison, the role for SGK1 in B-13 cells conversion into B-13/H cells has been extensively 
studied and identified.  
In 2011, Wallace and colleagues suggested that GR activation by DEX treatment in B-13 cells 
induces a marked increase in the serine/threonine kinase SGK1 before induction of C/EBPβ 256. 
A microarray study measured the levels of approximately 5000 transcripts in B-13 and 
compared them to those in B-13/H cells. In this study, SGK1 was identified as the highest 
induced transcript in B-13/H cells in response to glucocorticoid treatment 217. This observation 
provided a potential mechanism by which DEX treatment of B-13 cells could induce 
transdifferentiation/conversion via the WNT/β-catenin pathway, suggesting that SGK1, at least 
partially, phosphorylates the WNT signalling protein messenger β-catenin as an element of the 
mechanism that precedes stimulation of transcription factors such as CEBP-β 166,218 (Figure 
1.18). Further studies confirmed that the plasmid vector-mediated expression of either of SGK1 
isoforms which are identical except for alternative N-terminal domains (SGK1c and SGK1f) 
alone, resulted in the transdifferentiation of B-13 into B-13/H cells and inhibition of Tcf/Lef 
activity 256.  
Wallace et al. showed that inhibition of SGK1 expression by siRNA resulted in abrogation of 
dexamethasone-induced transdifferentiation. The in vitro experiment showed that recombinant 
SGK1 was efficient to phosphorylate recombinant β-catenin on the residues that target β-
catenin for ubiquitination and degradation 256. The process of β-catenin phosphorylation would 
be predicted to down-regulate the WNT signalling pathway in vivo. As mentioned previously 
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(Section 1.5.6), WNT signalling activity was high in B-13 cells, confirmed by a WNT signalling 
responsive promoter-reporter gene construct (top flash). Inhibition of WNT by over-expression 
of a mutant β-catenin or siRNA to knockdown β-catenin expression alone led to Cebp-β 
induction and trans-differentiation/conversion of B-13 cells into B-13/H cells 218. These 
findings suggest that Sgk1 isoforms may provide the link between GR activation and the WNT 
signalling pathway. This crosstalk could result in upstream Cebp-β induction and trans-
differentiation/conversion. It is unlikely to be operational in normal cells and operates only in 
pathological conditions, for instance, chronic high glucocorticoid levels.  
In 2016, Fairhall et al. discovered that continuous and pulse exposing of B-13 cells to DEX was 
sufficient to induce a robust increase in Sgk1c mRNA transcripts expression levels from 
undetectable levels in B-13 cells. Remarkably, expression of Sgk1c mRNA persisted 14 days 
later involving after pulse exposure to glucocorticoid. Moreover, this high induction Sgk1c 
mRNA transcripts was prevented by 5-azacytidine or by histone deacetylase inhibitors which 
propose that exposing B-13 cells to glucocorticoid-associated with a Gr-dependent pulse in 
DNA methylation and probably other epigenetic alterations such as histone modifications  
results in constitutive expression of Sgk1c and irreversible conversion of B-13 cells into B-
13/H cells 257. Understanding and application of these mechanism(s) could be used to generate 
a human equivalent B-13/H cell which could be used for drug and chemical toxicity screening 
as an alternative to primary human hepatocytes. 
 
 




Figure 1.18 Schematic diagram of suggested mechanism of B-13 cells conversion / trans-
differentiation into B-13/H cells 200






1.6 Pluripotent derived hepatocyte-like cells 
 Hepatocyte transplantation has recently turned into an option for orthotopic liver 
transplantation for the treatment of life-threatening metabolic liver diseases and acute liver 
failure 258. Besides their therapeutic capability, primary human hepatocytes are used to study 
the molecular and genetic features of human liver disease. Additionally, they offer a 
fundamental tool for drug toxicity screens and the discovery of new pharmaceuticals that can 
treat a broad group of metabolic diseases. However, the potential to use primary hepatocytes 
either for basic research or for therapeutic purposes has also been frustrated by the lack of 
donors and their affinity to quickly dedifferentiate and lose most hepatic functions following 
growth in a tissue culture condition 259. Besides, they are challenging to cryopreservation 260. 
The mature hepatocyte is patterned by the de-differentiation in reactions to the in vitro culture 
environment. De-differentiation may be initiated immediately after the cells isolation and 
probably induced by various factors, for example cell density, cell-matrix interactions, cell-cell 
interactions, deficiency of hormonal regulators and other factors in vitro 261 262,263. Under 
regular culture conditions such as culture on plastic, most of the original hepatocyte phenotype 
might be lost within a few days of culture. 
The need to expand primary hepatocytes purified from donor's livers could be avoided 
by using stem cells for hepatocytes production. In 2007, human hepatic stem cells isolated from 
adult livers appeared to be beneficial in vivo when they were transplanted back into a mouse 
model of liver injury 264. In 2009, mesenchymal stem cells from human adipose tissue were 
differentiated into hepatocyte-like cells in vitro and were determined to be able to engraft and 
express hepatic specific proteins when transplanted in mouse liver 265. However, the quantity 
of adult stem cells that should be extended in vitro and differentiated remains a drawback to 
these approaches. Human pluripotent stem cells (i.e., hESCs and hiPSCs) constitute a substitute 
supply of hepatocytes to elucidate the deficiency of liver cells for cells based therapy. Unlike 
adult stem cells, ESCs and iPSCs can proliferate indefinitely without loss of potency. Several 
studies have depicted the differentiation of hESCs into cells that display hepatic characteristics 
266. Similarly, iPSCs provide an alternative approach that avoids the arguments associated with 
the utilisation of human embryos to acquire pluripotent ES cells and they could supply 
autologous hepatocytes.  





Karim Si-Tayeb et al. (2010), is the first report demonstrating that mouse iPS cells can 
be used to generate hepatocyte-like cells efficiently 267. In this decade, hepatocyte 
differentiation technology has predominantly been improved. Several hiPSC differentiation 
protocols that mimic developmental processes and lead to hepatocyte-like cells with increasing 
efficiency were published and reviewed by Yiangou et al. 268 . Most of the hepatocyte 
differentiation protocols can be divided into three differentiation steps: DE differentiation, 
hepatoblast differentiation and hepatocyte maturation. In general, each of these differentiation 
steps is performed using growth factors and cytokines known to be necessary for liver 
development. Specifically, this involves the application of growth factors at defined times in 
order to differentiate the stem cells from pluripotency to endoderm induction, hepatic lineage 
specification and finally, maturation. 
The first step of differentiating pluripotent stem cells to DE cells is critical in hepatocyte 
differentiation. The critical part of this step includes exposing cells to activin A and BMP4 
269,270,271,272. Various protocols established the supplementation of the medium with high 
concentrations of Activin A to promote the endoderm formation from pluripotent stem cells 268. 
The efficiency of endoderm formation can be enhanced through modulating the WNT pathway 
either by supplementing recombinant WNT protein (or adding small molecules mimicking 
WNT, such as Chir99021) or by inhibition of GSK3-beta. Additionally, inhibition of PI3-kinase 
using small molecules LY294002 can enhance the efficiency of endoderm formation 269,273,274. 
FGF2 and BMP4 are considered as initiators of the differentiation into DE and their addition 
during the first 24-48 hours of differentiation may be further promote endoderm formation 275. 
Both, WNT and FGF are required for the normal formation of the primitive streak, as mentioned 
in Section 1.3.3 276. However, extended WNT3a exposure causes loss of hepatocyte 
differentiation capability 277 as repression of WNTs in the ADE is essential for liver development. 
After the DE differentiation, hepatoblast differentiation can be enhanced by repression of the 
WNT/b-catenin pathway 278. These facts propose that the operating time of WNT3a treatment 
should be precisely regulated in order to achieve an efficient DE differentiation. The resulting 
endoderm progenitors described by some protocols can be retained for a prolonged period while 
preserving their ability to differentiate into a variety of endodermal derivatives 279,280,281. It has 
been observed that foregut cells could be frozen after five pas-sages and then thawed to be 
expanded for at least five additional passages without any loss in gene expression profiles or 
observable loss of proliferation capacity 280. 
 





Cai et al. (2007), reported that the combination of FGF4 and BMP2 efficiently induced 
hepatoblast differentiation from DE cells 282. Brolen et al. used the mixture of BMP2/4 and 
FGF1/2/4 for the hepatoblast differentiation 283. Importantly, a low concentration of FGF2 has 
been shown to enhance the hepatocyte differentiation, while an intermediate or high 
concentration of FGF2 enhanced pancreatic or intestinal differentiation, respectively 284. 
According to this finding, the concentration of FGF should be controlled. 
For maturation of hepatocyte progenitors to hepatocyte-like cells, researchers 
recapitulated the physiological environment during perinatal and neonatal life. Therefore, the 
majority of the existing protocols use a particular hepatocyte maintenance medium 
supplemented with HGF and OSM in addition to DEX, which is known to induce expression 
of mature hepatic specific genes reviewed in 285. The longer the cells are subsequently grown 
in these conditions, the more their metabolic activity appears to increase. This stage of 
functional maturation can last up to 20–30 days with some protocols without DEX 52,283,286 and 
for 7-20 days with DEX 287. Hepatocytes produced from hPSCs express the critical transcription 
factors and functional markers, for instance hepatocyte nuclear factor 4 alpha (HNF4A), 
hepatocyte nuclear factor 6 (HNF6), CCAAT/enhancer-binding protein alpha (CEBPa), 
Prospero homeobox protein 1 (PROX1), Transcription factor GATA-4, ALB and CYP3A4. 
These hepatocyte-like cells were also shown to have liver-specific functions such as albumin 
secretion, glycogen synthesis, urea production, low-density lipoprotein (LDL) uptake and 
limited cytochrome P450 activity 52,267,283,286.  
Although human ES/iPS derived hepatocyte-like cells show various hepatic functions, 
the drug metabolic capacities in these cells are lower than those in primary human hepatocytes. 
Human ES/iPS derived hepatocyte-like cells also express high levels of immature hepatocyte 
markers, for example AFP, proposing a remaining immature/foetal phenotype 288,289. The 
characterisation of human hepatocyte-like cells functionality includes evaluating mature liver-
specific features that include albumin, urea, and fibrinogen synthesis, phase 1 and 2 metabolic 
enzyme activity (with specific substrates), and induction of drug metabolism enzyme and 
transporter (DMET) expression in response to specific inducers 279,290.  
1.7 Improving differentiation of iPSCs to hepatocyte-like cells 
The rapid dedifferentiation and immaturity of pluripotent derived hepatocyte-like cells have 
resulted in extensive attempts to manipulate the in vitro environment to generate or preserve 
hepatic functionality. These attempts include using co-culture systems in which paracrine 





influence is added or coculturing different supportive cell types. Pan et al. (2016), efficiently 
generated functional hepatocyte-like cells from mouse liver progenitor cells via indirect co-
culture with immortalised human hepatic stellate cells (Pan et al., 2016).  
Another commonly used method to promote cellular maturation is the three dimensional (3D) 
culture method 291,292. Yamashita et al. (2018), have established a method for bulk production 
of hepatocyte-like cells exploiting a 3D cell culture bioreactor that enabled them to achieve 
homogenous hepatocyte-like cells on a billion scale (>109 cells). Some hepatocyte markers 
genes such as alpha-1 antitrypsin, cytochrome (CYP) 1A2, CYP2D6 and HNF4a  have  higher 
expression levels in 3D-cultured hepatocyte-like cells in comparison to 2D-cultured 
hepatocyte-like cells 292. The flow culture method in which a continuously perfused system is 
applied, was also used and resulted in the retention of in vivo-like hepatocyte phenotype and 
metabolic function 293 Moreover, in several approaches, transcription factors that are expressed 
in several developmental stages have been expressed in various differentiation steps of iPSCs 
to hepatocyte-like cells. Recombinant adenoviral vectors have been used to express SOX17 294, 
HEX 295 and HNF4a 296 to improve the differentiation to definitive endoderm, hepatoblasts and 
hepatocyte-like cells, respectively. 
1.8 Adenoviral vectors for gene transfer 
Adenovirus-based vectors are commonly used as gene delivery vehicles for transduction of 
different cell types, specifically for quiescent, differentiated cells, in basic research and gene 
therapy applications. The significant advantages of using adenovirus-based vectors are that they 
provide the most efficient gene transfer among other viral vector systems for a wide variety of 
cell types. Additionally, it has a very efficient nuclear entry mechanism. Notably, they can 
transfer genes into both proliferating and quiescent cells 297. Regarding the production, it can 
be produced in high titers (> 1012 pfu/ml). In addition, adenovirus DNA does not integrate into 
the host cell genome 298. Recent improvements in the development of adenoviral vectors have 
brought significant advancement concerning problems like target cell specificity, long-term 
expression of the transgene, immunogenicity and toxicity in vivo.  
1.8.1 Adenovirus Structure and biology 
Since the first isolation of adenovirus from adenoid tissue in 1953 299, to date approximately 57 
different human serotypes have been identified 300. Type 2 and 5 are the most commonly studied 
adenovirus serotypes, both of which are the basis of the recombinant expression system in 





research today. Adenovirus is a non-enveloped virus with a linear, double-stranded DNA 
genome of 30-40 kb. Its nucleocapsid made up of 252 proteins in the form of 3 main types: 
hexon, fibre and penton based proteins 300 (Figure 1.19). Hexon based proteins are the structural 
basis of adenovirus and the major capsid protein. Both the fibre and penton based proteins are 
for receptor binding and internalisation of the adenovirus into host cells 301.  
The adenovirus capsid is accountable for the primary virus attachment to the cellular receptor, 
the coxsackie- and adenovirus receptor (CAR)302. Following initial attachment via CAR, the 
RGD-motif -motif in the penton based protein attaches to cell surface integrin receptors (αvβ1, 
αvβ3, or αvβ5), which act as a secondary or internalisation receptor. This step triggers the virus 
uptake by the host cell via endocytosis 303. After the endosomal uptake of the virus and release 
into the cytoplasm, the capsid of the virus is dismantled leading to the delivery of the core 
protein-coated viral genome to the nucleus. Inside the nucleus, the viral genes are expressed via 
the host cell’s replication machinery 304 (Figure 1.20). In the nucleus of infected cells, the virus 
genome is replicated and assembled, and mature viruses leave the host cell via disintegration. 
In contrast to other viruses, adenovirus DNA is not integrated into the host genome and remains 
in an episomal state 305.  
Episomes are non-integrated 306 extrachromosomal closed circular DNA molecules that may be 
replicated in the nucleus 306. The immediate early E1A gene is the first gene to be expressed 
once the adenovirus enters a host cell. The E1A gene is essential for adenovirus replication. 
Moreover, they encode a transactivator for the transcription of the delayed early genes in E1B, 
E2, E3 and E4 transcription units. The expression of these transcription units genes will modify 
a group of cellular genes in the host cell to facilitate adenovirus replication 307. The structural 
organisation of the Ad genome is shown in (Figure 1.21). Replication of the viral genome, 
which rely on ‘inverted terminal repeats’ (ITRs) of 100–140 bp in length at each end of the 
genome which contains cis-acting elements (origin of replication) and one copy of the terminal 
protein (TP) covalently attached to each 5’ (prime) end as an initiation primer, starts 
approximately 5–6 h after infection 307. Recognising the adenovirus replication cycle has 
allowed researchers to employ the vector to develop replication-defective (RD Ad Vector) 
versions for use in research. 










Figure 1.20 Transduction of Adenovirus 308
 





1.8.2 Replication- deficient adenovirus vectors  
Recombinant adenovirus expression vectors manipulate the low pathogenicity of the virus and 
the high nuclear transfer efficiency to deliver genes to the host cell. Most adenovirus vectors 
used in research are derived from adenovirus serotype 5 (Ad5). Replication-deficient can be 
produced by inserting or substituting the gene of interest into three regions of the viral genome: 
a region in E1, E3 and a short region between E4 and end of the genome (Figure 1.21). First-
generation vectors are based on the replacement of the E1 gene region with the transgene or 
therapeutic gene to be delivered to the cell of interest, with a highly active promoter like 
cytomegalovirus (CMV) promoter to motivate the expression of transgenes 301. As the E1 gene 
is essential for replication, the vector does not replicate in these cells under normal conditions. 
First-generation vectors can have an additional deletion in E3 which is dispensable for viral 
replication in cell culture, which make the total transgene capacity of these vectors up to 8kb. 
In order to propagate the recombinant virus that lacks E1 transgene expression, a 
complementing producer cell line, such as HEK293 which is a well-known cell line prepared 
by Frank Graham in 1977 is used 309. This cell line stably expresses the viral E1A and E1B 
proteins and thereby provides the essential E1 proteins for adenovirus replication. Despite the 
E1 and E3 deletion, evidence from animal experiments and human clinical studies demonstrated 
that viral genes are still expressed at low levels in cells transduced with first-generation vectors 
which can cause direct toxicity and immune response in vivo. This issue has led to the 
construction of ‘‘second-generation’ adenovirus vectors featured by additional deletions or 
inactivation (e.g., temperature-sensitive mutants) of E2 310 and/or E4 311 functions, which have 
improved transgene persistence and decreased inflammatory response in some studies; 
however, it did not ultimately solve the immunogenicity problem. The advantage though is that 
the second generation recombinant vectors can accommodate bigger transgene sizes. 






Figure 1.21 Schematic of the genome of adenovirus type 5 (Ad5) and Ad5 based 
Replication-defective vector  308







1.9 Project aim and hypothesis  
A common difficulty encountered with stem cell-derived differentiated cells in vitro is their 
maturation into fully differentiated phenotypes that quantitatively reflect the function of cells 
in vivo or directly after isolation from tissues. An example of this problem is the hepatocytes. 
Several reasons result in the immaturity of stem cell-derived hepatocyte-like cells. These 
include sub-optimal differentiation protocols, a sub-optimal in vitro environment and aberrant 
levels of regulating factors. These issues have resulted in extensive attempts to manipulate the 
in vitro environment to generate and/or preserve hepatic functionality.  
Numerous genetic approaches have revealed that the liver and pancreas cells are specified from 
the endoderm and regulated by a number of signalling pathways and transcription factors. 
Genetic studies revealed that they have a close developmental relationship which explains the 
in vivo transdifferentiation of pancreatic cells to hepatocyte-like cells and AR42JB-13 cells to 
B-13/H cells in response to dexamethasone in vitro. Moreover, in vitro transdifferentiation of 
B-13 cells is dependent on a transient suppression of Wnt signalling followed by induction of 
SGK1 via interactions with the GR. 
The project hypothesises that adenoviral-mediated expression of SGK1F will promote a mature 
hepatic phenotype in B-13/H cells and iPSCs derived hepatocyte-like cells. Accordingly, this 
project aims to: 
1. Examine the effect of the adenoviral-mediated expression of SGK1F on B-13 cells 
transdifferentiation into B-13/H cells. 
2. Investigate if SGK1F expression is upstream of β-catenin phosphorylation and WNT 
signalling changes in B-13 cells. 
3. Exploit the effect of SGK1F on B-13 cells and employ it on iPSCs directed toward 
hepatocyte-like-cells to potentiate their differentiation into hepatocytes (liver cells) so 
that their function more closely resembles human hepatocytes. 





 Materials and Methods 
2.1 Materials 
Ethical authorisation for human liver tissue and hepatocyte isolation was gained via the 
Newcastle Biobank (https://www.ncl.ac.uk/biobanks/) with over-arching ethical permission 
from the Newcastle & North Tyneside 1 Research Ethics Committee. WNT signalling reporter 
constructs “Topflash” and “Fopflash” were purchased  from Addgene 
 AdV-GFP was kindly offered by Dr Audrey Brown (Newcastle University). Professor 
Matthew Wright (Newcastle University, UK) provided The pFLAG-CMV2 SGK1F construct 
which encoded 2-241 amino acids of flagged protein 256 and was sub-cloned into adenovirus to 
produce a replication deficient AdV-SGK1F by Vector Biolabs (Eagleville, PA). AdV-null was 
kindly provided by Philip Probert (PhD student Newcastle University, UK). AD3 cells were 
grown in 6 well plates by Rachel Wilson and Charlotte Candlish from Professor Lyle 
Armstrong’s laboratory (Institute of Genetic Medicine, Newcastle University, UK). The 
isolation of human hepatocytes was performed by Ibrahim, Tarek Abdelghany and Alistair 
Leitch from the Wright lab 
2.2 Cell Culture 
2.2.1  Rat pancreatic progenitor cells 
AR42J-B-13 Cells were generously provided by Philip Probert (PhD student Newcastle 
University, UK). B-13 cells culture was routinely performed using low glucose (1g/L) 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% (v/v) foetal calf 
serum (FCS), 100units/ml penicillin, 100μg/ml streptomycin and 0.584g/L L-glutamine. Cells 
were retained in a humidified atmosphere at 37°C, 5% CO2 in the air. Cell culture media was 
changed every 2-3 days. DEX  treatment was used to transdifferentiate B-13 Cells into B-13/H 
by adding the 1000-fold molar ethanol solvated stocks. 0.1% (v/v) ethanol vehicle was used as 
the control treatment. 
2.2.2 HepG2 Cells  
The cell line (Hep G2) is a cell line that has been isolated from a liver biopsy sample belonging 
to a 15-year-old Caucasian male diagnosed with a well-differentiated hepatocellular carcinoma 
312. The cells secrete a variety of proteins such as α 1-antitrypsin, α2-macroglobulin, albumin, 
and transferrin. HepG2 cells were cultured in DMEM containing 10 % (v/v) FCS, 100units/ml 





penicillin, 100μg/ml streptomycin and 0.584g/L L-glutamine. Media was subsequently changed 
every 2-3 days and cells were sub-cultured when 90-95% confluent, as described in Section 
2.2.1 using 2x Trypsin- Ethylenediaminetetraacetic acid (EDTA) (Sigma), as explained in 
Section 2.2.7. 
2.2.3 MCF-7  
MCF-7 cell line is a human breast adenoma cell line isolated from the pleural effusion from a 
69-year-old female experiencing a breast adenocarcinoma. Some features of differentiated 
mammary epithelium are exhibited by this cell line. MCF-7 cells were cultured in DMEM- 
(Sigma D5546 1000mg/L glucose) containing 10 % (v/v) FCS, 100 units/ml penicillin, 
100μg/ml streptomycin and 0.584g/L L-glutamine. Additionally, the media was changed every 
2-3 days. 
2.2.4 HEK293 
Sarah Armour (PhD student, Newcastle University, UK) kindly provided human embryonic 
kidney 293 (HEK293) cells. The cells were routinely seeded into six-well plates at 1 x 105 
cells/well and cultured in low glucose (1g/L) DMEM supplemented with 10 % (v/v) FCS, 
100units/ml penicillin, 100μg/ml streptomycin and 0.584g/L L-glutamine until approximately 
80% confluent. 
2.2.5 AD3 (iPSCs) 
AD3 cells are human iPSCs reprogrammed from dermal fibroblast (Lonza) isolated from a 37-
year-old female using a CytoTune‐iPS 2.0 Sendai Reprogramming Kit (Invitrogen) which 
includes three vector preparations: Klf4–Oct3/4–Sox2, cMyc, and Klf4, as described in 
Neganova et al. (2009 & 2016) 313,314. AD3 were grown in 6 well plates, transferred to the 
Wright laboratory and differentiated into hepatocyte-like cells, as described by Hannan et al. 
(2013) 52. 
2.2.6 Primary human hepatocytes 
Collagenase perfusion was used for the isolation of human hepatocytes from liver tissue, as 
described by Diaz et al. (1990) 315. It is donated after circulatory death of 60 years old patient. 
The liver is weighing 1900 g with high Liver Injury and cholestatic marker. 





Cells were received, plated in 6 well plates and were cultured in Williams’ Medium E 
supplemented with 50 µg/ml gentamycin, 0.584g/L L-glutamine, 100units/ml penicillin, 
100μg/ml streptomycin 100nΜ insulin and incubated at 37ºC, an atmosphere air of 5% CO2. 
2.2.7 Cell passage  
When adherent cells reached 75-95% confluence, they were sub-cultured. The  medium was 
completely removed from the cells and washed once in phosphate buffered saline 8.0g/L NaCl; 
0.2g/L KCl; 0.2g/L KH2PO4,1.15g/L Na2HPO4) pH 7.4. Cells were incubated with 1 x 
Trypsin-EDTA (Sigma), diluted in 1x phosphate buffered saline (PBS)  (5ml per T75 flask and 
0.5ml per well of  six-well plate) and incubated at 37°C and 5% CO2 for 5-15 minutes. The 
culture vessel was then tapped gently to promote cell detachment which was confirmed by light 
microscopy and the trypsin was inactivated by adding an equal volume of FCS- containing 
culture media to the cell suspension. Cells suspension was then transferred to a 50 ml centrifuge 
tube (Fisher, Loughborough, UK). Cells were then centrifuged at 2000rpm for 5 minutes. The 
supernatant was discarded, and the cells re-suspended in fresh medium. The cells were then 
seeded as required for cell maintenance or kept frozen for cell storage.  
2.2.8 Long term cell storage  
Stocks for all cell lines were routinely frozen and stored long-term in -80°C or in liquid 
nitrogen. As soon as cells reached ⁓80% confluent, they were detached from the cell culture 
vessel and pelleted by centrifugation, as previously described in 2.2.7. After removing the 
supernatant, the pellet was re-suspended in freezing medium (10% Dimethyl sulfoxide (DMSO) 
and 90% FCS), typically 2ml per T752 flask. The suspension was then aliquoted into sterile 
cryovials (1ml/tube). Cryovials were placed in a Mr Frosty cooling device (Thermo Scientific, 
Loughborough, UK) which was prefilled with isopropanol and pre-chilled at - 80°C. Mr Frosty 
freezes cells at a rate of approximately 1°C per minute for optimal cell survival. Cryovials were 
left overnight, and then they were either transferred to the storage box at -80°C or retained for 
long term storage submerged in liquid nitrogen.  
2.2.9 Cell stock revival  
For the revival of frozen cells, cryovials were taken out from the storage box and rapidly 
defrosted in a water bath pre-warmed to 37°C. Once thawed, the cryovial contents were 
carefully pipetted into 50ml of fresh warmed culture medium in a falcon tube. The cells were 
then centrifuged at 600rpm for 4 minutes and the supernatant removed. The cell pellets were 





re-suspended in fresh media and transferred to a culture vessel (cells were initially seeded into 
small culture vessels, e.g. 6-well plates). Subsequently, the cells were incubated under standard 
conditions, as outlined in the cell culture section (see 2.2), until the cells had adhered to the 
culture flask (overnight). The culture medium was then aspirated. The medium was changed 
the following day.  
2.2.10 Determining cell number  
Following the trypsinisation and the pellet preparation, as described in Section 2.2.7, cells were 
re-suspended in a defined volume of medium (1-10ml). 1 volume aliquot of cell suspension was 
added to 1 volume of trypan blue (0.4% w/v in PBS), gently mixed and loaded into a 
haemocytometer counting grid with just enough cell suspension such that no liquid falls down 
the side gulleys. Using the microscope under normal illumination, the number of cells in 4-16 
small squares was counted (depending on cell density). Three counts were taken per sample 
and averaged. The number of viable cells which excluded trypan blue (i.e. colourless cells) per 
ml of original suspension was then calculated as follows:  
𝑛𝑛𝑛𝑛. 𝑛𝑛𝑜𝑜 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑝𝑝𝑐𝑐𝑝𝑝 𝑚𝑚𝑐𝑐 = 𝑎𝑎𝑎𝑎𝑐𝑐𝑝𝑝𝑎𝑎𝑎𝑎𝑐𝑐 𝑛𝑛𝑜𝑜 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑛𝑛𝑐𝑐𝑛𝑛𝑐𝑐 × 2 ×
16
𝑛𝑛𝑛𝑛. 𝑛𝑛𝑜𝑜 𝑐𝑐𝑠𝑠𝑐𝑐𝑎𝑎𝑝𝑝𝑐𝑐𝑐𝑐 𝑐𝑐𝑛𝑛𝑐𝑐𝑛𝑛𝑐𝑐𝑐𝑐𝑐𝑐 
× 10−4 
The cell suspension was then diluted as necessary based on the count as follows: 
 volume of the cells suspension needed ( µl)
= number of cells needed /no. of cells counted per ml of original suspensionx1000 
 Cells were then sub-cultured in 6 or 24 well plates at the desired density and incubated in an  
incubator at 37°C and 5% CO2 under humidified conditions. 
2.2.11 Cells viability test by trypan blue exclusion  
To assess the cells’ viability, 200ul of trypan blue (0.4% (w/v) was added to 2ml of cell media 
in 6 well plates and then aspirated off after 10 seconds had passed. Live cells which have intact 
plasma membrane exclude trypan blue stain, whereas dead cells fail to exclude it staining them 
blue. Cell photos were then taken using an OPTIKA bright-field microscope and imaged with 
a BUC2 Camera connected to a TOSHIBA computer set up with ScopeImage 9.0 software and 
ImageJ cell counter was used for counting the number of trypan blue positive (dead) and 
negative colourless cells (viable) cells. The number of non-viable cells and the total cell number 
in random views of fields were calculated and used to determine the percentage viability as 
follows:  





% Of cells viability =
no. of viable cells
total no. of cells 
 𝑥𝑥100 
2.2.12 Adenoviral production and titration. 
Replication-deficient adenovirus was produced via HEK293 cells routinely seeded into six-well 
plates at 1 x 105 cells/well and cultured, as described in 2.2.4, until approximately 80% 
confluent. Viral stocks were serially diluted typically between 10 x 10-4 - 10-9. The medium was 
removed from the HEK293 cells and 300 μl of each adenoviral dilution added to each well. The 
plate was gently rocked to ensure coverage of all cells by the viral solution and returned to the 
incubator for 1 hour. During this incubation, 5% agarose solution in PBS was dissolved by heat 
and cooled to 45°C separately with a culture medium. After the hour of incubation for infection, 
the viral dilutions were aspirated from the cells, 5% agarose solution was diluted to 0.5% in the 
culture medium. In addition, 2 ml of this solution was added per well and left to set. Once set, 
a further 2 ml of culture medium was added per well and the cells typically cultured for 7-10 
days. The medium was discarded, and cells were then stained with neutral red (0.03% (w/v) in 
PBS) for 2 hours. The viral titre was determined from the number of plaques counted as follows: 
no. of plaques
dilution factor x 0.3
= 𝑝𝑝𝑜𝑜𝑐𝑐/𝑚𝑚𝑐𝑐 
2.2.13 Multiplicity of infection (MOI) determinations 
For the determination of MOI in any particular cell type, typically cells were expanded to 
approximately 80% confluence and infected with a serially-diluted range of titred AdV-GFP.  
Infected cells were then returned to the incubator. Cultures were examined daily using a 
fluorescent microscope for up to 4 days and the percentage of cells positive for green 
fluorescent protein (GFP) determined from 5 randomly selected fields.  The titre and the number 
of cells was used to estimate the MOI as below: 
MOI =
the virus titre X the virus volume resulted in > 85 % infection rate
no. of cells per ml
 
2.2.14 Adenovirus protocol for Infecting Cells 
A day before infection, cells were sub-cultured into six-well plates to give approximately 50% 
confluency. An appropriate volume of titred virus suspension is added to the media to infect 
the cells based on the MOI of the cell line and the number of cells seeded. The adenovirus used 
either AdV-SGK1F encoding human SGK1F,  AdV-null, AdV-GFP or AdV-NTCP. Uninfected 





cells were included as controls. The cells were in some cases re-infected – with MOI altered as 
necessary – based on the extent of any apparent toxicity to previous infections in order to 
optimise both expression and cell viability. Cells cultured as outlined in (cell culture). To 
determine the amount of virus or plaque forming unit (PFU) to be added for a particular MOI, 
the following formula was used: 
Total no. of PFU needed = no. of cells x desired MOI . 
Subsequently, to calculate the total volume (ml) of the virus suspension needed to reach the 
desired dose, this formula was used: 




2.3 Plasmid DNA constructs and cells transfection 
2.3.1 Competent cell (TOP10) transformation  
Top 10 cells (Invitrogen, Paisley, UK) were transformed with the Plasmid of interest that 
propagate the DNA. TOP10 cells were stored at -80°C. When required, they were defrosted on 
ice and 50-100ng of plasmid DNA was combined in the vial and left on ice for 30 minutes. The 
cells were shocked by heating in a water bath at 42°C for 30 seconds without shaking, before 
being transferred to ice. 250 μl of super optimal broth (20mM glucose, 10mM NaCl, 2.5mM 
KCL, 10mM MgCl2, 10mM MgSO4, 2% tryptone and 0.5% extract of yeast) was added to the 
vial and retained in a 37°C incubator shaking at 225 rpm for 1 hour to allow cells to recover. 
The transformed cells (50-200 μl) were spread onto Luria broth (LB) ( LB-10g NaCl, 10 g 
Tryptone, 5 g yeast in 1 litre dH2O) agar plates containing the appropriate selection agent 
(kanamycin 25μg/ml or ampicillin 100μg/ml) and incubated over night at 37°C. The next 
morning a colony was picked and placed into 5 ml of LB with antibiotics as required and placed 
at 37°C in a shaking incubator at 220rpm overnight. The following day the cells were subjected 
to either mini- or maxi-prep or frozen, as described in, 2.3.2, 2.3.3 and 2.3.4 respectively.  
2.3.2 Miniprep purification of plasmid DNA  
Miniprep purification kits (Qiagen, Southampton, UK) were used for the purification of all 
plasmid DNA constructs following the manufacturer’s protocols. After alkaline lysis of the 
bacterial cell walls, the purification process continued with the adsorption of plasmid DNA onto 
a permeable silica membrane under high salt conditions 316. Additionally, 5 ml of culture was 
centrifuged in Eppendorf tubes at 16,000 g for one minute. The supernatant was discarded and 





250 μl of buffer P1 (containing RNase) was mixed with the pellet to remove any ribonucleic 
acid (RNA) contamination. This step was followed by adding 250 μl of buffer P2 (highly 
concentrated salt buffer containing (SDS sodium dodecyl sulphate). The tube was mixed to 
produce a clear solution and 350 μl of buffer N3 then was added (containing acetic acid to 
neutralise alkaline lysis buffer) and immediately inverted to mix. The solution was centrifuged 
at 16,000 g for 10 minutes resulting a white pellet. The supernatant was then carefully removed 
and pipetted into a Qiaprep spin column and centrifuged once again for 1 minute at 16000 g. 
The flow-through was discarded, and 500 μl of buffer PB dispensed into the column, which 
was then centrifuged again as before, and the supernatant removed. The column was again 
centrifuged at 16,000 g for 1 minute after adding 750 μl of buffer PE to remove excess salt and 
the flow through disposed of. The column centrifuged once more for 1 minute to remove the 
deposits. Then, the column was transferred to a sterile and nuclease-free water (50 μl) added 
directly to the column membrane. The column was left to stand for 1 minute then centrifuged 
for 1 minute at 16,000 g to elute the plasmid DNA. Plasmid DNA was then quantified by a 
spectrophotometer, as described in 2.4.2 
2.3.3 Maxiprep purification of plasmid DNA  
Maxiprep relied on the same theory as the miniprep but designed to produce larger yields. A 
maxi-prep was performed using the Qiagen Maxiprep kit to purify large quantities of plasmid 
DNA (up to 500μg). An overnight culture of 500 ml culture flasks was divided into 50 ml 
centrifuge tubes and then centrifuged for 10 minutes at 6,000 g. The pellets were re-suspended 
and combined in one tube. The bacteria pellet was then lysed by adding 10 ml of buffer P1 and 
10 ml P2 and mixed by inversion. The solution was allowed to remain for 5 minutes and 10 ml 
of buffer P3 (pre-chilled on ice) was then added and mixed by tube inversion. After this step, 
the lysate was transferred to a QIA filter cartridge and was kept at room temperature for 10 
minutes. Subsequently, the lysate was then applied to a Qiagen-tip 500 column that had been 
equilibrated by the addition of 10 ml of buffer QBT left to drain through. The supernatant was 
left to enter the column after which the column was rinsed twice with 30 ml of buffer QC. The 
flow-through was discarded. Then the plasmid DNA elution and precipitation was performed 
by the addition of 15 ml of buffer QF into a 50ml centrifuge and 10.5 ml of absolute isopropanol 
respectively. The sample was inverted to mix then centrifuged at 6,000g at 4°C for 30 minutes. 
The supernatant was removed, and the pellet washed with 70% ethanol. After another 
centrifugation step (6,000g for 30 minutes at 4°C), all the supernatant was aspirated, and the 
DNA pellet left to air dry for 10 minutes. The pellet was then re-suspended in nuclease-free 
water and quantified as described in 2.4.2  





2.3.4 glycerol stocks storage of DNA plasmids  
TOP10 cells transformed with plasmid DNA were stored long-term as glycerol stocks at -80°C. 
500μl of an overnight culture picked from a single colony was diluted 1:1 (v/v) with sterile LB 
media containing 30% (v/v) glycerol then transferred to a cryovial, labelled and frozen long 
term at -80°C. When required, previously stored bacteria were thawed, and a small sample (20-
30μl) streaked out on an agar plate augmented with a proper antibiotic such as ampicillin to 
select for transformed bacteria. After incubation overnight at 37°C, a single colony was picked 
from the plate and grown overnight in LB, with antibiotics as required, and plasmid DNA 
purified using a miniprep (2.3.2) or maxiprep (2.3.3).  
2.3.5 TOPflash/FOPflash plasmid transfection and dual luciferase assay 
WNT signalling reporter constructs M50 Super 8xTOPFlash and control plasmid Super 
8XFOPFlash were obtained from Addgene. The TOPFlash construct is a luciferase reporter of 
beta-catenin-mediated transcriptional activity. The construct backbone is the PTA-Luc vector, 
which delivers a minimal  promoter driving expression of the firefly luciferase gene. M50 Super 
8x TOPFlash reporter plasmid contains 7 copies of TCF/LEF binding sites 
(AGATCAAAGGgggta) which were cloned into the Mlu1 site of this vector, TCF/LEF binding 
site in CAP letters and a spacer in lower case, separating each copy of the TCF/LEF site. This 
plasmid was published as M50 Super 8x TOPFlash, however the plasmid contains only 7 
TCF/LEF sites. (Figure 2.1). Clone M51, Super8XFOPflash is the  appropriate control plasmid 
which has mutant TCF/LEF binding sites ( 
Figure 2.2). Top10 cells from Invitrogen (Paisley, UK) were transformed with the 
plasmid of interest to generate DNA. Miniprep and maxiprep purification of plasmid DNA were 
performed following the Qiagen protocol. 
Prior to transfection with plasmids, B-13 cells were sub-cultured onto 24 large plates using 
standard culture medium. The following day, 30 - 50% confluent cells that are actively dividing 
were used and two plasmid stocks were prepared (TOPFLASH and Luciferase containing reporter 
gene: RL-TK). A transfection with 6:1 fixed ratio for experimental to control plasmid DNA 
vectors were employed to control the transfection efficiencies between wells. (i.e. so that ratio 
of luciferase to the renilla vector will be identical in all transfected wells). For the 24 well plates, 
the total DNA concentration should be 0.34µg/well. Using Lipofectamine™ 2000 transfection 
Reagent (Promega), cells were transfected according to previously optimised protocol. DNA 
was diluted in 17.3 µl serum-free media (DMEM), mixed by tapping and left for 5 mins at room 





temperature (RT). Then, 3.5 µl of lipofectamine reagent was diluted in 17.3 µl serum-free media 
(DMEM), mixed by means of tapping and left for 5 mins at RT. The two dilutions were then 
combined 1:1 and left for 20 mins at RT. Next, 34 µl/well was dispensed and incubated for 24 
hours. At this point, cells were treated daily according to the experiment set up and examined 
to check the plasmid toxicity. Cells were harvested up to 72 hours after transfection.  
Following the manufacturer’s instructions, a Dual-Luciferase Reporter Assay kit from Promega 
was used to assess the activity of WNT signalling in cells transiently transfected with renilla 
and or firefly luciferase constructs. (TOP/FOPFLSH and RL-TK). Dual reporter systems work 
to increase experimental accuracy where two individual reporter enzymes are simultaneously 
expressed. The dual luciferase® assay utilises the luciferase activities of both firefly (photinus 
pyralis) and renilla (renilla reniformis, sea pansy) detecting the activities of both sources 
respectively (Figure 2.3). The difference in the structure of the two luciferase enzymes allows 
discrimination between their bioluminescence. Transfected cells were washed twice in 1 x PBS 
before 1 x passive lysis buffer (5 x stock diluted 1:4 with dH2O) was added to each well (100 
μl/well of 24 well plate) and shaken on an orbital shaker for 15 minutes to disrupt the cell 
membrane and lyse the cells. Luciferase assay reagent (LAR II) was prepared by resuspending 
the luciferase assay substrate with the luciferase assay buffer. Then, 100 μl of LAR II was 
pipetted into a polypropylene tube and 100 μl of cell lysate added and mixed. The activity of 
the luciferase was measured by a luminometer. Firefly luciferase activity was then quenched 
using a pre-diluted stock of stop and glo reagent containing the substrate for renilla luciferase. 
The luciferase activity of the RL-TK was subsequently measured and recorded. For all 
transfections, the relative luciferase of the experimental plasmid DNA construct (e.g. 
TOPFLASH) was normalised to RL-TK levels by dividing the firefly measurement by the 












Figure 2.1 Sequence Map for M50 Super 8x TOPFlash.  (addgene plasmid #12456)317 
 
 
Figure 2.2 Sequence Map for M51 Super 8x FOPFlash (TOPFlash mutant).  (addgene 
plasmid #12457)318
 






Figure 2.3 Firefly and Renilla luciferases bioluminescent reactions.  Fireflies emit light via 
a chemical reaction in which luciferin is converted to oxyluciferin by the action of luciferase 
enzyme (upper panel). Renilla luciferase converts coelenterazine into coelenteramide. The 
energy released by this reaction is in the form of light (lower panel).
 
2.4 Reverse transcription polymerase chain reaction (RT-PCR) and real-time reverse 
transcription  PCR (qRT-PCR) 
2.4.1 RNA isolation 
The medium was aspirated prior to washing the cells in PBS before isolation of the total RNA 
using TRIzol (Invitrogen), according to the manufacturer’s protocol. After the PBS wash, 1ml 
of TRIzol was added directly to the cells in the well and left on an orbital shaker for 5 minutes. 
The TRIzol was then transferred to RNAse free Eppendorf tubes. After a 5 minute incubation, 
200 μl of chloroform was added and mixed by inversion. The mixture was then centrifuged at 
16,000 g for 15 minutes to promote the formation of an aqueous phase, interphase and organic 
phase. RNA partitions in the aqueous phase, whereas DNA and proteins are localised to the 
interphase and organic phases. The aqueous phase was transferred to a new tube and 500 μl of 
isopropanol was added to precipitate the RNA. Then, the tube was mixed by inversion and left 
to stand on ice for 15 minutes. To pellet the RNA, the tube was centrifuged at 16,000 g for 10 
minutes. The isopropanol was aspirated off and 1 ml of 70% ethanol used to wash the pellet. 
The samples were centrifuged again as before, and all the ethanol removed. After 5-10 minutes 
of air drying at room temperature, the pellets were re-suspended in RNase free water. The RNA 
was then quantified and frozen at -80°C until required. 





2.4.2 RNA and DNA quantification  
For the determination and quantification of RNA or DNA in samples, their absorbance at 
260nm was measured using a Nanodrop 2000 spectrophotometer (Thermo Scientific) using 
RNase free water as the blank. The purity of the samples was measured by calculating the 
OD260/OD280 ratio. For pure nucleic acid samples, this should be between 1.8-2.1. Lower 
ratios suggest contamination, possibly by phenol or protein. The peak absorbance at 270nm 
rather than 260nm indicates significant phenol contamination which contribute to 
overestimation of nucleic acid concentration. After determining the quantity of RNAs. RNA 
samples were routinely diluted to 200ng/µl and 5ng/µl for RT-PCR and qRT-PCR respectively. 
2.4.3 1st strand synthesis and reverse transcription of RNA 
 Reverse transcription was performed using the RNA-dependent DNA polymerase M-MLV 
(Moloney Murine Leukemia Virus reverse transcriptase), essentially following the 
manufacturer's guidelines (Promega). To create complementary deoxyribonucleic acid 
(cDNA), RNA was diluted to a starting concentration of 200ng/μl. Additionally, 4μl of RNA 
(800ng) was incubated with 1 μl (50ng/μl) of random primers (Promega) at 95°C for 3 minutes. 
Samples were placed on ice. Master mix containing (per tube) 4 μl of 5x RT buffer (50mM 
Tris- HCl (pH 8.3 @ 25°C), 75mM KCl,3mM MgCl2 and 10mM DTT), 8 μl dH2O, 2 μl of 
10mM dNTP’s and 1 μl of MMLV was prepared on ice and added to each tube (15 μl total 
volume per reaction). The RNA was left for one hour at 42°C for optimal cDNA synthesis. 
Samples were stored at -20°C.  
2.4.4 Primers Design 
Forward and reverse PCR primers pairs were typically designed to amplify specific desired 
DNA sequences. The NCBI database (www.ncbi.nlm.nih.gov) was used to download 
nucleotide sequences of the required DNA sequences. Primer-blast was then used to design 
primer sequences for RT-PCR. PCR primers designed to flank the region of interest, range in 
length from 15–30 bases and contain 40–60% (G + C). Sequences that had minimal 
complementarity with themselves were avoided because they might produce an internal 
secondary structure. The 3 -ends of the primers were designed not be complementary to avoid 
the production of primer-dimers which deplete primers from the reaction and result in an 
unwanted polymerase reaction that competes with the desired reaction. Preferably, both primers 
had similar content of G and C to result in nearly identical melting temperatures (Tm= 2 ᵒC x 
(A + T) + 4 ᵒC x (G + C); in this way, both primers should anneal roughly at the same 





temperature. The annealing temperature of primer pairs is calculated as Tm -5ᵒC. (For the List 
of primers used for PCR see Appendix A). 
2.4.5 Polymerase chain reaction (PCR) 
 PCR relies on thermal cycling which involves many cycles of repeated heating and cooling 
allowing for DNA melting, primer annealing and polymerase enzymatic replication of the DNA 
templates. Primers are explicitly designed to target genes of interest allowing selective 
amplification of the target DNA. During the reaction, the DNA generated from earlier cycles 
can act as a target itself allowing the DNA to be exponentially amplified. Taq polymerase is the 
DNA polymerase enzyme that was used in the PCR reaction to amplify short segments of DNA.  
For PCR reactions, 1 μl of cDNA (40ng) was added to each reaction tube along with 20 μl of 
PCR master mix which contained (per tube): 10 μl 2x go-Taq green master mix (Taq DNA 
Polymerase, 1.6mM dNTPs, 3mM MgCl2 and reaction Buffers), 6 μl dH2O, 2 μl of 10pmol/μl 
of up and downstream primers. PCR procedures were optimised for each set of primers. The 
standard PCR procedure was as follows:  
Initial denaturation            95°C                                      1 minute  
Then 30-35 cycles of:      
Denature                           95°C                                        1 minute  
Anneal                             depends on primer design        1 minute    
Elongate                           73°C                                         1.5 minute  
Final elongation               73°C                                         8 minutes  
Hold                                 4°C  
PCR products were then visualised by running them out on an agarose gel (1- 2% dependent on 
amplicon size) and viewed under U.V light.  
2.4.6 Agarose gel electrophoresis 
Due to the presence of sugar-phosphate in the backbone of the DNA, the DNA is negatively 
charged. When DNA fragments are placed within an electric field, they migrate towards the 





positive electrode. All DNA migrates towards the anode; however, larger nucleic acid 
fragments migrate slower through the polymerised agarose gel. Agarose gel electrophoresis was 
used to separate DNA fragments by size. To resolve  DNA fragments greater than 400bp, a 1% 
agarose gel was used, whereas for amplicons smaller than 400bp, a 2% agarose gel was used.  
The gels were prepared by dissolving (1-2% (w/v) agarose powder in TAE (40mM Tris, 20mM 
acetic acid, 1mM EDTA) by means of heating and allowed to cool enough to hold before 5μg/ml 
ethidium bromide was added. Ethidium bromide is a nucleic acid inserting agent; upon exposure 
to UV light it fluoresces and allows nucleic acid samples to be visualised. Gels were then cast 
in a casting stand and a comb added to form wells. Subsequently, this was then left to set before 
electrophoresis. Once set, the gel was placed into the gel tank which was filled with 1 x TAE 
buffer and 10 μl of the reaction was loaded into an agarose gel alongside 100bp or 1Kbp DNA 
ladder (New England Biolabs). Agarose gels were run for approximately 45-60 minutes at 90 
volts. Once amplicons were resolved, they were imaged using a G: BOX transilluminator and 
bundled software. 
2.4.7 Total RNA isolation for qRT-PCR 
For qRT-PCR, High Pure RNA Isolation Kits were used (Roche), which included treatment of 
RNA with DNase, according to the supplier's instructions. Prior to running the TaqMan Gene 
Expression Assays, total RNAs were isolated to be used as a template for synthesis of single-
stranded cDNA. Working solutions were prepared as directed in the producer’s manual. Cells 
were suspended in 200 µl PBS and 400 µl Lysis/-Binding Buffer (4.5 M guanidine-HCl, 50 
mM Tris- HCl, 30% Triton X-100 (w/v), pH 6.6) was added and vortexed for 15 seconds and 
the entire sample was pipetted into the upper reservoir of a filter tube and centrifuged for 15 
seconds at 8,000 × g. Afterwards, the flowthrough liquid was discarded and 90 µl DNase 
incubation buffer (1 M NaCl, 20 mM Tris-HCl and 10 mM MnCl2, pH 7.0) per sample was 
pipetted and added to 10 µl DNase. Next, the solution was mixed, pipetted on the upper 
reservoir of the filter tube and incubated for 15 mins at +15 to +25° C. 500 µl Wash Buffer I (5 
M guanidine hydrochloride and 20 mM Tris-HCl, pH 6.6 (25° C); final concentrations after 
addition of 20 ml absolute ethanol was added to the upper reservoir of the filter tube and 
centrifuged 15 seconds at 8,000 × g. The flowthrough was discarded, the filter tube was 
combined with the collection tube and 500 µl Wash Buffer II (20 mM NaCl, 2 mM Tris-HCl, 
pH 7.5 (25°C) was poured into the upper reservoir of the assembly of the filter tube and 
centrifuged for 15 seconds at 8,000 × g. Subsequently, 200 µl of wash buffer II was then added 
to the upper reservoir of the filter tube assembly and centrifuged for 2 min at maximum speed 





(approx. 13,000 × g) to remove any residual wash buffer. The filter tube was then inserted into 
a clean, sterile 1.5 ml microcentrifuge tube to elute the RNA: Next, 50 µl of elution buffer was 
dispensed to the upper reservoir of the filter tube and centrifuged for 1 min at 8,000 × g. The 
eluted RNA was directly quantified, as previously described in 2.4.2 and used either in RT or 
at –80°C for later analysis. 
2.4.8  qRT-PCR protocol 
The relative expression of the genes of concern was compared between samples using TaqMan 
Gene Expression Assays for quantitative analysis. qRT-PCR works in a similar manner to 
standard PCR by amplifying sequences of interest though it was using TaqMan Universal PCR 
Master Mix (The mix contains Taq DNA Polymerase, reaction buffer, dNTP mix with dUTP 
instead of dTTP). Likewise, a gene-specific primer and probe mixture (predeveloped TaqMan 
Gene Expression Assays), contains two unlabelled primers (1✕ final concentration is 900 nM 
per primer; 20✕ stock concentration is 18 μM per primer). The TaqMan® MGB probe (1✕ 
final concentration is 250 nM; 20✕ stock concentration is 5 μM). TaqMan® MGB probes 
contain a reporter dye (6-FAMTM) linked to the 5′end of the probe, a minor groove binder 
(MGB) at the 3 ́ end of the probe in addition to a nonfluorescent quencher (NFQ) Figure 2.4 
The assay process (Steps 1 to 4 in Figure 2.4) occurs in every cycle during PCR amplification. 
The system depends upon the transfer of fluorescent energy between a reporter and a quencher. 
The TaqMan Minor-groove binding (MGB) oligonucleotide probe is covalently bonded to a 
fluorescent reporter. The TaqMan - (MGB) probe anneals specifically to a complementary 
sequence between the forward and reverse primer sites (Step 1). In these probes, a moiety that 
binds to the minor groove of dsDNA is covalently bonded to the 3' end of the probe, in addition 
to the quencher, providing increased stability for the probe-template duplex and increasing the 
annealing temperature. When the probe is intact (Steps 1 and  2), the closeness of the reporter 
dye to the quencher dye results in repression of the reporter fluorescence. As the DNA 
polymerase extends the template from the primer in a 5' to 3' direction, it cleaves only probes 
that are hybridised to the target (Step 3). The cleavage of the reporter dye from the quencher 
dye results in increased fluorescence by the reporter. The increase in fluorescence occurs if the 
target sequence is complementary only to the probe and is amplified during PCR. The 
fluorescence from the reporter dye is directly proportional to the number of amplicons 
generated. The polymerisation of the strand continues, however because the 3` end of the probe 
is blocked, no extension of the probe occurs during PCR (step 4).  





The TaqMan Gene Expression Assays applied are targeting the following human transcripts 
(OCT4, Hs04260367_gH; SOX2, Hs01053049_s1; SOX17, Hs00751752_s1; HEX, 
Hs00242160_m1; FOXA2, Hs00232764_m1; HNF4α, Hs00230853_m1; AFP, 
Hs01040598_m1; CYP1A2, Hs00167927_m1; CYP3A4, Hs00604506_m1; CYP3A7, 
Hs02511627_s1; CPS1, Hs00157048_m1; Albumin, Hs00609411_m1). The probe fluoresces 
once bound to double-stranded DNA (dsDNA). By the end of each cycle, the level of 
fluorescence is determined and used to calculate the amount of dsDNA present, thus allowing 
the amount of transcript of the target gene to be determined, relative to other samples. In a final 
volume of 20 µl the quantitative real-time PCR (qPCR) reaction mix was prepared by mixing 
TE buffer (0.5 µl), PCR grade water (7 µl), Taq man master mix (10 µl), TaqMan gene 
expression assay (0.5 µl) and 2 µl of 5ng/µ of each cDNA sample per well in an optical 96 well 
reaction plate. Each reaction was repeated in triplicate. The plates were sealed using optical 
film, vortexed gently and centrifuged at 250 g to collect the reaction mixture at the bottom of 
each well. Afterwards, the DNA was amplified using an Applied Biosystems 7500 Fast 
Thermocycler using standard ramp rate and the following Thermal cycling conditions: 














Transcript levels between treatments were determined using the comparative ΔΔCt method by 
normalising to 18S ribosomal RNA (18S rRNA)) as housekeeping control to account for any 
variations in the RNA template between samples. For more reliable results it would be better 










Figure 2.4 Schematic illustrations of TaqMan PCR.  (Step 1) During polymerisation, the 
TaqMan probe containing a reporter dye (R) and a quencher dye (Q) specifically anneals to one 
strand of the DNA template between forward and reverse PCR primers. (Step 2) During 
amplification, the fluorogenic probe is displaced by Taq polymerase; (Step 3) and then cleaved, 
releasing the reporter dye; (Step 4) after cleavage, the shortened probe dissociates from the 
template allowing polymerisation of the strand to complete. Fluorescence is relative to the 
amount of amplification product accumulated Adapted from Medhurst 2000 319






2.5 Protein isolation, quantification and analysis  
2.5.1 Tissue lysate preparation  
Rat liver tissue was snap frozen in liquid nitrogen then stored at -80°C until required. When 
needed, it was thawed on ice and rinsed in PBS to remove any blood. The tissue was then 
homogenised in 20mM Tris (pH 7.5). Protein concentration was then quantified by Lowry assay 
described in 2.5.3 and stored until required at -80°C. 
2.5.2 Preparation of cell lysate  
Cultured cells were washed twice in 1x PBS then scraped into 1ml (per well of 6 well plates) 
of PBS. The samples were then transferred to a clean Eppendorf tube and centrifuged 13,000 
rpm for 10 minutes and the pellet re-suspended in a known volume of 20mM Tris (pH 7.5). 
Samples were then quantified by Lowry assay (2.5.3), aliquoted and frozen at -80°C until 
needed.  
2.5.3 Lowry protein assay 
The Lowry assay was performed to determine protein concentration 320. The mechanism is that 
under alkaline conditions, copper reacts with peptide bonds. The addition of Folin-Ciocalteu 
reagent (FCR) produces a blue colour. The intensity of the colour is relative to the amount of 
protein present at 750 nm. With the use of protein standards, the concentration of protein in 
samples can therefore be easily calculated. Assay buffers were prepared fresh each time. Buffer 
ABC was made up as follows: Lowry A (2% (w/v) Na2CO3 and 4% (w/v) NaOH), Lowry B 
(2% (w/v) sodium tartrate) and Lowry C (1% (w/v) CuSO4) were combined at a ratio of 100:1:1 
(v:v:v). Folin’s reagent (Fluca, Switzerland) was diluted 1:1 in distilled water prior to use. BSA 
was used as the protein standard and was made up in 20mM Tris (pH 7.5) in concentrations 
ranging from 0-20mg/ml from a 20mg/ml stock diluted into dH2O. Then, 5 μl of each standard 
and sample was diluted with 50 μl of dH2O and 1 ml of ABC buffer. The diluted samples were 
briefly vortexed and left at room temperature for 10 minutes. Subsequently, 100 μl of diluted 
Folin’s reagent was added to each sample, mixed and incubated for 30 minutes. The samples 
were then transferred to 1 cm plastic cuvettes, and the absorbance at 750 nm was determined 
for each sample by a spectrophotometer. OD750 was measured using the 0mg/ml standard to 
blank. The OD750 of the standards was plotted against the concentration and used to calculate 
the protein concentrations of samples using the equation y = mχ + c.  





2.5.4 Sodium-dodecyl sulphate polyacrylamide gel electrophoresis (SDS- PAGE)  
In 1970, Laemmli first described the use of the SDS-PAGE method to separate proteins by their 
molecular weight 321. The proteins are initially denatured to polypeptide chains by heating in 
the presence of SDS and the reducing agent DL-dithiothreitol (DTT) which breaks any 
disulphide bonds in the secondary, tertiary and quaternary structure. Sodium-dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) depends on utilising sodium SDS which is an 
anionic detergent. When an electric difference is applied to SDS bound polypeptides, they 
migrate towards the anode (due to the binding of negatively charged SDS) via the 
polyacrylamide gel at a rate proportional to their molecular weight, which allows for separation 
of proteins in a solution.  
Regarding the SDS-PAGE, gels were cast between two glass plates held together with clamps 
and sealed at the bottom. Resolving gels (9%) were composed of 9% bis-acrylamide, 375mM 
Tris-HCl (pH 8.8), 0.1% (w/v) SDS, 0.05% (w/v) ammonium persulphate and 0.05% (v/v) 
tetramethylethylenediamine (TEMED). The ammonium persulphate and TEMED were added 
last as they catalyse the polymerisation of the acrylamide. After pouring the resolving gel, 100 
μl of isopropanol was layered on top to eliminate air bubbles and to produce a straight edge 
between the separating and stacking gel. Once set (within 1 hour), the isopropanol was washed 
off with distilled water. The stacking gel consisted of 4% acrylamide/bis (w/v), 125mM Tris 
(pH 6.8), 0.1% (w/v) SDS, 0.1% (w/v) ammonium persulphate and 0.1% (w/v). TEMED was 
immediately poured over the resolving gel and a comb inserted into the polymerising gel to 
form wells. Once set, the glass plates were unclamped and either stored in electrode running 
buffer (25mM Tris, 0.1% (w/v) SDS and 192mM glycine, pH 8.3) at 4°C for 2-3 days or placed 
in a gel tank filled with electrode running buffer for immediate use.  
2.5.5 Sample preparation for gel electrophoresis  
To prepare the protein samples for SDS-PAGE gel electrophoresis. They were diluted to 1- 
2μg/μl in reducing loading buffer (62.5mM Tris buffer pH 6.8, 10% v/v glycerol, 2% w/v SDS, 
100mM DTT and 0.02% w/v bromophenol blue and denatured by heating to 95°C for 5 minutes. 
Typically 20 μg of protein was loaded per well alongside a ladder containing coloured proteins 
of known molecular weights (ColorBurst Electrophoresis Marker, molecular weight 8-
220kDa). Electrophoresis was run at 100V until the migrating front reached the 
stacking/resolving interface at which point the voltage was increased to 160V. Once the samples 
had passed through the entire length of the gel, the proteins were transferred to nitrocellulose 
for Western blotting (described in 2.5.6).  





2.5.6 Western blotting  
Western blotting is the process of specific proteins detection utilising SDS-PAGE and 
immunodetection. After the protein samples have been separated by electrophoresis, filter paper 
and nitrocellulose membrane (Thermo-Scientific) were cut to the same gel size and dipped in 
pre-chilled transfer buffer (25mM Tris, 192mM glycine and 20% (v/v) methanol, pH 8.3). Then,  
the plates were removed, and the gel transferred to the nitrocellulose membrane. The gel and 
nitrocellulose membrane was sandwiched between filter paper and a scrubbing pad on both 
sides in a transfer cassette, placing the nitrocellulose membrane close to the anode. The cassette 
was placed in a tank filled with pre-chilled transfer buffer and an ice block. The transfer was 
run for 2 hours at 100V. Once the transfer had occurred, nitrocellulose membranes were washed 
twice with 1 xTBS-T ( 0.2M NaCl, 20mM Tris, and 0.05% v/v Tween 20, pH7.4) to remove 
any excess methanol. The membranes were then blocked in 3% (w/v) skimmed milk powder in 
TBS-T for 1 hour at room temperature or 16 hours at 4°C to block non-specific antibody 
binding. After blocking, the membranes were washed 3x 5 mins each in TBS-T, before 
immunodetection. The nitrocellulose membranes were then incubated in primary antibody 
(diluted in 0.3% (w/v) skimmed milk powder in TBS-T, (see Table 2.1 for dilutions) for 1 hour 
at room temperature or 16 hours at 4°C. After primary incubation, nitrocellulose membranes 
were washed 3x 5 mins in a 1xTBS-T buffer followed by incubation with the appropriate 
species-specific horseradish peroxidase (HRP) -conjugated secondary antibody diluted in 0.3% 
(w/v) skimmed milk powder in TBS-T before the nitrocellulose membrane was rewashed as 
before.  
To detect the proteins of interest, enhanced chemical luminescence reagents ECL (Thermo-
scientific) was used. 1 ml of reagents 1 and 2 were mixed and added to the membrane and left 
for 30 seconds. ECL is a chemiluminescent able to bind to the HRP conjugated on the secondary 
antibody allowing detection of proteins. The membrane was then blotted with tissue paper to 
remove excess ECL and wrapped in saran wrap in a film cassette. CL-Xposure films (Thermo 
scientific) were exposed to the nitrocellulose membrane in a dark room at different times 
(dependent on antibodies used), then developed using an automated developer (RP X-OMAT, 
Kodak, Hertfordshire, UK). Following development, the position of the ladder proteins was 
marked on the film. Nitrocellulose membranes in some cases were re-probed for an additional 
protein. After the initial probing, membranes were stripped by washing for 1 hour at room 
temperature in TBS-T, changing the TBS-T every 10 minutes. The membranes were then 
blocked and probed again as before. 





2.5.7 Fluorescence immunocytochemistry  
Cells cultured either in 6 well plates or in the NUNC® chamber were washed twice in PBS then 
permeabilised with 2 ml of ice-cold absolute methanol at 4°C for 10 minutes. The methanol 
was then aspirated, and the cells washed twice with PBS before fixation in 2 ml of fixative 
solution (0.2% (v/v) glutaraldehyde and 2% (v/v) formaldehyde in PBS, pH 7.4). After 15 
minutes at room temperature, the cells were incubated with 5% (v/v) FCS in PBS for 10 minutes 
to block non-specific binding of antibodies. After washing twice in 10mLs of PBS, the cells 
were incubated with the primary antibody diluted in PBS (see Table 2.1 for antibody details 
and dilutions) for 1 hour at RT followed by extensive washing in PBS, which was followed by 
incubation with the suitable secondary antibody at room temperature for 20-30 minutes.  
Secondary antibodies incubation was conducted in the dark, i.e., slides were covered in foil). 
Replicate wells stained identically except for incubation with no primary antibody were 
routinely included to determine the background level of fluorescence (no 1o Ab control). After 
extensive washing in PBS, the cells were incubated with the DNA intercalator 4',6-diamidino-
2-phenylindole (DAPI, 6μg/ml in PBS) for 20 minutes to identify cell nuclei. The cells were 
washed three times with PBS before and stored in 5 ml of PBS at 4°C in the dark before 
visualisation. For double staining, the cells were stained sequentially. They were reblocked with  
5% (v/v) FCS in PBS for 10 minutes and washed twice in 10mLs of PBS. This was followed 
by incubation for 1 hour with a second primary antibody diluted in PBS.  
The second primary antibody was raised in a species different from that of the first primary 
antibody (i.e., the first primary antibody was raised in a rabbit and the second primary antibody 
was raised in a mouse). This was followed by washing in PBS and incubation at room 
temperature for 20-30 minutes with a second secondary antibody conjugated with a fluorophore 
label that has a different colour from that of first secondary antibody (i.e. the first secondary 
antibody was anti rabbit IgG- fluorescein isothiocyanate (FITC) conjugated (green) and the 
second secondary antibody was anti-mouse IgG- Alexa  fluor 568 conjugated (red). This was 
subsequently followed by rinsing in PBS-and counterstaining with DAPI for 20 minutes at room 
temperature. Finally, chambers were removed from the slides before coverslips were mounted 














Dilution Comments and source 
                                                        Primary antibodies 
 
AFP n/a 1:100 ICC  
Mouse monoclonal IgG to alpha 1 Fetoprotein 
(ab3980) 
Albumin 60 1:3000 WB Rabbit polyclonal IgG from ICN (0855715). 
Albumin n/a 1:100 ICC Mouse monoclonal anti albumin (sc-271605) 
 
β-actin 44 1:3000 
WB 









 Rabbit polyclonal IgG Cytochrome P4502E1, Abcam 
(28146) 
 
CPS-1 160 WB 1:2000 
ICC 1:100 
Rabbit polyclonal IgG to CPS1 (ab3682) 
 
Cytokeratin 19 n/a 1:100 ICC Rabbit polyclonal IgG to Cytokeratin 19 (ab484632) 
 




95 1:1000 WB Mouse monoclonal to beta Catenin phosphorylated at 
serine 33 and 37, Abcam (ab11350) 
 







Dilution Comments and source 
DDDDK tag   48.9 1:2000 WB 
1:200 ICC 
Anti-DDDDK tag mouse antibody, Abcam (ab72469)  
 
SGK 55 1:1000 WB 
1:200 ICC 
 
SGK mouse Ab (sc-377360) 
                                                        Secondary antibodies 
Anti-rabbit 
IgG 
n/a 1:3000 WB 
 




n/a 1:3000 WB 
 




n/a 1:3000 ICC 
 




n/a 1:3000 ICC 
 
TRITC  conjugated rabbit Anti-Mouse IgG (whole 
molecule) -  SIGMA T2402 




2.6 SGK1 activity assay 
2.6.1 Buffer preparation 
1.    5X Reaction Buffer A: 200mM Tris [pH 7.5], 100mM MgCl2 and 0.5mg/ml BSA  
2.    4X Kinase Buffer: 4X Reaction Buffer A + 200μM DTT  =2µl/ml)  
3.    4X Kinase Buffer D: by adding 4% DMSO  
4.    1X Kinase Buffer: by diluting the 4X Kinase Buffer  





5.    1X Kinase Buffer D: by diluting 4X Kinase Buffer D 
6.    1X Kinase Buffer (5% DMSO): by diluting the 4XKinase Buffer and adding 5% DMSO 
2.6.2 SGK1 assay protocol 
The ADP-Glo Kinase Assay is a luminescent kinase assay which determines the amount of 
adenosine diphosphate (ADP) produced by a kinase reaction; ADP is changed into adenosine 
triphosphate (ATP), which is changed into light by Ultra-Glo Luciferase. The luminescent 
signal positively relates to kinase activity. 500ng/ml of cells lysate were prepared. Next, 20 µl 
kinase solution was made by mixing 13.33µl of (500ng/ml) of cells lysate, 5 µl kinase buffer D 
(4X Reaction Buffer A + 200μM DTT ) and 1.67 µl of H20 per samples. Additionally, the 
substrate mix was prepared by mixing 4X Kinase Buffer D, 100μM ATP (the 10x used to create 
the standard curve) and AKT Substrate (1mg/ml) in ratio 1:1:2. A kinase reaction was 
performed by adding 14 µl of 2.5X ATP/Substrate Mix into 20 µl of kinase solution, mixed for 
two mins and incubated for 40 minutes at room temperature. After the kinase reaction was 
completed, an equal volume of ADP-Glo Reagent was added and incubated for 40 minutes to 
terminate the kinase reaction and deplete the remaining ATP. Second, the kinase detection 
reagent was added and incubated for 30 to 60 minutes at room temperature to simultaneously 
convert ADP to ATP and allow the newly synthesised ATP to be measured using a 
luciferase/luciferin reaction Figure 2.5. The generated light was measured using a luminometer. 
The luminescence was correlated to ADP concentrations by using an ATP-to-ADP standard 
curve. The samples used to generate an ATP-to-ADP standard were created by combining the 
appropriate volumes of ATP and ADP stock solutions (Table 2.2). Making a standard curve 
that represents the luminescence corresponding to the conversion of ATP to ADP based on the 
ATP concentrations used in the kinase reaction.
 
%ADP    100      80 60      40 20 10 5 4 3 2 1 0 
%ATP      0 20 40 60 80 90 95 96 97 98 99 100 
Table 2.2 Percent Conversion of ATP to ADP Represented by the Standard Curve 






Figure 2.5 The ADP-Glo assay principle.  The assay comprised two steps. The first step (after 
the kinase or ATPase reaction) is the addition of the ADP-Glo™ reagent which ends the kinase 
reaction and depletes any remaining ATP (40-minute incubation time). The second step adds 
the kinase detection reagent which converts ADP to ATP and generates light from the newly 
synthesised ATP using a luciferase-luciferin reaction, is 30–60 minutes incubation time 
according to the ATP concentration used in the kinase reaction). The light produced is 
proportional to existing ADP and, consequently, kinase or ATPase activity 322.
 
2.7 Differentiation of IPSCs (AD3 cells) into hepatocyte-like cells. 
2.7.1 Reagent set up  
All media and reagents were purchased from Gibco unless stated 
CDM-PVA medium  
Chemically defined medium: Poly Vinyl Alcohol (CDM-PVA) medium was prepared for 
maintenance of human induced pluripotent stem cells and differentiation to endoderm. For 500 
ml, 0.5 grams of Poly Vinyl Alcohol (PVA) (Sigma) was dissolved in 5 ml of sterilised distilled 
water by gradual heating in a water bath till 90ºC  and mixed with 245 ml of Iscove’s Modified 
Dulbecco’s Medium (IMDM). This was then sterilised using 0.22 µm filtration device and 
added to 250 ml of DMEM-F12 before adding 5mL Concentrated lipids 20 μL Thioglycerol 
(Santa Cruz), 350 μL Insulin, (Roche) 250μL Transferrin(Roche), 100units/ml penicillin, 
100μg/ml streptomycin (Sigma). The medium was stored in 4ºC to be used up to four weeks 
after preparation and should to be warmed to 37 °C before use. For maintenance of hPSCs, 
10ng/ml  of recombinant Human/Mouse/Rat Activin A Protein(Activin A) (R&D systems), 
10ng/ml recombinant Human FGF basic Protein (bFGF) (R&D system) was freshly prepared 





by adding 1 µl of 100µg/ml stock per 10ml of CDM-PVA medium. For cell differentiation to 
endoderm CDM-PVA media was freshly prepared by mixing 10 ml of CDM-PVA media with 
10 µl of 100µg/ml stock Activin A (100ng/ml), 10 µl of 100µg/ml stock bFGF (100ng/ml), 1 
µl of 100µg/ml stock of recombinant Human Protein BMP4 (ThermoFisher Scientific) 
(10ng/ml), 2 µl LY294002 of (Promega) 50mM stock solution (10µM) and 7 µl of 4.29793mM 
CHIR99021(Sigma) (3µM) 
RPMI-B27  
Roswell Park Memorial Institute (RPMI) 1640 Medium supplemented with B27 (RPMI-B27) 
was prepared for differentiation of ADE and hepatoblast specification. For 500 ml of RPMI, 
B27 supplement was freshly prepared by mixing 0.05 mg Vitamin A acetate (sigma) (0.1mg/L), 
0.2125 g bovine serum albumin (BSA) (based on serum albumin concs of 0.35-0.5g/L), 5 ml 
ITS supplement (1:100 dilution) that consists of 1.0 mg/ml recombinant human insulin, 0.55 
mg/ml human transferrin and 0.5 μg/ml sodium selenite at the 100x concentration, 450 mg D-
galactose(Sigma) (900mg/L), 0.95 mg Ethanolamine HCl (1.9mg/L), 3.95 ml of L-Cartinine 
HCl (2mM) (Sigma), 5 ml concentrated lipids (1:100 dilution) which is a concentrated lipid 
emulsion formulated to substitute foetal bovine serum in cell culture, 0.04 mg Putrescine 2HCl 
(0.08mg/L) (Sigma), 5 µl of 10mM Triiodothyronine (T3) and 5 mg reduced glutathione 
(10mg/L).  
Subsequently, B27 supplement was added to 490 ml RPMI 1640 in addition to 5 ml Non-
Essential Amino Acids (NEAA) which were supplemented for cell culture medium to increase 
cell growth and viability. NEAA is constituted of 10mM glycine, 10mM L-alanine, 10mM L-
asparagine, 10mM L-aspartic acid, 10mM L-glutamic acid, 10mM L-proline and 10mM L-
serine. Additionally, 100units/ml of penicillin and100μg/ml streptomycin were also added to 
RPMI-B27. The medium was stored at 4 °C for up to 3 weeks and warmed up to 37 °C before 
use. For differentiation to Anterior Definitive Endoderm (ADE), RPMI-B27 + Activin A was 
freshly prepared by mixing 10 ml of RPMI-B27 with 5 µl of 100µg/ml stock of Activin A 
(50ng/ml). For hepatoblast specification, RPMI-B27 + BMP4 and FGF10 was freshly prepared 
by adding 1 µl of 100µg/ml stock of BMP4 (20ng/ml) and 0.5 µl of 100µg/ml stock of FGF10 
(ThermoFisher Scientific) (10ng/ml)







Hepatocyte Basal Medium (HBM) from Lonza (CC-3199 was used for maturation of 
hepatoblast into hepatocyte-like cells. 100units/ml penicillin, 100μg/ml streptomycin was 
added to 500 ml of HBM and per 10ml of HBM, 3 µl of 100µg/ml stock of recombinant human 
OSM (PEPROTECH), (30ng/ml) and 5 µl of 100µg/ml stock of  HGF (PEPROTECH) 50ng/ml 
were added when required. 
2.7.2 The procedure for AD3 cells differentiation toward hepatocyte-like cells 
Upon receiving iPSCs ad3 cells, cells were cultured with freshly prepared CDM-PVA with 
100ng/ml Activin A and 100ng/ml b FGF. After 24 hours, the cells were washed with calcium-
and magnesium-free PBS (137 mM NaCl, 27 mM KCl and 100 mM phosphate pH 7.4). The 
cells were then treated with freshly prepared CDM-PVA media containing 100ng/mL activin-
A, 100ng/mL FGF2, 10ng/mL bone morphogenetic protein 4 (BMP4), 10µM LY294002 and 
3μM CHIR99021 for 24 hours. This was followed by freshly prepared CDM-PVA with 
100ng/mL activin-A, 100ng FGF2, 10ng/mL BMP-4 and 10µM LY294002 for 24 hours to 
produce a culture enriched for definitive endodermal cells (DE) 52 (DEF ENDODERM d3). DE 
cells represent the earliest precursors for all endodermal organs. The culture medium was then 
changed to RPMI-B27 medium containing 100ng/mL activin-A and 100ng/mL FGF2 to 
promote the formation of anterior definitive endodermal cells 52.  
From days five to seven, cells were treated daily with RPMI-B27 differentiation medium with 
Activin-A (50 ng/ml). At this time ADE specification takes place (ANT DEF ENDODERM 
d8). ). These cells represent a common progenitor between the liver, pancreas, lung and thyroid. 
At day 8, hepatic differentiation was induced by replacing the medium with RPMI-B27 
differentiation medium containing 20ng/mL BMP4 and 10ng/mL fibroblast growth factor 
(FGF10). The medium was changed daily for the subsequent four days leading to cell cultures 
enriched with hepatoblasts (HEPATOBLASTS d12). Formation of hepatocyte-like cells was 
subsequently promoted by culturing hepatoblasts in basal hepatocyte medium (Lonza CC-3199) 
containing 30ng/Ml OSM and 50ng/mL HGF. The medium was changed every two days 
(HEPATOCYTE-LIKE dX). 





2.8 Image analysis  
Cells were viewed using an OPTIKA bright-field microscope and imaged with a BUC2 Camera 
connected to a TOSHIBA computer set up with ScopeImage 9.0 software. Fluorescently stained 
cells were imaged using either a Zeiss fluorescence (Cambridge, UK) or a Nikon SP2 laser scanning 
confocal (Kingston-upon-Thames, UK) microscope. AdV-GFP infected cells were imaged by 
confocal microscope (Leica). The cells were counted using ImageJ. Percentage of the GFP 
fluorescence cells determined. The threshold for positive staining was specified and kept constant 
for each batch of stained slides. 
2.9 Statistics  
Data in this project were analysed using SPSS statistical software version 19 (IBM, Armonk, NY, 
USA). To determine the statistically significant differences between groups, the mean values of the 
groups were analysed using one way ANOVA and the Student’s 2-tailed t-test. Despite the 
hypothesis test used, significance was achieved where p<0.05. 




 Investigating the role of SGK1 in B-13 trans-differentiation to B-
13/H cells 
3.1 Introduction 
The B-13 pancreatic cell line is a progenitor cell line with a unique capacity to generate 
hepatocyte-like (B-13/H) cells after exposure to glucocorticoid hormone alone 198,200. The 
mechanism(s) controlling the conversion/trans-differentiation of B-13 cells to B-13/H cells 
could therefore be used to stimulate/maintain differentiated phenotype in stem cell-derived 
specialised cells. 
In the Tg (Crh) mouse model of Cushing's disease, which produces a prevalent expression of 
hepatocyte-specific gene expression in the acinar pancreas by 21 weeks of age, Sgk1c was 
induced from undetectable levels in the pancreas 226,231. A further study in 2013, demonstrated 
that the human pancreas contained hepatocyte levels of hepatocytes marker genes after long-
term systemic treatment with glucocorticoid and culturing human acinar cells with 
glucocorticoid also results in expression of hepatocyte-specific genes. These modifications 
were associated with an induction in the expression of the SGK1F variant 227. Moreover, a 
previous study identified that Sgk1 is significantly upregulated in B-13 cells when treated with 
glucocorticoid, most noticeably an alternatively transcribed variant c. Transfecting B-13 cells 
with expression vectors encoding the different human SGK1 variants demonstrated that SGK1C 
and the human-specific F variant converted B-13 cells into hepatocytes without glucocorticoid 
treatment. In addition, kinase-dead (KD) mutant SGK1C and SGK1F proteins failed to induce 
expression of CYP2E1 or albumin in contrast to the wild-type equivalents.  
All these findings suggest that the kinase function of SGK1C and F isoforms are essential for 
promoting the trans-differentiation of B-13 cells to B-13/H cells 226. Thus, expression of SGK1 
was considered as a potential future route to promoting the maturation of human iPSC-derived 
hepatocytes. An adenoviral vector system was selected given that liver cells are readily infected 
by adenovirus and the human SGK1F cDNA sequence was chosen because i) the intention was 
to work with human iPSCs and it encodes a human-specific sequence; ii) previous data 
suggested it functioned in B-13 cells, which were to be used to test functionality prior to moving 
into limited iPSCs resources and iii) avoid the use of SGK1C ensured that any complications 
with endogenous Sgk1c could be avoided (i.e., it would be evident that any influence on the B-
13 cells was associated with ectopic gene expression).  




3.2  DEX induced the conversion of B-13 into B-13/H and SGK1 induction 
B-13 cells have been observed to transdifferentiate from a pancreatic exocrine-like cell to an 
hepatocyte-like-cell (B13/H cells) in response to DEX treatment323.To examine the effect of 
DEX on the conversion of B-13 cells into B-13/H cells and the induction of SGK1, B-13 cells 
were treated with 10 nM DEX for 14 days. Changes in cells morphology were readily observed. 
The size of DEX treated B-13 cells increased and their shape changed from round spherical to 
a flattened polygonal shape indicating the change in cells phenotype (Figure 3.1).To confirm 
the trans-differentiation of the cells into hepatic phenotype, fluorescence immuno-cytochemical 
staining was used to detect the expression of the hepatocyte-specific genes, such as carbamoyl 
phosphate synthase (CpsI) cytochrome P450 (Cyp2e1) and Albumin 324.Figure 3.2 illustrates 
the marked expression of Cps1 and moderate to low expression of Cyp2e1 and Albumin 
proteins respectively. Moreover, using the standard glucocorticoid-dependent differentiation 
protocol (14 days treatment with 10nM DEX, fluorescence immunocytochemistry results 
demonstrated expression of both CpsI and Sgk1 in B-13/H cells, with higher punctate staining 
(likely due to the mitochondrial localization of CpsI) correlating with cells expressing the 
highest levels of Sgk1 protein (Figure 3.3). 
 
Figure 3.1 10 nM DEX induced morphological alterations of B-13 cells into B-13/H cells 
phenotype. B-13 cells treated with 10nMDEX for 14 days. A Photomicrograph of B-13 cells 









Figure 3.2  10 nM DEX induced the conversion of B-13 into B-13/H. B-13 cells were treated 
with 10nM DEX for 14 days (to generate B-13/H cells) and cells fixed. The detection of 
hepatocyte markers for indicated protein expression (green) determined by 
immunocytochemistry with DAPI (blue) for identification of nuclei (upper panel). Percentage 
of B-13/H cells expressing Cps1, Cyp2e1 and albumin proteins were quantified (lower panel). 
Data are typical of 4 separate experiments. All images were taken under identical spectral 
conditions and processed identically. 
 





Figure 3.3  10 nM DEX induced the conversion of B-13 into B-13/H and SGK1 induction. 
Confocal images of B-13/H cells produced via exposure to10nM DEX glucocorticoid and 
examined for the expression of CpsI and Sgk1. Data are typical of 4 separate experiments. All 




images were taken under identical spectral conditions and processed identically.Adenovirus 
efficiently infected B-13 cells but impacted on cell viability 
To increase the likelihood that a significant proportion of cells express SGK1F, an 
adenoviral vector system was employed and to optimise the efficiency of B-13 infection with 
the adenovirus, B-13 cells were infected AdV-GFP at different multiplicity of infections 
(MOIs). B-13 and B-13/H cells were infected with MOI 0, MOI 1, MOI 5, MOI 10 and 
incubated for 24 hours. Cells were imaged by fluorescence microscopy and infected cells 
identified by means of their expression of the fluorescent GFP protein. The mean percentage of 
GFP positive cells per random fields of view were calculated. As presented in Figure 3.4 A&B 
the rate of infection was proportional to the MOI and resulted in more than 80% of B-13 and 
B-13/H cells being infected with an adenovirus encoding green fluorescent protein (AdV-GFP) 
at an MOI of 15. Trypan blue viability test was conducted to assess the B-13 and B-13/H cells 
viability post 6 days of infection with different MOIs of AdV-GFP. The percentage of cells 
excluding trypan blue dye was high in control cells or cells infected with a low MOI of 1, 
though marked toxicity was observed at MOIs of 10 and 15 in B-13 cells and MOI 15 in B-
13/H cells as demonstrated in Figure 3.5 A & B. Therefore, an MOI of 1 was chosen to infect 
cells over an extended 14 day period, with repeated infection every 2 days. As judged by GFP 
expression, the infection at an MOI of 1 resulted in moderate (~20%) infection with minimal 
toxicity, repeated infection at an MOI of 1 was employed to maximise the proportion of cells 
infected, whilst reducing toxicity (Figure 3.6). This approach was successful for roughly 10 
days but typically, significant toxicity after this time was observed, which limited the scope for 
testing the effects of SGK1F expression. 
 
 






Figure 3.4 Infecting B-13 and B-13/H cells with AdV-GFP results in more than 80% 
infection and expression of GFP rate.  A, B-13 cells were infected with AdV-GFP at the 
indicated MOI. left panel: typical view of B-13 cells after 24 hours post infection as indicated. 
right panel: the mean percentage and SD of cells expressing GFP determined by fluorescence 
microscopy from 3 randomly selected views from the same experiment. B, B-13/H cells were 
infected with AdV-GFP at the indicated MOI. Left panel typical view of 14 days DEX treated 
B-13 cells (B-13/H) after 24 hours post infection as indicated. Right panel: mean and SD 
percentage GFP positive cells from 3 randomly selected fields of view from the same 
experiment. Data are the mean and SD of 3 determinations from the same experiment. Data 
typical of 3 separate experiments. *Significantly different infection (P < 0.05) from uninfected 
cells using one way ANOVA followed by a Tukey post hoc test. 
 
 






Figure 3.5 Infecting B-13 and B-13/H cells with AdV-GFP impacted on cell viability. B-13 
and B-13/H cells were infected with AdV-GFP at the indicated MOI :(A) Left panel: 
photomicrographs of B-13 cells infected or treated as indicated for 6 days and stained with 
trypan blue as a marker for cell viability (excludes dye); Right panel: trypan blue exclusion; 
data are the mean and SD of 3 determinations from the same experiment. (B) Left panel, 
photomicrographs of 14 days DEX treated B-13 cells (B-13/H) infected or treated as indicated 
for 6 days and stained with trypan blue as a marker for cell viability (excludes dye); right panel: 
trypan blue exclusion. Data are the mean and SD of 3 determinations from the same experiment. 
*Significantly different trypan blue exclusion (P <0.05) from uninfected cells using oneway 
ANOVA followed by a Tukey post hoc test. Data typical of 3 separate experiments. The arrows 
in the figures indicating the dead cells (trypan blue stained). 
 
 





Figure 3.6 Effect of repeated infection of B-13 cells with AdV-GFP at MOI 1 on the 
expression of GFP. B-13 cells were infected at an MOI of 1.0 as indicated by the arrows and 
the mean percentage and SD of cells expressing GFP determined by fluorescence microscopy 
from 3 randomly selected views. Data typical of 3 separate experiments. *Significantly different 
(P <0.05) from time zero uninfected cells using one way ANOVA followed by a Tukey post 





3.4 Infection of B-13 cells with AdV-SGK1F results in expression of SGK1 kinase activity 
To determine the functionality of SGK1F expressed in B-13 cells, B-13 cells were 
infected repeatedly at an MOI 1 with AdV-SGK1F for 14 days (in the absence of DEX). Cell 




lysates were made from day 0, 2, 4, 6 and 14 and 500ng/ml concentration of protein was 
prepared from each sample. After incubating the sample with 100 µMATP and 1mg/ml AKT 
substrate, SGK1 activity versus the times cultured with MO 1 of AdV-SGK1F was measured 
using the ADP-Glo Kinase Assay that measures ADP formed from a kinase reaction; ADP is 
converted into ATP, the levels of which are determined using light emitted by Ultra-Glo 
Luciferase. As can be seen from A, AdV-SGK1F infection resulted in detectable increases in 
Sgk1/SGK1F kinase activity. Employing fluorescence immunocytochemistry technique 
exhibited widespread increased expression of Sgk1/SGK1F in infected remaining viable cells 
(Figure 3.7B) and co-expression of CpsI with SGK1F-expressing cells (determined specifically 



















Figure 3.7 Expression of B-13-derived Sgk1 and AdV-SGK1F in B-13 cells. A: 
SGK1F/Sgk1 kinase activity in B-13 cells infected with AdV-SGK1F. Infection with AdV-
SGK1F results in an increase in SGK1 kinase activity. B-13 cells were repeatedly infected with 
AdV-SGK1F at an MOI of 1 and SGK1 kinase activity determined in cell extracts, as outlined 
in the methods section. Data are the mean and SD of 3 replicates from the same experiment, 
typical of 3 separate experiments. *Significantly different (P <0.05) from time zero uninfected 
cells using one way ANOVA followed by a Tukey post hoc test.  B: Immunocytochemical 
detection of SGK1 expression. B-13 cells were repeatedly infected with AdV-SGK1F at an 
MOI of 1, cells fixed and Sgk1/SGK1F expression (green) determined by 
immunocytochemistry with DAPI (blue) for identification of nuclei. Data typical of 3 separate 




experiments. All images were taken under identical spectral conditions and processed 
identically 
 
Figure 3.8 Immunocytochemical detection of CpsI and SGK1-F expression in B-13 cells. 
 B-13 cells were repeatedly infected with AdV-SGK1F using repeated infection at an MOI of 
1 for 14 days, cells fixed and the co expression of CpsI (green) and SGK1F tag (red) determined 
by immunocytochemistry with DAPI (blue) for identification of nuclei. Data typical of 3 
separate experiments. All images were taken under identical spectral conditions and processed 
identically. Panel labelled “arrow” is an expanded view of the cell identified by an arrow in 
the lower right hand panel.




3.5 Adenoviral-mediated expression of SGK1F induces the conversion of B-13 cells into 
B-13/H cells without the addition of glucocorticoid 
To examine the effect of SGK1F, B-13 cells were infected over 8 days with AdV-SGK1F (MOI 
of 5) or a control adenovirus (AdV-null) by employing the repeated infection strategy in B-13 
cells (in the absence of DEX) to maximise infection and SGK1F expression and minimise cell 
death, although this also resulted in a degree of cell death. B-13 cells were also separately 
treated with 10nM DEX with/without AdV-SGK1F.RT- PCR using primers designed for h-
SGK1F, Cyp2e1 and CpsI. Double bands can be seen in RT-PCR  for Cps1 Figure 3.9 which 
could be due to nonspecific bands formed by the primer-template DNA binding. This 
nonspecific binding of the primer could be eliminated by increasing the annealing temperature. 
The adoption of an hepatocyte-like phenotype by B-13 cells in response to AdV-SGK1F 
infection was confirmed by detection of liver-enriched and liver-specific gene transcripts 
Cyp2e1 and CpsI respectively, similar to cells treated with DEX for (Figure 3.11A). The 
observations were further confirmed by examining protein expression by Western blotting and 
immunocytochemistry. Western blot analysis demonstrated that the expression of the 
SGK1F/Sgk1 protein was higher in cells infected with AdV-SGK1F. In addition, albumin 
protein was expressed by B-13 cells infected with AdV-SGK1F. Expression was low compared 
to the expression by B-13 cells treated with a combination of DEX and AdV-SGK1F. Cps1 
protein was clearly expressed by B-13 cells treated with a combination of DEX and AdV-
SGK1F and barely detectable by B-13 cells infected with AdV-SGK1F. However, Cyp2e1 
protein was not detected by Western blot analysis yet was expressed by B-13 cells treated with 
a combination of DEX and AdV-SGK1F (Figure 3.10). B-13 cells were repeatedly infected 
with AdV-SGK1F (MOI of 5) for 10 days or treated with 10nM DEX for 14 days (to generate 
B-13/H cells) and cells fixed immunocytochemistry was performed to  determine liver marker 
protein expression using anti-rat Cyp2e1and anti-rat CpsI (Figure 3.11). There was readily 
detectable expression for CpsI in the majority of the cells and weak expression for Cyp2e1 
hepatic markers in B-13 cells infected with AdV-SGK1F. Infection with AdV-SGK1F also 
resulted in morphological alteration of B-13 cells from small round cells with low cytoplasm 
to nucleus ratio to hepatocyte-like cells with high cytoplasmic to nuclear ratio. This change in 
cell morphology resembles the change in B-13 cells in response to DEX treatment (Figure 3.12). 
 





Figure 3.9 Infecting B-13 cells with AdV-SGK1F leads to the expression of hepatic 
markers. 
 B-13 cells were repeatedly infected with the indicated AdV before total RNA was isolated at 
day 8 and transcript expression determined by RT-PCR, as outlined in the methods 
section. Gapdh was used as a housekeeping gene. Upper panel demonstrates the bands 
separated by gel electrophoresis, which quantified using ImageJ software in the lower panel. 




Data are typical of 3 separate experiments.
 
Figure 3.10 Infecting B-13 cells with AdV-SGK1F leads to the expression of hepatic 
markers.  Western blot analysis of protein expression. B-13 cells were repeatedly infected with 
the indicated AdV before indicated protein expression was determined by Western blotting at 
day 8. β-actin protein was used as loading control. Western blot results in the upper panel were 
quantified using ImageJ software in the lower panel. Data are typical of 3 separate experiments.  
 





Figure 3.11 Immunocytochemical detection of CpsI and Cyp2e1 expression in DEX 
treated B-13 cells and AdV-SGK1F infected cell.syle B-13 cells were repeatedly infected 
with AdV-SGK1F (MOI of 5) for 10 days or treated with 10nM DEX for 14 days (to generate 
B-13/H cells) and cells fixed and indicated protein expression (green) determined by 
immunocytochemistry with DAPI (blue) for identification of nuclei (upper panel). Percentage 
of cells expression of hepatocyte proteins in response to the indicated treatment was determined 
(lower panel). Data are the mean and SD of 3 replicates from the same experiment, typical of 3 
separate experiments. All images were taken under identical spectral conditions and processed 
identically. 
   





Figure 3.12 Morphology of B-13 cells after infection with AdV-SGK1F. Infecting B-13 cells 
with AdV-SGK1F leads to a morphological change into the B-13/H phenotype Light 
micrographs of B-13 cells infected with the indicated AdV (MOI of 5) or treated with 10nM 
DEX for 14 days (B-13/H cells). Ethanol vehicle-treated appears identical to AdV-null treated 
cells. Dotted squares demonstrate the area of cells magnified in the small squares.    
 
3.6 Sgk1 inhibitor and glucocorticoid receptor antagonist (Ru486) prevent the conversion 
of B-13 cells treated with 10nM DEX or AdV-SGK1F into B1-13/H   
To determine whether Sgk1 kinase activity is essential in B-13 conversion into B-13/H 
cells, B-13 cells were treated with 10nM DEX, 100nM GSK 650394 (an Sgk1 kinase inhibitor) 




and 10μM Ru486 (glucocorticoid receptor antagonist). RNA was isolated after 7 days and it 
was established that 100nM GSK 650394 prevented the morphological change observed in 
response to DEX and inhibited DEX-dependent expression of the liver marker gene Cyp2e1 
(Figure 3.13). Figure 3.14 compares the effect of B-13 cells infected with either AdV-SGK1F 
or AdV-null (AdV-control) at an MOI 5 and treated with ethanol vehicle, DEX (10nM DEX), 
glucocorticoid receptor antagonist (10 μMRU486) or the SGK1 antagonist GSK 650394 
(100nM GSK). The cells were treated for 8 days prior to analysing hepatic marker expression 
at the protein level by way of Western blotting. Cell morphology confirms that over-expression 
of SGK1F induced a trans-differentiation of B-13 cells to B-13/H cells without the addition of 
glucocorticoid. Supporting the information obtained from RT-PCR of the previous 
experiments, only cells treated with DEX or a combination of DEX and AdV-SGK1F expressed 
the liver markers proteins albumin and Cyp2e1 as demonstrated in  Figure 3.14 (middle panel 
and lower panel). Thus, Sgk1 kinase activity appears to be important in the trans-differentiation 
process of B-13 into B-13/H cells.  





Figure 3.13 SGK1F kinase activity is important in trans-differentiation of B-13 cells to B-
13/H cells. B-13 cells were treated with DEX, sgk1 inhibitor or glucocorticoid antagonist as 
indicated. Upper panel, light micrographs of B-13 cells after treatment with 10nM DEX and/or 
100nM SGK1 inhibitor (GSK 650394), 10 μM RU486 (glucocorticoid antagonist) in addition 
to 0.1% ethanol vehicle for 7 days. Lower panel: RT-PCR analysis for gene expression for the 
liver marker (Cyp2e1) was performed as outlined in the methods section. Total RNA was 




isolated on day 7. Gapdh was used as a house keeping gene.  Data are typical of 3 separate 
experiments 
 .  
Figure 3.14 SGK1F kinase activity is important in trans-differentiation of B-13 cells to B-
13/H cells.  B-13 cells were infected with an adenovirus encoding the human SGK1F isoform 
(AdV-SGK1F) or a control adenovirus encoding NTCP (AdV-control) and treated with 0.1% 
ethanol vehicle, 10nM DEX, 100nM SGK1 inhibitor (GSK 650394) or 10 μM RU486 
(glucocorticoid antagonist) as indicated. Morphology was examined after 5 days. Upper panel: 
light micrographs of B-13 cells after treatment with the indicated treatment. Middle panel: 
protein expression, B-13 cells were treated with the indicated treatments before indicated 
protein expression was determined by Western blotting at day at 8. Percentages of indicated 




proteins expression in response to the indicated treatment were quantified using ImageJ 
software (lower panel). β-actin protein was used as loading control. Data are typical of 3 
separate experiments.
3.7 B-13 conversion to B-13/H cells in response to DEX is primarily associated with 
glucocorticoid receptor activation and an induction of Sgk1 activity 
Mineralcorticoid receptors (MR) are known to regulate the induction of sgk1 in the kidney 233. 
To determine whether Sgk1 induction in B-13 cells is associated with glucocorticoid receptor 
activation in response to DEX – rather than or in association with the MR activation, B-13 cells 
were cultured in serum-free media for 1 day. RNA at time zero sample was isolated. 
Subsequently, B-13 cells were treated with ascending gradients of DEX and 
mineralocorticoid hormone; aldosterone (ALD) (1nM 10 nM 100 nM). After 3 days, RNA was 
isolated and a concentration of 500ng/ml of protein was prepared from cells lysate from each 
treatment. Primers for the detection of rat Sgk1 transcript isoforms were designed (sgk1a, 
sgk1b, sgk1x2) including a recently identified Sgk1 -like sequence (LOC). RT-PCR results 
confirmed that sgk1a, sgk1b, sgk1c are all induced in B-13 cells treated with 100nM DEX, 
sgk1x2 was expressed constitutively and induced in cells treated with DEX.   
There was no expression of the liver marker Cyp2e1 which could be explained by the limited 
exposure time and low level of Sgk1c expression at this stage. However, in ALD treated cells, 
only Sgk1a was induced in B-13 cells treated with 10nM ALD. Similarly, Cyp2e1 expression 
was not detected (Figure 3.15). In addition, Sgk1 kinase activity was examined. SGK1 activity 
versus ascending gradient of DEX and ALD was measured using the ADP-Glo Kinase Assay 
that measures ADP formed from a kinase reaction; ADP. The luminescent signal showed a 
significant difference between ethanol vehicle-treated cells and cells treated with different 
gradients of DEX and ALD, however, the signal does not correlate with sgk1 isoform 
expression detected by RT-PCR, which might be due to the non-specificity of this assay to 
detect the phosphorylation produced by Sgk1, as it might detect phosphorylation resulting from 
the action of other kinases in the cells (Figure 3.16). Furthermore, an additional experiment was 
performed to assess the effect of DEX and ALD on B-13 conversion into B-13/H cells. B-13 
cells were treated with an ascending gradient of DEX and ALD (1nM ,10nnM, 100nM) for 14 
days. Proteins were isolated for Western blotting for liver markers (Cyp2e1, Cps1). The results 
demonstrate that only DEX converted B-13 into B-13/H cells (Figure 3.17 upper panel). 
However, a limited number of cells treated with 100nM ALD morphologically revealed the 
hepatocyte-like phenotype. This may be associated with the high concentration of ALD and 
activation of the GR ( Figure 3.17 lower panel). These observations suggest that SGK1a induced 




by both DEX and ALD is not involved in the trans-differentiating process of B-13 into B1-13/H 
cells as only DEX resulted in B-13 conversion  into B1-13/H. 
 
Figure 3.15 Conversion of B-13 to B-13/H cells is associated with an induction of Sgk1 
kinase activity. RT-PCR for the indicated transcripts. B-13 cells were treated with serum free 
media for 24 h, then treated with the indicated concentration of DEX (left panel), ALD (right 
panel) or ethanol control vehicle for 3 days as outlined in the methods section. Gapdh was used 
as a house keeping gene. 
 Table 3.1 RT-PCR summary of results for Sgk1 isoforms expression in B-13 cells, DEX 














Sgk like (loc) low transient n/a detectable 
Sgk1 x2 low (GR) transient detectable 




Weak MR (GR &MR) 
n/d= not detectable, n/a= no or weak effect 
 
 
Figure 3.16 DEX and ALD treatment is associated with an induction of Sgk1 kinase 
activity in B-13 and B-13/H. Skg1 kinase activities in B-13 cells treated for 3 days with the 
indicated concentration of DEX or ALD. Data are the mean and SD of 3 separate determinations 
from the same experiment. *Significantly different (P <0.05) from ethanol vehicle treated cells 
using oneway ANOVA followed by a Tukey post hoc test. 
  
 





Figure 3.17 Conversion of B-13 to B-13/H cells is associated with an induction of Sgk1 
kinase activity.  C: Western blot for the indicated proteins after treatment for 14 days with the 
indicated concentration of DEX or ALD (20 µg protein/lane). β-actin protein was used as 
loading control (upper panel). The data are typical of 3 separate experiments. Lower panel: 
photomicrographs of cells treated as indicated, typical of at least 3 separate experiments.
 




3.8 Treating B-13 cells with different growth factors has no effect on Sgk1 expression and 
B-13 cells conversion into B-13/H cells 
Given that some growth factors induce Skg1, one might expect growth factors could 
replace DEX – and therefore potentially turn B-13 cells into B-13/H cells. To test this possible 
effect, B-13 cells were cultured in serum-free media for 24 h to synchronise the cells. RNA 
from time zero sample was isolated. Cells were then treated for 3 days with: 0.0 % (v/v) FCS 
as the negative control: 1% (v/v) FCS, 5% (v/v) FCS, 10% (v/v) FCS, 5% (v/v) FCS+10ng/ml 
epidermal growth factor (EGF), a growth factor that acts a potent mitogenic factor for B-13 
cells (Probert et al., 2014) and 5% (v/v) FCS + 30ng/ml OSM, an interleukin-6 family cytokine, 
which has been found - in combination with glucocorticoid – to promote the maturation of stem 
cell derived-hepatocytes 325. Morphologically, growth factors did not change cells to 
hepatocyte-like cells. Interestingly, OSM has shown an impact on B-13 cells size (Figure 3.18 
left panel). Moreover, increasing the FCS concentration resulted in an increase in B-13 cell 
replication (Figure 3.18 left panel), the increase in replication was determined visually by an 
apparent increase in cell number, but was not quantified. RT-PCR results did not detect any 
Sgk1 isoforms expression (Figure 3.18 right panel). Treating B-13 cells with 10ng/ml EGF and 
30ng/ml OSM for 14 days did not results in B-13 cell conversion into B-13/H cell as shown in 


















Figure 3.18 Treating B-13 cells with different growth factors has no effect on Sgk1 
induction.  B-13 cells were treated with serum free media for 24 h, then treated with 0.0 % 
(v/v) FCS as the negative control: 1% (v/v) FCS, 5% (v/v) FCS, 10% (v/v) FCS, 5% (v/v) 
FCS+10ng/ml EGF and 5% (v/v) FCS + 30ng/ml OSM. A: photomicrographs of cells treated 












Table 3.2 RT-PCR summary of results for Sgk1 isoforms expression in B-13 cells treated 




SF FCS OSM EGF Rat liver 
Sgk1a n/a n/a n/a n/a n/a Detectable 
Sgk1b n/a n/a n/a n/a n/a n/a 
Sgk1c n/a n/a n/a n/a n/a Detectable 
Sgk like (loc) n/a n/a n/a n/a n/a detectable 
Sgk1 x2 n/a n/a n/a n/a n/a detectable 
n/d= not detectable, n/a= no or weak effect 
 
 
Figure 3.19 Treating B-13 cells with different growth factors has no effect on B-13 
conversion into B-13/H.  C: B-13 cells were treated with 10ng/ml EGF, 30ng/ml OSM for 14 
days: RNA was isolated, and RT-PCR was performed for the detection of liver marker genes 
(Albumin and Cyp2e1). Data are typical of 3 separate experiments.
 




3.9 Chapter discussion  
The transdifferentiation of B-13 cells into B-13/H cells after 14 days of exposure to DEX results 
in qualitative and quantitative similar gene expression similar to that of primary hepatocytes197. 
Understanding the mechanism(s) controlling the conversion/trans-differentiation of B-13 cells 
to B-13/H cells could be used to stimulate/maintain differentiation phenotype in stem cell-
derived specialised cells. The data in this chapter demonstrate that adenoviral-mediated SGK1F 
expression in B-13 cells induces their differentiation into B-13/H cells similar to their response 
to exposure to glucocorticoid. The mechanisms involved in B13 cell transdifferentiation into 
B13/H cells still requires further investigation. The rat Sgk1 gene is currently known to encode 
3 validated mRNA transcripts and possibly 1 further transcript [NCBI database, see also Table 
3.3 . and appendix B]. All 4 transcripts encode an identical core amino acid sequence and differ 
only in their N terminal amino acid sequences. It is not known whether the Sgk1 isoforms have 
different functions, however, only the rat Sgk1c transcript appears to be irreversibly induced in 
B-13 cells after exposure to glucocorticoid 326. This suggests that endogenous Sgk1c may be 
responsible for its differentiating effects in B-13 cells. This is supported by the high expression 
of the murine orthologue in pancreatic tissue from mice with high circulating endogenous 
glucocorticoids (these mice experience a conversion of the pancreatic exocrine tissue into 
hepatocyte-like cells 231.  
Wallace et al. (2011), used the plasmid transfection technique to direct the expression of a series 
of human SGK1 expression constructs. Their data demonstrated that expression of either the 
human SGK1C (orthologous to the c form in rat) or SGK1F (which has no orthologue in the rat) 
isoforms alone resulting in transdifferentiation of B-13 cells. In another experiment, it was 
found that kinase-dead (KD) mutants of SGK1C and SGK1F proteins failed to inhibit Tcf/Lef 
transcriptional function or induce expression of CYP2E1 or albumin in comparison to the wild-
type parallels 226. These findings suggest that the kinase function of SGK1C and SGK1F is 
essential for promoting B-13 transdifferentiation, Based on this, the cDNA for this transcript 
was cloned into a replication-deficient adenoviral genome. The rationale for focusing on 
SGK1F was also driven by the knowledge that the pancreas from a patient treated for many 
decades with systemic glucocorticoid experienced a degree of hepatic differentiation and also 
contained high levels of SGK1F mRNA transcripts 227. 
In this approach, replication-deficient recombinant adenoviruses were used to introduce the 
genetic material (SGK1F) into B-13 cells. There are numerous advantages to using adenovirus 
to insert genetic material into host cells. These viruses can be used to infect many mammalian 




cell types. Moreover, recombinant adenoviruses can also be used to infect various sensitive 
cells with low MOI and to obtain a high proportion of infected cells 307. Adenovirus vector 
genomes carrying gene of interest constructs can mediate homologous recombination with 
target loci in a cellular genome at efficiencies 103–104-fold higher than plasmid constructs 327. 
The efficiency of B-13 infection with the adenovirus was optimised. B-13 cells were found to 
be readily infectable with AdV-GFP, but marked toxicity was observed at MOIs of 10 and 15. 
Therefore, an MOI 1 was chosen to infect cells over an extended 14 day period, with repeated 
infection every two days or MOI 5 for the shorter period (8 days with repeated infection every 
two days). AdV-SGK1F overexpression was used to investigate the role of SGK1 in B-13 trans-
differentiation to B-13/H cells. MOI 5 was used every two days to maximise infection and 
expression, although this also resulted in a degree of cell death. Due to this, cells infected with 
MOI 5 were not cultured after the initial infection for more than eight days. However, B-13 cell 
transdifferentiation to B-13/H cells was seen morphologically and was detected by RT-PCR for 
the expression of liver transcript marker genes such as Cyp2e1 and Cps1.  
Western blot detection of SGK1F/Sgk1 protein expression demonstrated that SGK1F/Sgk1 
protein was higher in cells treated with AdV-SGK1F. Additionally, albumin protein was 
expressed by B-13 cells infected with AdV-SGK1F. Expression was low compared to the 
expression by B-13 cells treated with a combination of DEX and AdV-SGK1F. Cps1 protein 
was clearly expressed by B-13 cells treated with a combination of DEX and AdV-SGK1F and 
barely detectable by B-13 cells infected with AdV-SGK1F. However, the Cyp2e1 protein was 
not yet detected by Western blot analysis and it was expressed by B-13 cells treated with a 
combination of DEX and AdV-SGK1F. Furthermore, 100nM GSK 650394 (an Sgk1 kinase 
inhibitor), which has never been tested before, was used to examine whether Sgk1 kinase 
activity is important in B-13 conversion into B-13/H cells. It was observed that 100nM GSK 
650394 prevented the morphological change observed in response to DEX and inhibited DEX-
dependent expression of the liver marker Cyp2e1. Supporting this information, only cells 
treated with DEX or a combination of DEX and AdV-SGK1F expressed the liver markers 
proteins albumin and Cyp2e1. Thus, Sgk1 kinase activity appears to be important in the trans-
differentiation process of B-13 into B-13/H cells. 
The RT-PCR results for different Sgk1 transcripts showed that Sgk1a, Sgk1b and Sgk1c 
isoforms are expressed by cells treated with 100nM DEX. In comparison to ALD treated cells, 
only Sgk1a was expressed by B-13 cells treated with 10nM ALD. In both treatments, Cyp2e1 
expression was not detected, which could be explained by the low Sgk1 level at this stage (3 
days). Sgk1 kinase activity from the same DEX and ALD treated cells, which has never been 




examined, was measured. The luminescent signal exhibited a significant difference between 
ethanol vehicle-treated cells and cells treated with different gradients of DEX and ALD. 
However, the signal does not correlate with Sgk1 isoform expression detected by RT-PCR, 
which might be due to non-specificity of this assay to detect the phosphorylation produced by 
Sgk1 only, it might detect phosphorylation by other kinases in the cells.  Another possible 
reason is that the sgk1 transcription to mRNA had occurred but significant translation to 
protein had not occurred at the time of sampling.  
 The effect of 14 days treatment of DEX or ALD on B-13 conversion into B-13/H cells 
was assessed by WB analysis. The results demonstrate that only DEX converted B-13 into B-
13/H cells. However, few numbers of cells treated with 100nM ALD, morphologically show 
the hepatocyte-like phenotype. That might be caused by using a high concentration of ALD 
which might result in the activation of the GR. These observations suggest that Sgk1a induced 
by both DEX and ALD is not involved in the trans-differentiating process of B-13 into B1-13/H 
cells and indicates the involvement of Sgk1c. Synchronised B13 cells were treated with different 
growth factors, such as serial concentrations of FCS, EGF and OSM to investigate their effect 
on Sgk1 induction and B-13 conversion to B-13/H cells. RT-PCR results did not detect any 
Sgk1 isoform expression. The data also revealed the failure of the natural MR agonist ALD to 
convert B-13 cells into B-13/H cells except with a very high concentration (100nМ ALD). 
These data support the idea that the effect of DEX on transdifferentiation are mediated  
primarily through the GR 226.  
The data in this chapter show that B13 cells are readily infected with adenovirus.  
However, marked toxicity was observed with high MOIs. The data also suggest that Sgk1 
activity is crucial in B13 conversion into B-13/H cells following DEX treatment. The data also 
demonstrated that adenoviral-mediated SGK1F expression in B-13 cells induces their 
differentiation into B-13/H cells, similar to their response to exposure to glucocorticoid. 
Accordingly, SGK1F is implicated in the transdifferentiation of B-13 cells into B-13/H 
hepatocyte-like cells. Further investigation is essential to understand the mechanism of B-13 
conversion into B-13/H and how Sgk1 is involved in the process, as this could offer an insight 
into potential ways to manipulate stem cells differentiation to generate hepatocytes in vitro for 
a wide range of uses, from toxicological screening to hepatocytes transplantation.
 
  
Table 3.3 Rat and human Sgk1 proteins.  Underlined sequence, flag sequence. For raw sequence data Appendix B. 
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 Investigating if SGK1F expression is upstream of β-catenin 
phosphorylation and WNT signalling changes in B-13 cells 
4.1 Introduction 
   WNT signalling is known to be involved in liver development 328,329,330,331 and also to regulate 
zonal hepatocyte gene expression in the adult liver 332. High glucocorticoid levels lead to the 
conversion of B-13 cells onto B-13/H cells as a result of a process that involves the transient 
repression of WNT signalling upstream of the induction of C/EBP-β 218.  However, the 
mechanism by which glucocorticoid mediates WNT signalling repression is obscure. An earlier 
study revealed that B-13 transdifferentiation is mediated via the glucocorticoid receptor and not 
the mineralocorticoid receptor 227. In addition, microarray data has indicated that the 
transdifferentiation of B-13 cells into B-13/H cells results in a significant (>100-fold) increase 
in Sgk1 mRNA transcripts in B-13/H cells. In contrast, few changes were detected in the 
expression levels of mRNAs encoding other components of the WNT and PI3K signalling 
pathways 197.  
Initial work by Wallace et al. (2011) has demonstrated that β-catenin phosphorylation and 
reductions in the levels of β-catenin are early upstream events in relation to C/EBP-β induction 
and B-13 transdifferentiation to B13/H cells. When the effects of SGK1C, SGK1F or SGK1A 
(as a control) transfection on β -catenin was examined, it was found that SGK1C and SGK1F 
expression resulted in phosphorylation of β-catenin and reduced levels of total β-catenin, while 
the SGK1A isoform had no influence. In the same study-, they demonstrated that purified 
recombinant SGK1 was incubated with purified recombinant β-catenin and that 
phosphorylation was examined by Western blotting. β - catenin phosphorylation only occurred 
when SGK1 and ATP were present which determined that SGK1 could directly phosphorylate 
β- catenin 226.  
For a better understanding, the mechanism(s) regulating the conversion/trans-differentiation of 
B-13 cells to B-13/H cells and whether Sgk1c/F cross-talks with the WNT signalling pathway 
based on distal Tcf/Lef transcriptional activity, Tcf/Lef-dependent luciferase expression 
(Topflash) was used to examine the effect of DEX and AdV-SGK1F expression on WNT 
signalling activity. Also in this approach, Western blot analysis was used to investigate if DEX 
and SGK1F are upstream of β-catenin phosphorylation in B-13 cells. 




4.2 Trans-differentiation of B-13 cells into B-13/H cells is associated with a repression of 
WNT signalling based on a repression in Tcf/Lef transcriptional Activity.  
    To determine whether treatment of B-13 cells with DEX results in WNT signalling 
repression, the influence on Tcf/Lef transcriptional activity was examined. B-13 cells were 
treated with DEX (10 nM and 100 nM), 50 μM WNT antagonist (quercetin), ethanol and DMSO 
as vehicle controls and transfected with TCF-TK promoter construct (T cell factor reporter 
[TOPFLASH] plasmid and renilla reporter plasmid RL-TK in the 6:1 ratio. Additionally, B-13 
cells were also transfected with a control vector (FOPFLASH) containing identical sequences 
except for the concatamer of Tcf/Lef binding response elements and RL-TK construct in the 
6:1 ratio as a plasmid negative control. After 24 hours, cells were harvested and luciferase and 
renilla activities determined. Figure 4.1 shows that treatment with 10nM DEX significantly 
suppressed WNT signalling based on reduced relative TopFlash luciferase activity (~50% of 
constitutive level) reflected in B-13 cells treated with 10nM DEX in comparison to ethanol 
vehicle-treated cells (p value= 0.009). Moreover, increasing concentration to 100 nM DEX led 
to more repression in WNT signalling with p-value = 0.001 in comparison to ethanol control. 
Treatment of 50 μM quercetin suppressed ~70% of basal TopFlash luciferase activity, p-value 










Figure 4.1 Treatment of B-13 cells with DEX repressed WNT signalling and Tcf/Lef 
transcriptional activity.  B-13 cells were seeded in 24 well plates at a density of 50,000 
cells/well for 24 hours. Then, cells were treated with the following treatments: DEX (10 nM 
and 100 nM), which were added to the medium from a 1000-fold concentrated stock in ethanol. 
Ethanol treatment as a control 50 μM WNT antagonist (quercetin) was added to the medium 
from a 1000-fold concentrated stock in DMSO. DMSO treatment as control was 0.1% (v/v) 
DMSO, B-13 cells with DMEM only. 48 hours later, all treated cells were transfected with 
TCF-TK promoter construct (T cell factor reporter plasmid TOPFLASH) and renilla reporter 
plasmid RL-TK in the 6:1 ratio. B-13 cell without DEX treated with mutated copy of TCF 
(FOPFLASH) and RL-TK construct in the 6:1 ratio as a plasmid negative control. After 24 
hours, cells were harvested, and dual luciferase assay was carried. Data are the mean and 
standard deviation of six replicates from the same experiment. Significantly different (P<0.05) 











4.3 Treatment of B-13 cells with DEX resulted in β -catenin depletion and 
phosphorylation.  
In order to confirm the inhibitory effect of DEX on the WNT/β-catenin signalling pathway as 
observed by luciferase assay and to investigate DEX treatment upstream of β-catenin 
phosphorylation, the stability of β-catenin was examined. B-13 cells were treated with 10nM 
DEX, 100nM DEX, 50 µM WNT antagonist (tcf/lef inhibitor) for 14 days. Protein extracts were 
isolated and protein assay was performed. Western blotting analysis was performed for 
phosphorylated β-catenin, total beta-catenin and β-actin. The results showed that there was a 
depletion of total β-catenin levels in cells treated with DEX and WNT antagonist compared to 
B-13 cells treated with the ethanol vehicle only. Ser33- and Ser37- phosphorylated β-catenin 
was detected in B-13 cells treated with 10nM and robust expression of phosphorylated β-catenin 
was detected in 100nM DEX treated cells (Figure 4.2). To examine the effect of DEX on β-
catenin phosphorylation and total β-catenin level in a time less than 14 days (which has never 
been investigated), B-13 cells were treated with 10nM DEX  and 0.1% ethanol vehicle for 10 
days only. Western blot analysis showed that Ser33- and Ser37- phosphorylated β-catenin was 
detected in B-13 cells treated with 0.1% ethanol vehicle and 10nM DEX. However, there is no 
complete loss of total beta-catenin protein compared to the complete loss of total beta-catenin 









Figure 4.2Treatment of B-13 cells with DEX upstream for beta-catenin depletion and 
phosphorylation. Cells were treated for 14 days with the indicated treatments: 0.1% ethanol, 
DEX (10 nM,100nM) and quercetin (50 µM). Total cell lysates were collected and subjected to 
western blotting to analyse the stability of β-catenin protein and β-catenin phosphorylation, 
while β-actin was measured as the loading control (upper panel). The proteins expression level 
were quantified using ImageJ software in the lower panel. All data typical of at least three 
separate experiments. 
 





Figure 4.3 Treatment of B-13 cells with DEX upstream for beta-catenin depletion and 
phosphorylation. Cells were treated for 10 days with indicated treatment: 0.1% ethanol and 
10nMDEX. Western blots were performed for the indicated protein at the indicated time of 
culture to analyse the stability of β-catenin protein and β-catenin phosphorylation, while β-actin 














4.4 Trans-differentiation of B-13 cells into B- 13/H cells is dependent on glucocorticoid 
interaction with the glucocorticoid receptor 
To confirm that the GR is involved in changes in WNT signalling, B-13 cells were treated with 
100nM DEX, 10μM RU486 (GR antagonist), 100nM DEX + 10μM RU486 and ethanol as a 
control. 48 hours later, cells were transfected with the TOPFLASH construct (and renilla 
reporter plasmid RL-TK in 6:1 ratio) or FOPFLASH (and RL-TK construct in 6:1 ratio, used 
as a plasmid negative control). After 24 hours, cells were harvested, and a dual luciferase assay 
was carried out. Figure 4.4 demonstrates that treating cells with 100nM DEX resulted in WNT 
signalling reduction with p-value =0.008. However, adding RU486 (GR antagonist) to 100nM 
DEX led to non-significant difference in WNT signalling when compared to DEX treated cells 
with p value= 0.719. Surprisingly, RU486-only treated cells showed markedly decreased WNT 
signalling with P value=0.008. The reduction in WNT signalling in B-13 cells treated with 
RU486 only, could be due to activation of other nuclear receptors contacted by RU486. 
To determine whether other nuclear receptors known to be contacted by RU486 are responsible 
for the suppression of WNT activity in B-13 cells when treated with RU486, the potential role 
of the progesterone receptor (Pgr) and pregnane x receptor (PXR) were examined. RT-PCR 
was first performed to determine whether they are expressed. The data in Figure 4.5 (upper 
panel) exclude a role for PXR as it is expressed by B-13/H cells only. However, Pgr was found 
to be expressed in both B-13 and B-13/H cells Figure 4.5 (middle and lower panel). Further 
investigations were conducted to examine if progesterone exposure would convert B-13 into B-
13/H cells. B-13 cells were treated with different concentrations of progesterone (10nM,100nM 
and1µM) and 10nM DEX for 14 days. Photomicrographs were taken and RT-PCR performed 
for the liver marker Cyp2e1. The results in Figure 4.6 show that progesterone exposure did not 
convert B-13 into B-13/H cells. According to the cell morphology, there is no morphological 
phenotype change in B-13 cells treated with progesterone and RT-PCR results showed that 












Figure 4.4 Treatment of B-13 with DEX and glucocorticoid antagonist (RU486) increased 
WNT signalling and Tcf/Lef transcriptional activity in comparison to DEX treated cells. 
B-13 cells were seeded in 24 well plates with a density of 30,000 cells/well for 24 hours. Then, 
cells were treated with the following treatments: 100 nM DEX, which was added to the medium 
from a 1000-fold concentrated stock in ethanol. 0.1% (v/v) ethanol as a control, 10 μM RU486 
(GR antagonist) was added to the medium from a 1000-fold concentrated stock in ethanol, 100 
nM DEX+ 10 μM RU486 and DMDEM only. 48 hours later, all treated cells transfected with 
TCF-TK promoter construct (T cell factor reporter plasmid TOPFLASH ) and renilla reporter 
plasmid RL-TK in the 6:1 ratio, except B-13 cell with DMEM medium only treated with a 
mutated copy of TCF (FOPFLASH) and RL-TK construct in the 6:1 ratio as a plasmid negative 
control. After 24 hours cells were harvested, and dual luciferase assay was carried out. Data are 
the mean and standard deviation of six replicates from the same experiment. Significantly 
different (P<0.05) using one way ANOVA (Dunnet test).  
 





Figure 4.5 Several other nuclear receptors bind glucocorticoids. To define if there are other 
nuclear receptors that might react, glucocorticoids rather than GR: B-13 cells were treated with 
10 nM DEX for 9 days, and RNA was isolated from B-13/H, B-13 and cell extracts from rat 
liver and ovary tissues were used as controls. RT-PCR was performed for r- PXR ( upper 
panel)and r –Pgr (middle panel ). RT-PCR results for Pgr were quantified using ImageJ 




software, Gapdh was used as a loading control. All data typical of at least three separate 
experiments. 
 
Figure 4.6 Trans-differentiation of B-13 cells into B- 13/H cells is dependent on 
glucocorticoid interaction with the glucocorticoid receptor. B-13 cells were treated with 
different concentrations of progesterone (10nM,100nM,1µM) and 10nM DEX for 14 days. 
Photomicrograph pictures (upper panel) and RT-PCR for the liver marker cyp2e1(lower panel), 
Gapdh was used as a loading control. All data typical of at least three separate experiments. 
 




4.5 Treatment of B-13 with DEX and SGK1 inhibitor did not increase WNT signalling in 
comparison to DEX-treated cells 
To determine whether SGK1 kinase activity is involved in the regulation of WNT 
signalling in B-13 cells, B-13 cells were seeded in 24 well plates with a density of 2500 
cells/well for 72 hours. Then, cells were treated with the following treatments: 10nM DEX was 
added to the medium from a 1000- fold concentrated stock in ethanol, ethanol treatment as a 
control and 500nM SGK1 inhibitor (GSK 650394) was added to the medium from a 1000-fold 
concentrated stock in DMSO, 10nM DEX + 500nM SGK1 inhibitor. 48 hours later, cells were 
transfected with TOPFLASH (and renilla reporter plasmid RL-TK in the 6:1 ratio) or 
FOPFLASH (and RL-TK construct in the 6:1 ratio as a plasmid negative control). After 24 
hours, cells were harvested, and dual luciferase assay was carried out. Figure 4.7 shows that 
treating cells with 10nM DEX reduced the WNT signalling with p-value = 0.01 when compared 
to ethanol vehicle control treated cells. Treating cells with a combination of 10nM DEX and 
500nM SGK1 inhibitor has not significantly increased the signal when compared to10nM DEX 
treated cells (p-value 0.966). Likewise, there was no significant difference when compared to 
DMSO treated cells. 
 
 






Figure 4.7 Treatment of B-13 cells  with DEX and SGK1 inhibitor (GSK 650394 ) did not 
increase WNT signalling in comparison to DEX-treated cells.  B13 cells were seeded in a 
24 well plate with a density of 2500 cells/well for 72 hours. Then, cells were treated with the 
following treatments: 10nM DEX, which was added to the medium from a 1000-fold 
concentrated stock in ethanol. Ethanol treatment as a control. 500nM SGK1 inhibitor (GSK 
650394) which was added to the medium from a 1000-fold concentrated stock in DMSO. 10nM 
DEX+ 500nM SGK1 inhibitor. 48 hours later, cells were transfected with TCF-TK promoter 
construct (T cell factor reporter plasmid TOPFLASH) and renilla reporter plasmid RL-TK in 
the 6:1 ratio, b13 cell treated with DMEM medium only were transfected with a mutated copy 
of TCF (FOPFLASH) and RL-TK  construct in the 6:1 ratio as  a plasmid negative control. 
After 24 hours cells were harvested, and dual luciferase assay was carried out. Data are the 
mean and standard deviation of six replicates from the same experiment. Significantly different 










4.6 Over-expression of SGK1F repressed WNT signalling and resulted in β-catenin 
phosphorylation  
To further test the role of Sgk1 kinase activity in B-13 cells and WNT signalling, B-13 cells 
were infected with AdV-SGK1F and the effects on WNT signalling examined using 
TOPFLASH and FOPFLASH. B-13 cells were transfected with either TOPFLASH or 
FOPFLASH, both with RL-TK to normalise for transfection efficiencies. After 24 hours, cells 
were then infected with either AdV-SGK1F or AdV-GFP (as control) at an MOI of 5. After a 
further 24 hours, luciferase and renilla activities were determined. Figure 4.8 shows that 
infection of B-13 cells with AdV-SGK1F resulted in suppression of WNT signalling activity 
.Moreover, to investigate if SGK1F overexpression resulted in β-catenin phosphorylation, B-
13 cells were infected every 2 days with AdV-SGK1F (MOI 5) or the control AdVs (AdV-GFP, 
AdV-null) at an MOI of 5 over a 4 day period. Protein was isolated from each treatment after 4 
days, and protein assay was performed. Western blot analysis was performed using 20µg 
protein/lane of protein for β -catenin phosphorylated, total β-catenin and the β-actin as a loading 
control. The results in Figure 4.9 clearly reveal that infection of B-13 cells  with AdV-SGK1F 
resulted in changes in the ratio of β-catenin/phosphorylated-β-catenin, however the total β-
catenin was still detectable in AdV-SGK1F infected cells. In contrast, phosphorylated β-catenin 
was undetectable in B-13 cells infected with AdV-GFP or AdV-null.  





Figure 4.8 Infecting B-13 cells with AdV-SGK1F leads to reduction in Tcf/Lef (WNT 
signalling) transcriptional activity.  B-13 cells were transfected with a mixture of the 
indicated reporter gene constructs as indicated. After 24 hours, cells were then infected with 
the indicated AdV at an MOI of 5. After a further 24 hours, cells were lysed and the levels of 
luciferase and renilla determined, as outlined in the methods section. Data are the mean and SD 
of 5 separate determinations from the same experiment, typical of 3 separate experiments. 
Significantly different (p < 0.05) normalized luciferase activity versus (*) Foplash or (#) AdV-
GFP infected cells using the Student’s T test (two tailed).  
 
 





Figure 4.9 Phosphorylation of β-catenin in B-13 cells in response to AdV-SGK1F infection.  
B-13 cells were repeatedly infected with AdV-SGK1F or the control AdVs (AdV-GFP, AdV-
null) at an MOI of 5 over a 4 day period before expression levels of the indicated proteins were 
determined by Western blot (20µg cell protein/lane), β-actin was used as a loading control. Data 
typical of 3 separate experiments




4.7 Chapter discussion 
WNT signalling is a passive signalling pathway in adult liver tissue and regulates the 
expression of several genes in the liver 332. The WNT signalling concentration gradient is high 
in centrilobular regions and low in periportal regions. Additionally, WNT up-regulates genes 
such as glutamine synthetase (Gs); Idh3a isocitrate dehydrogenase 3a; Dlat dihydrolipoamide. 
S-acetyltransferase and Gstm glutathione S-transferase mu, cyp1a2 and cyp2e1. Genes down-
regulated by WNT signalling include Cps1 and arginase 1 (Arg1), Phosphoenolpyruvate 
carboxykinase 1  (pck1), fructose bisphosphatase (FBPase), Cytochrome P450 2F 2(Cyp2f2) 
and sulfotransferase  (Sult5a1)91. Wallace et al. (2010), demonstrated that B-13 cells express 
the WNT3a protein and have high WNT signalling activity. Treatment with DEX caused a 
temporary loss of WNT3a expression, which was linked to a reduction in WNT signalling 
activity and the subsequent transdifferentiation of B-13 cells into hepatocyte-like B-13/H cells. 
Their data suggested that suppression of WNT signalling by glucocorticoid is a vital mechanism 
controlling B-13 transdifferentiation, furthermore, knockdown of the intracellular WNT 
messenger protein β-catenin replaced DEX and also generated rapid transdifferentiation 218.  
The data in this chapter confirm that B-13 cells treated with the 10nM DEX treatment resulted 
in a significant decrease in WNT signalling. Moreover, increasing the concentration to 100nM 
DEX led to more repression in WNT signalling in comparison to the ethanol control. The data 
also indicate that 50 µΜ quercetin inhibited WNT signalling.  Quercetin has been observed to 
lack the ability to promote transdifferentiation into B-13/H cells but to potentiate 
glucocorticoid-mediated transdifferentiation 218. The mechanism by which glucocorticoid 
mediates WNT signalling repression has not therefore been fully explained. There are only a 
few investigations studying the interaction of glucocorticoids with WNT signalling, which 
appear to depend on the cell type assessed. It has been shown that glucocorticoid exposure 
reduces the expression of β-catenin in pituitary cells 333 and inhibition of β-catenin expression 
by DEX promotes the differentiation of mesenchymal progenitor cells into adipocytes 334, while 
it does not influence osteoblasts 335.  
In B-13 cells, it has been detected that there is a constitutive WNT3a expression and moreover, 
after 14 days of 10nМ DEX treatment, glucocorticoid treatment resulted in phosphorylation 
and depletion of β-catenin and loss of β-catenin nuclear localisation, besides significant 
reductions in T-cell factor/lymphoid enhancer factor (Tcf/Lef) transcriptional activity before 
obvious changes in phenotype into hepatocyte-like (B-13/H) cells. A reoccurrence of higher 
Tcf/Lef transcriptional activity was noted along with the re-expression of WNT3a in B-13/H 




cells. β-catenin knockdown alone was substituted for glucocorticoid-dependent 
transdifferentiation. Overexpression of a mutant β-catenin protein blocked glucocorticoid-
dependent suppression of Tcf/Lef activity and resulted in inhibition of transdifferentiation 218. 
The data in this chapter also confirms that in addition to the DEX effect on WNT signalling 
repression, β-catenin phosphorylation was also was resulted. In a previous work by Fairhall and 
colleagues, it has been shown that B-13 transdifferentiation is mediated via the glucocorticoid 
receptor and probably not by the mineralocorticoid receptor 227. In this study, treating cells with 
100nM DEX resulted in significant reduction of WNT signalling transcriptional activity. 
Meanwhile, as demonstrated in the previous chapter, the GR antagonist mifepristone (RU486) 
prevented transdifferentiation of B-13 into B-13/H cells. However, adding RU486 to 100nM 
DEX did not result in a significant difference in WNT signalling transcriptional activity when 
compared to DEX-treated cells. Surprisingly, RU486 treated cells exhibited markedly 
decreased WNT signalling. The reduction in WNT signalling in B-13 cells treated with RU486 
only could be due to weakly acting nuclear receptors responding to the high concentration of 
RU486.  Therefore, the expression of the Pgr and PXR, which are known to be contacted by 
RU486 was examined. Pgr was found to be expressed in both B-13 and B-13/H cells. However, 
progesterone exposure failed to convert B-13 into B-13/H cells. As shown in the flowchart 
Figure 4.10), antagonising the progesterone receptor with RU486 should have the same effect 
as DEX on WNT signalling. However, while both RU486 and DEX repressed WNT signalling, 
only DEX converted B-13 cells into B-13/H cells. DEX exposure might result in epigenetic 
changes, for instance the up-regulation of Gr mRNA expression and increased expression and 
translation of a functional N-terminally truncated Gr protein that shows increased nuclear 
localisation in B-13/H cells 326. This effect of DEX could explain its influence on B-13 trans-
differentiation into B13/H cells. 
Data in this chapter demonstrate a novel regulatory role for Sgk1 (SGK1F) in WNT 
signalling changes and suggested that SGK1F overexpression is upstream of β-catenin 
phosphorylation changes. The likelihood is therefore that the conversion of B-13 cells into B-
13/H cells in response to glucocorticoid is associated with Sgk1 induction and WNT signalling 
changes. The mRNA expression of WNT related genes and WNT signalling inhibitors genes 
(Dkk1, DDKK3 and sFRP), could be assessed using real-time PCR. The changes in genes at 
protein levels can be validated by Western blotting. Understanding the mechanisms is essential 
to recognise the cellular differentiation of stem cells, progenitor cells and terminally 
differentiated cells. 






Figure 4.10: Schematic diagram illustrates the effect of glucocorticoid antagonist (RU486) 
on GR and Pgr and their effect on WNT signalling and B-13 cells conversion into B-13/H 
cells. 




 Conversion of human iPSCs into human hepatocyte-like cells 
5.1 Introduction 
    Liver transplantation and hepatocyte transplantation are effective treatments against chronic 
liver failure, acute liver failure and hereditary liver disease 336. In addition, in vitro toxicity 
assays using human hepatocytes is currently the gold standard for accurate assessment of drug 
toxicity and safety 337. However, several factors limit hepatocyte utility. Hepatocytes do not 
proliferate in vitro and therefore cannot be expanded in vitro. Furthermore, culture results in 
dedifferentiation and loss of function 338,339,340. Moreover, their sources are limited, which 
results in difficulty in obtaining the ample quantities required for large-scale drug toxicity 
screening 341,342. A disadvantage of using human hepatocellular carcinoma cell lines (such as 
HepG2 cells), is that they do not correctly reflect hepatic function 343. In addition, animal 
models can be used, but they introduce the problem of inter-species differences 344. Therefore, 
hepatocyte-like cells generated from hESCs and iPSCs are expected to provide an alternative 
model for drug toxicity screening and hepatocyte transplantation. 
Hepatocyte differentiation technology has improved over the years and it has become possible 
to generate ESCs/iPSCs-derived human hepatocyte-like-cells that have drug metabolic capacity 
and responsiveness to specific treatment, as these cells could be used for diseases modelling. 
This suggests that human ESCs/iPSCs-hepatocyte-like-cells may be a useful model for drug 
toxicity assays. However, they still have an immature phenotype in most of the differentiations 
experiments 268. As mentioned in section 1.7 of this dissertation there are some attempts to 
manipulate the in vitro environment to generate or preserve hepatic functionality293,345. Thus, 
further improvements in hepatic differentiation technology will be required before human 
ESCs/iPSCs-derived hepatocyte-like-cells can be a worthwhile alternative to primary human 
hepatocytes in drug toxicity prediction and screening. Unpublished studies in the laboratory 
conducted by (Wallace and Wright, unpublished data) investigated the effect of plasmid-driven 
human SGK1 expression on ES cell differentiation and maturation into hepatocyte-like-cells. 
Cells were transfected with SGK1F, SGK1C or SGK1A after 7 days of differentiation. The 
transfections did not result in any detectable alteration in hepatocyte-like-cells differentiation. 
In another experiment, cells were transfected with SGK1F, SGK1C, SGK1A just before day 11 
of differentiation. The transfections did not result in any detectable alteration in mature 
hepatocyte differentiation. However, it was not considered a robust test because transfection 
rates were extremely low. 




Induced pluripotent stem cells (iPSCs) are generated by reprogramming somatic cells to a 
pluripotent state by the introduction of specific factors 46,47. In this approach, iPSCs received 
from Prof. Lyle Armstrong (Institute of Genetic Medicine, Newcastle University) were 
reprogrammed using a Sendai reprogramming kit. This kit includes three vector preparations: 
polycistronic Klf4–Oct3/4–Sox2, cMyc, and Klf4 for iPSC derivation from adult dermal 
fibroblasts (AD3 cells). Following a natural path of development hiPSCs (AD3) were 
differentiated into hepatocyte-like cells according to the protocol by 52. The effect of AdV-
SGK1F overexpression on hepatocyte-like cells maturation was examined at different stages of 
differentiation. The effect of AdV-SGK1F overexpression on adult human hepatocytes 
dedifferentiation were examined also. As SGK1 is a glucocorticoid-induced gene, the effect of 
glucocorticoid exposure (1µMDEX)  at the hepatoblast stage of differentiation, was also 
examined.  
5.2 The initial protocol employed  
Following a natural path of development, hiPSCs (AD3) were initially differentiated into 
hepatoblasts according to the protocol by Hannan et al. (2013) 52 (Figure 5.1 upper panel). On 
day 1 the RT-PCR result shows expression of stem cells marker OCT4 (Figure 5.2). Cells were 
cultured with CDM-PVA with Activin-A (100ng/mL) and b FGF (100ng/mL) and incubated 
for 24 hours for the pluripotency maintenance. The next day, cells were washed with DPBS and 
differentiation was induced by treating cells with freshly prepared CDM-PVA containing 
Activin-A (100ng/mL), bFGF (100ng/mL), BMP-4 (10ng/mL), LY294002 (10μM), 
CHIR99021 (3μM) for a further 24 hours. Then, the medium was replaced with freshly prepared 
CDM-PVA with Activin-A (100ng/ mL), bFGF (100ng/mL), BMP-4 (10ng/mL) and 
LY294002 (10μM). This change in media induced endoderm specification over the next 24 
hours 52. Cells were incubated for 24 hours only and the medium replaced with freshly prepared 
RPMI- B27 medium containing Activin-A (100ng/mL) and bFGF (100ng/mL). This change in 
media creates endoderm commitment over the next 24 hours which can be detected by the 
increase in cell size (Figure 5.1 lower panel) and expression of endoderm marker (sox17) , even 
though pluripotency marker (OCT4) expression was still detectable by RT-PCR after 4 days 
(Figure 5.2). Next, the medium was replaced with RPMI-B27 differentiation medium with 
Activin-A (50 ng/ml). After 3 days of daily medium changes, hepatic specification was induced 
by treating cells with RPMI-B27 differentiation medium with Activin-A (50 ng/ml) and FGF10 
(10ng/mL) for 3 days. It should be noted that foregut endoderm is reported to be specified over 
this period, according to the protocol issued by Hannan et al (2013) 52. It can be seen from 
Figure 5.1 (lower panel) day 12 that the cells take on a polygonal shape and organise into an 




epithelium with canaliculi-like structures (indicated by the white arrow) and a dark cytoplasm. 
After 12 days, hepatic specification was determined by the expression of alpha-fetoprotein 
(AFP) (Figure 5.2). Cells were treated with hepatocyte basal medium supplemented with OSM 
(30ng/mL) and HGF (50ng/mL), and the media was replaced every two days. RT-PCR results 
demonstrate that cells expressed the hepatoblasts marker (AFP) and ductal marker (CK19) after 
15 days, although no expression was detected by RT-PCR of albumin or CYP2E1 at this stage 
of differentiation (Figure 5.2). Immunocytochemical staining showed an expression of CK19, 
AFP and a weak expression of albumin after 16 days of differentiation (Figure 5.3 A,B&C). 
These data demonstrate that the cells only achieve an immature phenotype. In the subsequent 
differentiation trials the hiPSCs (AD3) were subjected to prolonged maturation protocol as 
described in Figure 5.4 . The RT-PCR results revealed a marked reduction in pluripotency 
markers OCT4 and SOX2 after day 7 and were completely absent at day 26; a clear expression 
of DE marker SOX17 at day 5, expression of ADE marker HHEX at day 5, FOXA2 at day 5-
26. The cells still show an immature phenotype through expression of AFP and CYP3A7, 
although mature liver genes albumin expression is detected (Figure 5.5). 
Q-RT-PCR was employed to provide a more quantitative determination in the progression of 
cultured AD3 cells toward hepatic lineage, which is widely seen to occur by means of four 
stages (endoderm, anterior definitive endoderm, hepatoblast and hepatocyte-like). The 
expression of specific genes markers for each differentiation stage was examined. Q-RT-PCR 
for the progression of cultured AD3 cells toward hepatic lineages from day 1 to day 26 showed 
significant expression of pluripotency genes (OCT4, SOX2) at day 1. After three days of 
differentiation, the cells continued to express the same level of pluripotency markers and 
scarcely detectable amounts of the endodermal marker gene SOX17. On day 7, the cells 
displayed a significant level of endodermal marker SOX17 expression; the pluripotency 
markers gene expression levels were now very low in comparison to SOX17. HEX and FOXA2 
transcript levels were detectable at this stage; however, the hepatoblast marker gene AFP was 
not detected at this stage. Expression of hepatoblast marker genes was detected by day 12. After 
26 days, pluripotency and endodermal markers were not expressed although the levels of AFP 
were diminished. The liver transcription factor HNF4α was detected along with low levels of 
the mature hepatocyte marker (CYP3A4). These data indicate that a prolonged differentiation 
protocol (26 days) resulted in a diminished level of hepatoblasts marker and suggested the 
expression of mature hepatocyte markers may require an inducer or prolonged protocol beyond 
26 days to be detectable (Figure 5.6). The aim was to track the differentiation stage to confirm 
the cells are differentiating from the pluripotent stage (day0-1) into endoderm (days 3-5), ADE 




(days 5-7), hepatoblasts (days 8- 12) and hepatocyte-like-cells (days 12-29). Sometimes the 
RNA concentration selected was too low or lack purity, which required some flexibility 
around the day of culture used for some analyses. 
 
Figure 5.1 Initial protocol employed for iPSCs (AD3) differentiation into hepatocyte- like-
cells. Flow chart outlining the growth factors and media used for the generation of mature 




hepatocyte (upper panel). In the lower panel, iPSCs (AD3) differentiate into hepatocytes (white 
light/phase contrast pictures): Following a natural path of development hiPSCs (AD3) were 
differentiated into hepatic endoderm (hepatoblasts): Day 1 bright field picture demonstrating 
tightly packed colonies of Pluripotent cells with well-defined borders showing a high nuclear 
to cytoplasmic ratio. By the end of the day 4, definitive endoderm commitment can be detected 
by the increase in cell size and migration of cells away from the original colony. At days 12 
and 14 hepatoblasts display polygonal shape and organised into an epithelium with canaliculi-
like structures (indicated by the white arrow) and a dark cytoplasm. Data are typical for at least 
3 separate experiments. Panel labelled “arrow” is an expanded view of the cell identified by an 




Figure 5.2 Initial protocol employed for iPSCs (AD3) differentiation into hepatocyte- like-
cells. 
 RT-PCR for indicated genes, Gapdh was used as loading control; mRNA isolated from 
differentiated AD3 cells at different stages of differentiation as indicated. mRNA also isolated 
from human hepatocytes and used as a control. Data are typical for at least 3 separate 
experiments. 















Figure 5.3 Initial protocol employed for iPSCs (AD3) differentiation into hepatocyte- like- 
cells.  Confocal images of AD3 cells directed to differentiate into hepatocyte-like-cells: cells 
were fixed after 16 days of differentiation into hepatocyte-like-cells and examined alongside 
positive control cells for the expression of (A) CK19, (B) AFP and (C) Albumin. Data are mean 
and SD for at least 3 separate experiments. All images were taken under identical spectral 
conditions.






Figure 5.4 Final protocol employed to direct iPSCs toward hepatocyte-like cells. Schematic 
diagram depicting the protocol (Hannan et al., 2013) employed to direct iPSCs toward 
hepatocyte-like cells (upper panel). light micrographs of iPSCs at different stages – as indicated 
- of differentiation to hepatocyte-like cells. Results typical of 10 separate experiments. 
  





Figure 5.5 Final protocol employed to direct iPSCs toward hepatocyte-like cells.  RT-PCR 
for selected transcripts in iPSCs at different stages of differentiation to hepatocyte-like cells. 
GAPDH was used as loading control. Results typical of 10 separate experiments. 




Figure 5.6 Q-RT-PCR for the progression of cultured AD3 cells toward hepatic lineages from day 1 to day 26.  AD3 cells (iPSCs) were 
differentiated into hepatocyte-like cells for 26 days. qRTPCR results showed expression of (OCT4 and/or SOX2) at days 1-12. DE marker gene 
expression (SOX17) at day 1 and day 7. ADE markers (HEX and FOXA2) transcript levels were also detectable at day 7. Expression of hepatoblasts 
marker genes (AFP) was detected at day 12. After 26 days, pluripotency and endodermal markers are completely absent, AFP were diminished. 
hepatoblasts marker (AFP) and liver transcription factor HNF4α were detected with scarcely any detection of mature hepatocyte marker (CYP3A4). Data 
are represented as mean±standard deviation using ∆∆Ct method. 
140 




5.3 Functionality of AdV-GFP, AdV-SGK1F in AD3 cells (iPSCs) at different stages of 
differentiation into hepatocyte-like-cells 
In order to examine  the efficiency of iPSCS derived hepatocytes infected with the adenovirus, 
hepatocyte-like-cells were subjected to the hepatocyte differentiation protocol outlined in the 
methods section and schematically described previously in Figure 5.4 . At day 1, cells were 
repeatedly infected with AdV-GFP at MOI 20. Limited trial and error suggested that that this 
approach gave the best infection rates whilst limiting losses in cell viability. Cells expressing 
GFP were determined by fluorescence microscopy from 3 randomly selected views up to 3 days 
later. Figure 5.7 demonstrates that infection of differentiating iPSCs (from day 1) at a MOI of 
20 gave rise to low infection rates typically in the mean range of 7% by day 3. Infecting cells 
with AdV-SGK1F at day 1, when the cells are at a pluripotent/early transition to an endoderm 
stage of development resulted in low levels of expression of a protein immunoreactive to the 
mouse anti-SGK1 antibody (Figure 5.8). However, the size of this protein (~ 57 kDa) differed 
to the predicted size of the tagged SGK1F protein (48.9 kDa), the protein may be aberrantly 
modified post translationally (e.g. phosphorylation) which is a common issue with iPSCs. Also, 
the loading control protein (β-actin) is higher in the AdV-SGK1F infected sample, which could 
interfere with the detection of low levels of SGK1F.  Increased total protein loading in this 
sample would help to obtain a clearer – more quantitative - SGK1F protein band. 
Infecting cells with AdV-GFP at days 4-5, when the cells are transiting between the 
endodermal/anterior definitive endoderm stages of development at an MOI of 20 was able to 
give rise to infection rates typically in the mean range of approximately 70% by day 7, based 
on GFP expression (Figure 5.9). Infection with AdV-SGK1F during this period gave rise to the 
robust expression of a protein in the range of the predicted 48.9 kDa size for the tagged SGK1F 
protein (Figure 5.10). Infecting cells with AdV-GFP at day 26, when the cells are at the post-
hepatoblast/foetal hepatocyte (hepatocyte-like) stage of development - at a MOI of 20 - was 
able to give rise to infection rates typically in the mean range of approximately 80% by day 29, 
based on GFP expression (Figure 5.11) and robust expression of the 48.9 kDa tagged SGK1F 
protein (Figure 5.12). 





Figure 5.7 Early infection (at day 1) of iPSCs with AdV-GFP resulted in low infection 
rate.  Effect of repeated infection of iPSCs after 1 day of differentiation with AdV-GFP on the 
expression of GFP.  iPSCs were infected at a MOI of 20.0 and the mean percentage and SD of 
cells expressing GFP determined by fluorescence microscopy from 3 randomly selected views  
up to 3 days later. Typical views shown. Data typical of 3 separate experiments.  
 





Figure 5.8 Early infection (at day 1) of iPSCs with AdV-SGK1F resulted in low levels of 
expression of SGK1F.  Western blot analysed for the expression of flag tagged SGK1F 
followed by β-actin. Cells were repeatedly infected at day 0 at a MOI of 20.0 with the indicated 
AdV-SGK1F construct prior to harvest at day 3 and total cell protein analysis by Western 
blotting. Each lane contained a 20 μg protein/lane.β-actin was used as loading protein. Data 
typical of 3 separate experiments.  
 
 





Figure 5.9 Infection of iPSCs at day 5 with AdV-GFP resulted in high infection rate. Effect 
of repeated infection of iPSCs after 5 days of differentiation with AdV-GFP on the percentage 
of cells expressing GFP at the indicated timepoints. iPSCs were infected at a MOI of 20 and 
the mean percentage and SD of cells expressing GFP determined by fluorescence microscopy 
from 3 randomly selected views (lower panel). Typical view shown in the upper panel. Data 
typical of 3 separate experiments.   
 
 






Figure 5.10 Infection of iPSCs at day 5 AdV-SGK1F resulted a robust SGK1F expression. 
Western blot analysed for the expression of flag tagged SGK1F followed by β-actin. Cells were 
repeatedly infected at day 4 at a MOI of 20.0 with the indicated AdV construct prior to harvest 
at day 7 and total cell protein analysis by Western blotting. Infection with AdV-SGK1F during 
this period  (day5 to day 7)gave rise to the robust expression of a protein in the range of the 




predicted 48.9 kDa size for the tagged SGK1F protein. Each lane contained a 20 μg protein/lane. 
β-actin was used as loading protein Data typical of 3 separate experiments.  
 
Figure 5.11 Infection of iPSCs at day 26 with AdV-GFP resulted in a high infection rate. 
Effect of repeated infection of iPSCs after 26 days of differentiation with AdV-GFP on the 
percentage of cells expressing GFP at the indicated timepoints. iPSC-derived hepatocytes were 
infected at a MOI of 20 and the mean percentage and SD of cells expressing GFP determined 




by fluorescence microscopy from 3 randomly selected views (lower panel). Typical views 




Figure 5.12 Infection of iPSCs at day 26 with AdV-SGK1F resulted in a robust SGK1F 
expression.  Western blot analysed for the expression of flag tagged SGK1F followed by β-
actin. Cells were repeatedly infected at day 26 at a MOI of 20.0 with the indicated AdV 
construct prior to harvest at day 29 and total cell protein analysis by Western blotting. Each 
lane contained a 20 μg protein/lane. β-actin was used as loading protein. Data typical of 3 
separate experiments. 







5.4 d SGK1 activity in hepatocyte-like-cells 
To examine SGK1 activity in hepatocyte-like-cells, the SGK1F  was expressed in  hepatocyte-
like-cells. Cells infected with AdV-SGK1F at an MOI 20 with AdV-SGK1F and AdV-GFP 
form day16 for 3days.  Cell lysates and RNA were made from time 0, 24h, 48h, and 72h. RT-
PCR was performed for SGK1 transcripts (A, B, C, D, F). As shown in Figure 5.13 SGK 1c 
expression was detected in cells infected with AdV-SGK1F for 24 h and  SGK1F expressed by 
cells infected with AdV-SGK1F. Furthermore, a 500ng/ml concentration of protein was 
prepared from the cells lysate. After incubating the sample with 100 µM ATP and 1mg/ml AKT 
substrate, SGK1 activity versus the times cultured with MO 20 of AdV-SGK1F was measured 
using the ADP-Glo Kinase Assay that measures ADP formed from the kinase reaction; ADP is 
converted into ATP, which is converted into light by Ultra-Glo Luciferase. The luminescent 
signal is significantly different from the time zero infected cells, as can be seen from Figure 
5.14. However, increased SGK1 activity was observed in AdV-GFP infected cells too. 





Figure 5.13 Expression of different SGK isoforms after repeated infection with AdV-
SGK1F and AdV-GFP and its effect on SGK activity. Transcript expression: iPSCs were 
infected repeatedly at a MOI of 20.0 with AdV-SGK1F and AdV-GFP at day 16 of 
differentiation for 72 hours.  RNA were isolated after 24 h, 48 h and 72 h and RT-PCR was 
performed to detect the indicated SGK1 isoforms. GAPDH was used as loading control. 
Agarose gel image (upper panel) was quantified using ImageJ software, GAPDH normailsed ( 
lower panel). Data are similar for 3 separate experiments. 
 





Figure 5.14 Repeated infection with AdV-SGK1F and AdV-GFP and its effect on SGK 
activity. SGK1 kinase activity: iPSCs were infected repeatedly at a MOI of 20.0 with AdV-
SGK1F and AdV-GFP at day 16 of differentiation for 72 hours. Cells lysates was prepared from 
cells cultures after 24 hours, 48 hours and 72 hours and SGK1 kinase activity determined in 
cell extracts, as outlined in the methods section. Data are similar for 3 separate experiments. 
Significantly different results (*= P< 0.05) determined using the one way Anova test followed 









5.5 Expression of SGK1F promotes a hepatoblast state in stem cells directed to 
differentiate into hepatocytes 
To test whether SGK1F over-expression at different differentiation stages has an effect on the 
maturity of iPSCs directed to hepatocyte-like cells. The hepatocyte differentiation protocol 
described previously was employed and the differentiating iPSCs were infected with AdV-
SGK1F and AdV-null (at an MOI of 20) from day 1 when the cells are at a pluripotent/early 
transition to an endoderm stage of development, at day 5 when the cells are transiting between 
endodermal/anterior definitive endoderm stages of development and at day 26 when the cells 
are at the post-hepatoblast/foetal hepatocyte (hepatocyte-like) stage of development (Figure 
5.15.A). RNA was isolated from AdV-SGK1F and AdV-null infected cells for qRT-PCR 
analysis, in addition to freshly isolated human liver which was used as a control. The RNA 
concentrations were quantified by Nanodrop spectrophotometer. Additionally, cDNA 
synthesised from 5 ng of total RNA was mixed with TaqMan Universal PCR Master Mix 
(Applied Biosystems) and a gene specific primer and probe mixture (predeveloped TaqMan 
Gene Expression Assays, Applied Biosystems) in a final volume of 20 µl was used. The probe 
sets used were designed to specifically amplify regions of the cDNAs for OCT4, SOX2, 
FOXA2, HEX, SOX17, HNF4α AFP, CYP3A7, Albumin, CPS1, CYP1A2 and CYP3A4). All 
samples were run in triplicate. The mRNA concentrations of specific genes were expressed in 
arbitrary units and normalised to the mean of 18s ribosomal RNA concentrations to correct the 
differences in cDNA loading. 
The extent of the differentiation of AdV-SGK1F infected cells was compared to AdV-null 
infected cells. Figure 5.15B indicates that the SGK1F expression resulted in no significant 
changes in any transcript level (when compared to the AdV-null control) after 3 days of 
infection at the early stage of differentiation (day 1). These data suggest that early expression 
of SGK1F in iPSCs directed to differentiate into endoderm does not promote progression to 
endodermal cells, either because of low rates of infection (resulting in low levels of expression 
as demonstrated in Figure 5.8 in Section 5.3) or because any expressed protein is rapidly 
degraded. 
The relative expression of hepatoblasts markers (AFP and CYP3A7) and mature hepatocyte 
markers (CPS1, ALB, CYPA1A2 and CYP3A4) after 7 day is shown in Figure 5.15 C  which 
illustrates that SGK1F expression significantly increased hepatoblast transcript. This result 
suggests that the expression of SGK1F in iPSCs-derived endoderm directed to differentiate into 
anterior definitive endoderm and hepatoblasts results in promotion to an hepatoblast phenotype. 




The relative expression of hepatoblast markers (AFP, CYP3A7) and mature hepatocyte (CPSI, 
albumin, CYP1A2 and CYP3A4) at day 29 showed in Figure 5.15D. This figure indicates 
SGK1F expression significantly increased the hepatoblast transcripts AFP and CYP3A7. In 
addition, there was a significant decrease in the mature transcript albumin and a tendency – 
though not significantly – for a reduction in CPSI transcripts. In contrast, the adult mature 
hepatocyte transcripts such as CYP1A2 and CYP3A4 were not reliably detectable in iPSC-
derived hepatocyte-like cells (Figure 5.15D). Notably, SGK1F expression did not promote a 
more mature phenotype in hepatoblasts directed to differentiate towards a mature hepatocyte 
phenotype.   
These data suggest that expression of SGK1F in iPSCs differentiating toward hepatocyte-like 















Figure 5.15 Adenoviral-mediated expression of SGK1F promotes an hepatoblast state in 
stem cells directed to differentiate into hepatocytes.  A: schematic diagram depicting the 
protocol (Hannan et al., 2013) employed to direct iPSCs toward hepatocyte-like cells and the 
AdV-SGK1F infection stages. B: Early expression of SGK1F in iPSCs directed to differentiate 
into endoderm has no effect on progression to endodermal cells. Transcript expression. iPSCs 
after 1 day of differentiation were infected with the indicated AdV before total RNA was 
isolated at day 3 and transcript expression determined by qRT-PCR, as outlined in the methods 
section. Data are typical of 3 separate experiments. C: Expression of SGK1F in iPSCs-derived 
endoderm directed to differentiate into hepatoblasts promotes a hepatoblast phenotype. 
Transcript expression. iPSCs after 5 days of differentiation were infected with the indicated 
AdV before total RNA was isolated at day 8 and transcript expression determined by qRT-PCR 
as outlined in the methods section. Data are typical of 3 separate experiments. D: Expression 
of SGK1F in iPSC-derived hepatocytes results in promotion back to a hepatoblast phenotype. 
Transcript expression. iPSC-derived hepatocytes after 26 days of differentiation were infected 
with the indicated AdV before total RNA was isolated at day 29 and transcript expression 
determined by qRT-PCR, as outlined in the methods section. Data are typical of 3 separate 









5.6 Adult human hepatocytes efficiently infected with AdV-GFP and AdV-hSGK1F 
Human hepatocytes (HH) were isolated from a 60 year old male donor by collagenase perfusion 
(performed at the Freeman Hospital by colleagues in the Wright lab) and collagen coated 6 well 
plates of HH were obtained in order to examine the efficiency of HH infection with the 
adenovirus, HH infected repeatedly from day one of isolation with AdV-GFP at MOI 20 HH 
cells were found amenable to adenoviral infection based on infection with AdV-GFP, an 
approximate MOI of 20 resulted in high infection rates > 80 %  by day 3 (Figure 5.16). 
Moreover, after 5 days of infection with AdV-SGK1F MOI 20, high level expression of the 
48.9 kDa tagged SGK1F protein detected by Western blotting  in AdV-SGK1F infected cells 









Figure 5.16 Adult human hepatocytes efficiently infected with AdV-GFP.  Effect of 
repeated infection of adult human hepatocytes (HH) with AdV-GFP on the expression of GFP. 
HH were infected at a MOI of 20.0 on day 1 of isolation and the mean percentage and SD of 
cells expressing GFP determined by fluorescence microscopy from 3 randomly selected views 
up to 3 days later (lower panel). Typical views shown in the upper panel. Significantly different 
results (*= P< 0.05) determined using the one way Anova test followed by the post-hoc test. 
Data typical of 3 separate experiments (n=1). 
 





Figure 5.17 Adult human hepatocytes efficiently infected with AdV-SGK1F.  Western blot 
analysed for the expression of flag tagged SGK1F followed by β-actin. Cells were repeatedly 
infected at day 1 at a MOI of 20.0 with the indicated AdV construct prior to harvest at day 5 
and total cell protein analysis by Western blotting. Each lane contained a 20 μg protein/lane. 
Data typical of 3 separate experiments (n=1).
 
5.7 Expression of SGK1F did not promote mature adult hepatocyte reversal into a 
hepatoblast phenotype.   
In order to investigate the effect of adenovirus mediated SGK1F gene expression on HH de-
differentiation, cells were infected with AdV-SGK1F at a MOI 20 and AdV-null at a MOI 20. 
After 5 days, RNA was isolated from AdV-SGK1F and AdV-null infected cells in addition to 
freshly isolated HH (day 1) for qRT-PCR analysis. The RNA concentrations were quantified 
by Nanodrop spectrophotometer. cDNA synthesised from 5 ng of total RNA was mixed with 
TaqMan Universal PCR Master Mix (Applied Biosystems) and a gene specific primer and 
probe mixture (predeveloped TaqMan Gene Expression Assays, Applied Biosystems) in a final 
volume of 20 µl used. The probe sets used were designed to specifically amplify regions of the 




cDNAs for FOXA2, HEX, AFP, CYP3A7, CPS1, ALBUMIN, CYP1A2 and CYP3A4. All 
samples were run in triplicate (technical replicates). The mRNA concentrations of specific 
genes were expressed in arbitrary units and normalised to the mean 18s ribosomal RNA 
concentrations to correct for differences in cDNA loading. qRT-PCR results shown in Figure 
5.18.A, B and C, indicate that SGK1F expression resulted in no significant changes in any 
transcript level (when compared to AdV-null control). These data suggest that the expression 
of SGK1F in HH did not promote the dedifferentiation of mature human hepatocytes into an 
hepatoblast phenotype.   
 
 





Figure 5.18 Adenoviral mediated expression of SGK1F did not result in a significant effect 
on HH transcripts levels.  A: Expression of SGK1F did not promote significant changes in 
HEX and FOXA2 expression levels in adult hepatocyte. HH after 1 day of isolation were 
infected at a MOI of 20.0 with the indicated AdV before total RNA isolated at day 5 and 
transcript expression determined by qRT-PCR, as outlined in the methods section. Data are 
typical of 3 separate experiments. B: expression of SGK1F did not promote significant changes 
in AFP and CYP3A7 expression levels in adult hepatocyte. HH after 1 day of isolation were 
infected at a MOI of 20.0 with the indicated AdV before total RNA was isolated at day 5 and 
transcript expression determined by qRT-PCR, as outlined in the methods section. Data are 
typical of 3 separate experiments. C: expression of SGK1F did not promote significant changes 
in the expression levels of mature liver marker genes in  adult hepatocyte. HH after 1 day of 
isolation were infected at a MOI of 20 with the indicated AdV before total RNA isolated at day 
5 and transcript expression determined by qRT-PCR, as outlined in the methods section. The 
mRNA concentrations of specific genes were expressed in arbitrary units and normalised to the 
mean 18s ribosomal RNA concentrations Dotted lines indicate the level of time zero control 
sample (HH) used for results normalization. Data presented using the ΔΔCt methodology are 
typical of 3 separate experiments (technical replicates). 
  
5.8 Addition of 1µM Dexamethasone to the initial protocol enhanced hepatic phenotype 
in iPSC-derived hepatocytes 
To determine whether glucocorticoid affects the maturation of iPSCs into hepatocytes, AD3 
cells where differentiated using the standard protocol with the addition of 1µΜ DEX at day 12. 
AD3 cells were differentiated over 26 days using three different protocols: the previously used 
standard protocol (a combination 30ng/ml OSM and 50ng/ml HGF), the amended protocols (a 
combination of 1µΜDEX, 50ng/ml HGF and 30ng/ml OSM) and only 1µΜ DEX. Additionally, 
mRNA was isolated from cells treated with different treatments at day 26 in addition to AD3 
cells at days 1, 5, 12 and 16 of the differentiation into hepatocyte-like-cells employing the 
standard protocol. RNA was purified and RT-PCR was performed. The results show a change 




in the cell morphology, passing from colonies of small round cells with a high nuclear to 
cytoplasm ratio into individual large cells with a low nuclear to cytoplasm ratio with a more 
polygonal shape in day 26 (Figure 5.19 upper panel). RT-PCR results demonstrate that AD3 
cells differentiated with the amended protocol used a combination of 1µΜDEX, 50ng/ml HGF 
and 30ng/ml OSM show a robust expression of the mature liver marker gene, albumin. 
However, albumin transcript is also expressed at day 26 by cells subjected to the standard 
protocol (without DEX) but the expression seems low in comparison to cells treated with a 
combination of 1µΜDEX, 50ng/ml HGF and 30ng/ml OSM. Moreover, CYP2E1 transcript 
expression were detected only in cells subjected to differentiation by the protocol which used a 
combination of 1µΜDEX, 50ng/ml HGF and 30ng/ml OSM. The hepatocyte-like cells 
compared with human adult liver cells. Although RT-PCR is a semi-quantitative technique, this 
result suggests hepatocyte-like cells maturation is enhanced by the addition of 1µМ DEX 
(Figure 5.19 lower panel). A weakness in this experiment is that ethanol vehicle control was 
not used (due to limitation in cells amount) to exclude the effect of the ethanol. 
 





Figure 5.19 Addition of 1µM DEX to the initial protocol used enhanced hepatic phenotype 
in iPSCs derived hepatocyte-like cells. Upper panel: optical morphology of AD3 cells at day 
zero round cells with a high nuclear to cytoplasm ratio grow in colonies. Day 26 without DEX 
and day 26 with DEX from day 12; individual large cells with a low nuclear to cytoplasm ratio 
with a more polygonal shape. Lower panel: RT-PCR for Albumin, CYP2E1 and the house 
keeping gene (GAPDH). mRNA isolated at day 26 from AD3 cells differentiated with different 
combinations of 1µΜDEX, 50ng/ml HGF and 30ng/ml OSM from day 12. Data are typical in 
at least 3 separate experiments.




5.9 Effect of SGK1F expression and/or dexamethasone treatment on the differentiation of 
human iPSCs into hepatocyte-like cells 
iPSCs (AD3 cells) were differentiated to 26 days by the modified protocol using a combination 
of 1µΜDEX, 50ng/ml HGF and 30ng/ml OSM from day 12 in addition to infection at a MOI 
of 20 for three days with AdV-SGK1F at day 5 (endoderm stage) and day 16 (early hepatocyte 
stage) and AdV-null at day 16. RT-PCR was performed for the housekeeping gene (GAPDH), 
SGK1F, OCT4, Nanog, CK19, SOX17, C/EBPα, C/EBP β, HNF4α, AFP, CYP3A7, Albumin, 
CPS1, CYP3A4, CYP2C19 and CYP1A2. All these approaches were compared to time zero cells 
(day 1) and human hepatocytes. The semi quantitative RT-PCR results Figure 5.20 demonstrate 
clear expression of SGK1F by AdV-SGK1F infected cells. However, the level is higher via day 
16 infected cells than those in day five, which suggests more mature cells are less resistant to 
adenoviral infection than those in the early differentiation stage which is consistent with the 
previous finding in Section 5.3. The results in Figure 5.20  also show pluripotency marker genes 
transcripts (OCT4 and Nanog) and the endodermal marker gene SOX17 were only detected in 
day 1 cells and completely absent in day 26 cells. A weak expression of epithelial marker gene 
CK19 was shown by hepatocyte-like cells. Conversely, liver transcription factors genes 
C/EBPα, C/EBPβ and HNF4α were expressed by hepatocyte-like cells. Hepatoblast marker 
genes transcripts (AFP and CYP3A7) were readily expressed in all hepatocyte-like cells. 
Interestingly, liver mature transcripts albumin, CYP3A4 and CYP2C19 was expressed by cells 
treated with DEX and without SGK1F expression at a level similar to that in human 
hepatocytes. In contrast, AdV-SGK1F infected cells showed low expression levels of CYP3A4 
and albumin, which is lower in AdV-SGK1F infected cells at day 16 where there was more 
expression of AdV-SGK1F. This suggests that SGK1F did not promote a more mature 
phenotype in hepatocyte-like cells and conversely, the cells maturation appears to have 
decreased or reversed into an hepatoblast phenotype. 






Figure 5.20 Effect of SGK1F expression and/or DEX treatment on the differentiation of 
human iPSCs derived hepatocyte-like cells.   AD3 cells were differentiated to 26 days by 
being treated with1µΜ DEX from day 12 in addition to infection with MOI 20 AdV-SGK1F at 
day 5 (endoderm stage) for three days and day 16 (early hepatocyte stage) for three days. RT-
PCR was carried out for the indicated transcripts.  A house keeping gene, GAPDH, was used 
as a control. Densitometry analysis was performed using the ImageJ software and data for 
relative intensity was plotted as columns in graphs. Data are similar in at least three separate 
experiments.




A further experiment was performed to assess the effect of DEX treatment on the differentiation 
of human iPSCs into hepatocyte-like cells. AD3 cells were differentiated into hepatocyte-like 
cells (day 26) with the addition of 1µΜDEX from day 12 and without DEX (standard protocol), 
as shown in the schematic diagram in Figure 5.21, upper panel. RNA was purified and 
quantified for qRT-PCR. The probe sets used were designed to specifically amplify regions of 
the cDNAs for HNF4α, AFP, CYP3A7, Albumin, CPS1, CYP1A2, CYP2E1 and CYP3A4. 
Hepatocyte-like cells were compared to freshly isolated human hepatocytes. The results 
revealed a significant difference in AFP levels; DEX treated cells exhibited a lower level of 
immature liver marker transcript (AFP). In contrast, the CYP3A7 transcript expression level is 
significantly high in the DEX treated cell suggesting the effect of DEX on CYP3A7 induction. 
In addition, the expression levels of mature liver marker transcripts CPSI and albumin (however 
it is not significant) is higher in DEX treated cells in comparison to cells subjected to standard 
differentiation protocol. Surprisingly, the CYP3A4 transcript expression level is markedly 
induced by DEX treatment when compared to the expression level in cells treated without DEX. 
The very high expression level of CYP3A4 transcript confirms the effect of DEX on the 





















Figure 5.21 Effect of SGK1F expression and DEX treatment on the differentiation of 
human iPSCs into hepatocyte-like cells.  AD3 cells were differentiated into hepatocyte-like 
cells (day26) with 1µΜDEX from day 12 and without DEX, as demonstrated in the schematic 
flow chart in the upper panel. Q-RT-PCR  was performed using TaqMan Gene Expression 
Assays for liver genes HNF4α, AFP, CYP3A7, Albumin, CPS1, CYP1A2, CYP2E1 and 
CYP3A4 (lower panel). *Significantly different (P<0.05) versus without DEX treated cells 
using Student’s t-test (two tailed). All results typical of at least three separate experiments. 
 
iPSCs derived hepatocyte-like cells at day 16 of differentiation were found amenable to 
adenoviral infection based on infection with adenovirus encoding green fluorescent protein 




(AdV-GFP) with an approximate MOI of 20 which resulted in an infection rate of 
approximately 80% after 3 days (Figure 5.22).  
 
Figure 5.22 iPSCs derived hepatocyte-like cells (at early hepatocyte stage) are efficiently 
infected with AdV-GFP.  iPSCs subjected to standard differentiation protocol and the derived 
hepatocyte-like cells at the early hepatocyte-like stage (day 16) were infected repeatedly with 
approximately MOI 20 of AdV-GFP, the mean percentage and SD of cells expressing GFP 
determined by fluorescence microscopy from 3 randomly selected views up to 3 days later 
(lower planel). In the upper panel typical views shown for uninfected control cells (left) and 
AdV-GFP infected cells day 18 (right). Data typical of 3 separate experiments. *Significantly 
different (P<0.05) was determined by using the one way Anova test followed by the post hoc 
test.
 




To examine the effect of SGK1F overexpression at day 16 (without the addition of DEX) on 
cells directed to hepatocyte-like-cells. iPSCs (AD3 cells) were subjected to the standard 
differentiation protocol and infected with AdV-SGK1F and AdV-null (at an MOI of 20) at day 
16 for three days (Figure 5.23, upper panel). RNA was isolated from hepatocyte-like cells at 
day 26 and purified for qRT-PCR using predeveloped TaqMan Gene Expression Assays for 
HNF4α, AFP, CYP3A7, Albumin, CPS1, CYP1A2, CYP2E1 and CYP3A4. RNA from  freshly 
isolated human hepatocyte was used as a control (case 1). As shown in Figure 5.23.lower panel, 
there is no significant change in the mature liver markers transcripts level; however, there is a 
significant difference in the expression of hepatoblast markers AFP, CYP3A7 in AdV-SGK1F 
infected cells in comparison to AdV-null infected cells. This is consistent with previous findings 
that suggest SGK1F reverse hepatocyte-like cells into an hepatoblast phenotype rather than 






















Figure 5.23 qRT-PCR for the effect of SGK1F expression on the differentiation of human 
iPSCs into hepatocytes-like cells at the early hepatocyte stage (day 16).  RNA isolated from  
Ad3 cells were subjected to the standard protocol differentiation and cells infected with MOI 
20 of AdV-SGK1F at day 16 for three days outlined in the schematic flow chart (upper panel)  
and RNA were isolated at day 26 of differentiation. QRT-PCR using TaqMan Gene Expression 
Assays was performed for the transcripts HNF4a, AFP, CYP3A7, Albumin, CPS1, CYP1A2, 
CYP2E1 and CYP3A4. Data are the mean and standard deviation of three replicates from the 
same experiment. Significantly different (P<0.05) versus AdV-null infected cells using 
Student’s t-test (two tailed). All results typical of at least three separate experiments.




5.10 Chapter discussion 
Although the differentiation of human embryonic stem cells and induced pluripotent stem cells 
into hepatocyte-like cells has been reported 346, additional development of this technology could 
lead to the scalable production of functional hepatocyte-like cells to be used for drug screening 
and to provide an alternative source of hepatocytes for liver transplantation.  
SGK1 is transcriptionally upregulated by glucocorticoids and mineralocorticoids, and 
furthermore, it primarily regulates epithelial Na+ channel (ENaC) and sodium re-absorption by 
the kidney 233. Cell line-based data associating SGK1 activation to particular developmental or 
differentiation pathways are somewhat limited. Wu et al. (2013) and Heitkamp et al. (2014) 
reported that SGK1 plays roles in cells differentiation 254,255, however, there is no apparent 
phenotype – developmental or otherwise - in Sgk1-/- mice (although there is impaired renal 
Na+ retention if mice are exposed to salt depletion 252,347. Given that selected isoforms of Sgk1 
have been shown to substitute for glucocorticoid and be critical for promoting differentiation 
to B-13/H cells (Wallace et al., 2011), we hypothesized that expression of the human SGK1F 
isoform will promote and maintain a hepatocyte phenotype in human stem cells directed to 
differentiate into hepatocyte-like cells. 
In this chapter, a protocol comprising four stages to mimic the embryonic development of the 
liver 52, was used to convert iPSCs (AD3) into hepatocyte-like cells. After 26 days, the 
differentiated cells revealed hepatocyte-like phenotype judged by the disappearance of 
pluripotency and endodermal markers and expression mature hepatic markers transcript 
(Albumin); however, the cells still - at least in part- remained in an immature phenotype as 
confirmed by expression of foetal liver markers transcripts (AFP and CYP3A7). AdV-hSGK1 
overexpression were used to study the effect of SGK1 on iPSC stem cells (AD3) differentiation 
and maturation for the first time. Adenovirus was used as a vector to introduce SGK1F into the 
cells. Adenovirus vector has attracted attention for its ability to safely and efficiently mediate 
gene targeting in a variety of cell types 348 327. Infecting differentiating iPSCs (from day 1) when 
the cells are at a pluripotent/early transition to an endoderm stage of development resulted in a 
low infection rate and low levels of the expression of a protein immunoreactive to the mouse 
anti-SGK1 antibody. In contrast, infecting cells at day 4-5 when the cells are transiting between 
endodermal/anterior definitive endoderm stages of development and at day 26 when the cells 
are at a post-hepatoblast/foetal hepatocyte (hepatocyte-like) stage of development resulted in a 
high rate of infection and robust expression of tagged SGK1F protein. Additionally, SGK1 
enzyme activity showed significant differences with non-infected cells; however, the enzyme 




activity was also significantly different in AdV-GFP infected cells as well, when compared to 
non-infected cells. An explanation for this could be for the reason that this assay is not certain 
to detect the ADP resulting only from SGK1 phosphorylation of AKT substrate. Possibly other 
enzymes catalysed the decomposition of ATP into ADP and a free phosphate ion. Likewise, the 
stress applied to the cells by adenoviral infection alone appears to induce SGK1 transcription, 
as the oxidative stress has been shown to induce SGK1 gene transcription 349 and this could 
mean using adenovirus for therapeutic purposes as gene delivery tool is unsafe. Besides, SGK1 
mRNA has a short half-life, disappearing within 20 min of transcription 246. All previous data 
confirm the functionality of the adenoviral-derived SGK1F protein in iPSCs directed to 
hepatocyte-like-cells.  
In a study conducted by Wallace and Wright (unpublished data), the cells generated from ES 
differentiation into hepatocyte-like cells did not exhibit any detectable maturation phenotype 
after the plasmid-driven human SGK1 expression. However, it was not considered test since 
the transfection rates were extremely low.  The data in this chapter obtained by Q-RT-PCR 
using TaqMan Gene Expression Assays suggest that progression to endoderm was not affected 
by expression of SGK1F soon after stimulation to differentiate from stem cells into endoderm, 
although this may be related to low levels of the infection of cells at this stage of development. 
However, expression of SGK1F in iPSCs-derived endoderm directed to differentiate into 
hepatoblasts resulted in the promotion to an hepatoblast phenotype. Despite this maturing effect 
on endoderm, late expression of SGK1F in iPSCs-derived hepatocytes resulted in an enhanced 
hepatoblast phenotype. On this basis, therefore, SGK1F expression does not act to promote an 
increase in the maturation of stem cell-derived terminally differentiating hepatocytes. Instead, 
SGK1F expression promoted the formation of hepatoblasts from both endoderm and 
hepatocytes. Accordingly, these data disregard the role of SGK1F in the differentiation of AD3 
cells into mature hepatocytes but opens the question as to whether SGK1F expression promotes 
primary hepatocyte dedifferentiation into foetal hepatic phenotype in vitro? Preliminary results 
obtained from adenoviral mediated overexpression of SGK1F in adult hepatocytes soon after 
isolation for five days did not detect any significant changes in liver marker transcript levels 
when compared to AdV-null infected cells.    
As SGK1 is a glucocorticoid-induced gene, the effect of glucocorticoid exposure (1µMDEX)  
at the hepatoblast stage of differentiation, (day12) was also examined. Schoneveld et al. (2004), 
used dexamethasone as a mature hepatic inducer. Clotman et al. (2005), used  oncostatin or 
follistatin and HGF mixed along with dexamethasone to induce the maturation stage 350. The 
use of follistatin or oncostatin is used to favour hepatocyte over cholangiocyte differentiation, 




whereas HGF is used universally to mimic the hepatic environment 350. Recently, Arnaud 
Carpentier et al. (2016), noticed that AFP positive hPSCs- derived hepatocyte-like cells could 
mature into positive albumin cells after dexamethasone treatment 351. RT-PCR results 
demonstrate that AD3 cells differentiation with a combination of 1µMDEX, 50ng/ml HGF and 
30ng/ml OSM at day 12 (hepatoblasts stage) resulted in mature liver marker genes albumin at 
a level similar to that expressed in human hepatocyte.  
The effect of a combination of dexamethasone and SGK1F expression was examined. The semi-
quantitative RT-PCR results demonstrated that the level of expression of SGK1F by AdV-
SGK1F infected cells was higher by day 16 infected cells than those in day five. This 
observation suggested the less mature cells are more resistant to adenoviral infection. It was 
noticed that the expression of foetal markers - AFP and CYP3A7 - was extreme in all cells, 
including those infected with AdV-SGK1F at day five, day 16, as well as AdV-null infected 
cells. Notably, albumin was expressed by cells treated with DEX and AdV-null at a level similar 
to that in human hepatocytes. Conversely, albumin expression is less in cells treated with a 
combination of both DEX and AdV-SGK1F at day 16, which highly express hSGK1F. These 
findings suggest that the maturity is reduced in cells treated with SGK1F overexpression. 
Q-RT-PCR was used to compare the effect of DEX (as mature hepatic inducer) to the standard 
protocol. After 26 days, in DEX-treated cells, CPS1 was high (although it is not a significant 
difference) and CYP3A4 were significantly induced by DEX treatment when compared to 
primary hepatocytes. The very high expression of CYP3A4 confirms the effect of DEX on the 
maturation of cells besides its impact on cytochrome p450 enzyme induction. The effect of 
SGK1F overexpression at day 16 without DEX via the standard protocol was also compared. 
Q-RT-PCR results exhibited that SGK1F overexpression did not enhance hepatocyte-like 
maturation, though there was a significant difference in the expression of AFP, CYP3A7 in 
AdV-SGK1F infected cells in comparison to AdV-null infected cells. This was consistent with 
previous findings that SGK1F overexpression results in hepatocyte dedifferentiation.  
Taken together, the effect of expressing SGK1F in human iPSC-derived cells contrasts with its 
effects when expressed in B-13 cells. However, these effects on stem cells suggest that the role 
of Sgk1 in B-13 cell differentiation to B-13/H cells is likely associated with the induction of a 
(transient) hepatoblast-like phenotype. Previous investigations in B-13 cells suggest that Sgk1 
cross-talks with the WNT signalling pathway through phosphorylation of β-catenin and thereby 
to reduced Tcf/Lef transcriptional activity 218 . However, it was also noted that these effects 
were transient and that WNT signalling activity (and Wnt3a expression, likely acting in an 




autocrine fashion in B-13 cells) returned to near B-13 levels in B-13/H cells. However, the 
effect of dexamethasone (which SGK1 induces) is confirmed as an hepatic maturation inducer. 
The data in this chapter support a significant role for SGK1 that extends beyond what has 
continuously been considered SGK1’s primary function (the control of ion transport across 
membranes). Understanding the mechanism underlying the involvement of SGK1 in promoting 
the hepatoblast differentiation and reversal of hepatocyte-like cells into the hepatoblasts stage 
in stem cells directed to differentiate into hepatocyte-like cells could help to improve stem cells 
differentiation to hepatoblast and to improve primary hepatocyte in vitro culturing.




 General Discussion  
A common difficulty experienced with stem cell-derived differentiated cells in vitro is their 
maturation into completely differentiated phenotypes that quantitatively exhibit the function of 
cells in vivo or straight after isolation from tissues 352,353,354. The primary functional cell of the 
liver – hepatocytes – is a paradigm of this setback 355. Hepatocytes in vivo are extremely 
metabolically active and play a diverse range of functions (many of which are specific to this 
cell type). Stem cell-derived hepatocyte-like cells may resist functioning as hepatocytes in vitro 
for several reasons. These include sub-optimal differentiation protocols; a sub-optimal in vitro 
environment (e.g. extracellular matrix, appropriate cell-cell contacts, cell density) and abnormal 
levels of regulating factors (e.g. hormones controlling gene expression). Together they 
stimulate a de-differentiation process, a response also faced when hepatocytes are isolated from 
undamaged organs and placed under the same environments in vitro 355. These problems have 
resulted in comprehensive attempts to modify the in vitro environment in order to generate 
and/or preserve hepatic functionality (e.g. co-culture systems 345, 3D culture systems 345 and 
flow cultures 293 etc). 
Liver disease models and stem cell-derived hepatocyte-like-cellsimplantation experiments 
suggest that stem/progenitor cell-derived cells maintain the capacity to function sufficiently as 
hepatocytes (when in the appropriate in vivo environment) 356,357,358. Thus, the degree to which 
stem cell-derived hepatocytes will find widespread exploitation for in vitro studies (e.g. drug 
metabolism and toxicity studies), will rely on how complicated and expensive it will be to copy 
the in vivo environment in culture systems. 
An alternative method for generating more mature phenotypes in vitro is via forced over-
expression of suitable transcription factors. The AR42J-B13 (B-13) cell provides reliability for 
this condition, given that B-13 cells are capable of differentiating into a mature hepatocyte 
phenotype (B-13/H cells) without a complex cultural environment. 
In response to glucocorticoids, B-13 cell replication ceases, changes occur morphologically and 
several of the genes specific to hepatocytes are expressed at levels quantitatively comparable 
to normal rat hepatocytes 198,200,218,323. The mechanism controlling this differentiation includes 
an activation of the glucocorticoid receptor; critical epigenetic alterations; induction of 
serine/threonine protein kinase 1 (Sgk1); Sgk1-dependent repression of constitutive WNT cell 
signalling activity and expression of a host of transcription factors that drive the hepatic 
phenotype 218,226,326. This response takes place on simple plastic substrata [although it may also 




occur in 3D and is enhanced by extracellular matrix 359 and in comparison to normal hepatocytes 
is not reversed by de-differentiation, at least for several weeks 218. 
The rat Sgk1 gene is at present known to encode three validated mRNA transcripts and possibly 
one further transcript [NCBI database, see also Table 3.3]. All four transcripts encode an 
identical core amino acid sequence and differ only in their N terminal amino acid sequences.   
It is not known whether the Sgk1 isoforms have other functions; however, only the rat Sgk1c 
transcript appears to be irreversibly induced in B-13 cells after exposure to glucocorticoid 326. 
This finding proposes that endogenous Sgk1c may be accountable for its differentiating effects 
in B-13 cells. This is supported by the high expression of the murine orthologue of Sgk1c in 
pancreatic tissue from transgenic mice with high levels of circulating endogenous 
glucocorticoids (these mice experience the transdifferentiation of the pancreatic exocrine tissue 
into hepatocyte-like cells ), whereas wild type mice expressed neither liver markers nor Sgk1c 
mRNA 231. 
Selected isoforms of Sgk1 (including SGK1F) have been shown to substitute for glucocorticoid 
and be critical for promoting differentiation to B-13/H cells 226. Similarly, high levels of SGK1F 
mRNA transcripts were detected in the pancreas from a patient treated for many decades with 
systemic glucocorticoid experienced a degree of hepatic differentiation 227. These data have 
driven the focus on SGK1F. Accordingly, this thesis hypothesises that the expression of the 
human SGK1F isoform will promote and maintain a hepatocyte phenotype in human stem cells 
directed to differentiate into hepatocyte-like cells. Additionally, cDNA for SGK1F transcript 
was cloned into a replication-deficient adenoviral genome to introduce the genetic material 
(SGK1F) into B-13 cells and iPSCs (AD3 cells) directed to differentiate to hepatocyte-like cells. 
The data in this thesis demonstrate that glucocorticoid receptor antagonist (Ru486) prevented 
DEX-dependent trans-differentiation of B-13 cells into B1-13/H cells. This data support that 
the effect of DEX on transdifferentiation are mediated through the GR 226. Moreover, the data 
demonstrate that B-13 cells treated with 10nM DEX treatment resulted in a significant decrease 
in WNT signalling. Moreover, in addition to the DEX effect on WNT signalling repression, it 
has also resulted in β-catenin phosphorylation which is consistent with findings of Wallace et 
al 231. Antagonising progesterone receptor with RU486 have the same effect as DEX on WNT 
signalling. However, both RU486 and DEX repressed WNT signalling, and only DEX 
converted B-13 cells into B-13/H cells. This effect is probably because exposing B-13 cells to 
glucocorticoid leads to a Gr-dependent pulse in DNA methylation and possibly other epigenetic 




changes, such as histone modifications that results in the constitutive expression of Sgk1c and 
the irreversible reprogramming of B-13 cells into B-13/H cells 326. 
The data in this thesis reveals that B13 cells are readily infected with adenovirus. However, 
marked toxicity was observed with high MOIs. Therefore, the repeated infection strategy was 
employed in B-13 cells to maximise infection and SGK1F expression and minimise cell death. 
The data also demonstrates that adenoviral-mediated SGK1F expression in B-13 cells induces 
their differentiation into B-13/H cells, similar to their response to exposure to glucocorticoid 
also suggesting that Sgk1 activity is crucial in B13 conversion into B-13/H. Accordingly, 
SGK1F is implicated in the transdifferentiation of B-13 cells into B-13/H hepatocyte-like cells. 
Furthermore, the role of Sgk1 kinase activity in B-13 cells and WNT signalling was further 
tested by examining the effect of AdV-hSGK1F overexpression on WNT signalling 
transcriptional activity. Data in this thesis demonstrated a regulatory role for Sgk1 (SGK1F) in 
WNT signalling changes and suggested that SGK1F overexpression is upstream of β-catenin 
phosphorylation changes. The likelihood is therefore that the conversion of B-13 cells into B-
13/H cells in response to glucocorticoid is associated with Sgk1 induction and WNT signalling 
changes. Taken together, these data therefore support the proposed glucocorticoid-dependent 
mechanism for converting B-13 cells into B-13/H cells, as schematically outlined in Figure 8, 
involving glucocorticoid receptor activation, Sgk1 induction, phosphorylation of β-catenin and 
suppression of endogenously high WNT signalling activity in B-13 cells. 
The data in this thesis obtained by investigating (for the first time) the effect of adenoviral-
mediated expression of SGK1F on iPSCs (AD3 cells) directed to differentiate into hepatocyte-
like cells, propose that the expression of SGK1F did not influence differentiation to endoderm 
immediately after induction of stem cells differentiation into the endodermal stage. Even though 
this might be due to low levels of cells infection at this stage of development. Limited trial and 
error led us to the conclusion that MOI of 20 gave the best infection rates whilst limiting 
significant losses in cell viability. We were limited to the range of pilot studies we could 
perform because there were limitations to the number of iPSCs that could be generated each 
time and accordingly, limitations on examining the many potential variables impacting on 
optimal infection and gene expression. Conversely, expression of SGK1F in iPSCs-derived 
endoderm directed to differentiate into hepatoblasts phenotype resulted in promotion to an 
hepatoblast phenotype. Regardless of this maturing impact in endoderm, late expression of 
SGK1F in iPSCs-derived hepatocytes resulted in the boosted hepatoblast phenotype. According 
to this, SGK1F expression does not act to promote an increase in the maturation of stem cell-
derived terminally differentiating hepatocytes. Instead, SGK1F expression promoted the 




formation of hepatoblasts from both endoderm and hepatocytes. Therefore, these effects in stem 
cells suggest that the role of Sgk1 in B-13 cell differentiation to B-13/H cells is likely associated 
with the induction of a (transient) hepatoblast-like phenotype. The exact timepoints not 
analysed throughout in chapter 5 because of limitations in the number of iPSCs that can be 
matured. In addition, sometimes the RNA concentration selected was too low or lack purity, 
which required some flexibility around the day of culture used for some analyses. 
In conclusion, the effect of expressing SGK1F in human iPSC-derived cells appears 
contrasting to its effects when expressed in B-13 cells; however, these effects in stem cells 
suggest that the role of Sgk1 in B-13 cell differentiation to B-13/H cells is likely associated 
with the induction of a (transient) hepatoblast-like phenotype. Preceding investigations in B-13 
cells indicate that Sgk1 cross-talks with the WNT signalling pathway via phosphorylation of β-
catenin to reduce Tcf/Lef transcriptional activity 218. Though it was also observed that these 
effects were transient and that WNT signalling activity (and Wnt3a expression, possibly acting 
in an autocrine fashion in B-13 cells) returned to near B-13 levels in B-13/H cells. Besides, 
glucocorticoid exposure in B-13 cells initiates an epigenetic change(s) that accounts for the 
inability of B-13/H cells to revert to B-13 cells (and which may also be critical for their near 
quantitative functional trans-differentiation into hepatocytes)326 (Figure 6.1). However, adding 
dexamethasone at the hepatoblast stage somewhat enhanced the stem cells maturity which is 
judged by the expression of higher expression level albumin in comparison to the no DEX 
treated cells. Future work could be directed to identifying what factors induce SGK1C and to 
identifying the precise epigenetic changes controlling Sgk1c expression in B-13 cells. Ideally, 
one would sequence the entire genome, however, this is impractical and remains costly at 
present. Additional work could examine why specific isoforms (sgk1c and SGK1F) interact 
with β-catenin, lead to β-catenin phosphorylation and result in a suppression of WNT 
signalling  Although, there is no significant amino acid sequence similarity between SGK1F 
and SGK1C N- terminal sequences, peptides of these proteins sequences could be constructed 
and transfected to B-13 cells to examine their effect on beta-catenin phosphorylation using 
an immunoprecipitation technique. Moreover, SGK1F overexpression could be used to 
enhance B-13 transdifferentiation into B-13/H cells and to promote the hepatoblasts stage to 



















Appendix A. List of DNA oligonucleotide sequences employed in RT-
PCR 
Oligo ID  Primer sequence (5'-3')  Comments  


















Will hybridise to 
human SOX2 cDNA 
sequence 
[NM_003106] and 












2, cDNA sequence 
NM_001297698.1 and 












Will hybridise to 
human SOX17 cDNA 
sequence 
[NM_022454] and 








Will hybridise to 
human FOXA2 cDNA 
sequence transcript 
variant 1[NM_021784] 
and transcript variant 2 
[NM_153675] to 







Will hybridise to 
human HHEX cDNA 
sequence 
[NM_002729] and 








Will amplify sequence 
of 198 bp of human 
hepatocyte nuclear 














Will amplify sequence 
of 110 bp of human 
hepatocyte nuclear 












Will amplify sequence 
of 105 bp of human 
CCAAT enhancer 
binding protein beta 
(CEBPA), transcript 
variant 









Will amplify sequence 
of 264 bp of human 
CCAAT enhancer 
binding protein beta 
(CEBPB), transcript 








Will amplify sequence 
















Will hybridise to human 
CYP3A7 cDNA 
sequence [NM_000765] 








Will hybridise to human 
CK19 cDNA sequence 
[NM_002276.4] and 
amplify a fragment of 





Will hybridise to human 
Cps1  cDNA sequence ( 
NM_001122633.2) and 
amplify a fragment of 





Will amplify sequence 







Will amplify sequence 













Will amplify sequence 
of 136 bp Human 
cytochrome P450 
family 3 subfamily A 
member 4 (CYP3A4), 







Will amplify sequence 
of 93 bp cytochrome 
P450 family 2 













Will hybridise to human 
CYP2E1  cDNA 
sequence 
(NM_000773.4) and 










Will amplify sequence of 80 
bp cytochrome P450 family 















Will amplify sequence of 
116 bp  of cytochrome P450 
family 2 subfamily C 
member 19 (CYP2C19) 
NM_000769.4 DS AGATAGTGAAATTTGG
ACCAGAGGA 

















Will amplify Rattus 
norvegicus nuclear receptor 
subfamily 1, group I, 
member 2 (Nr1i2 ( 
NM_052980.2)115) cDNA 








Will hybridise to rat CpsI 
cDNA (NM_017072.1) 
sequence of 173bp at 59° C 
to produce a single 
amplimer 326.  
 
DS CGCATTCCAACAG




























Will amplify a rat 
CYP2E (NM_031543) 
cDNA sequence of 





Will hybridise to rat 
albumin cDNA 
(NM_134326.2) 
sequence of 192bp at 






hSGK1a (w/t) US  
 CGAGCCGGTCTTTG   
CGAGCCGGTCTTTGAG
CGCTAAC 
Will amplify 118bp of 
human SGK1 variant 1 
mRNA 
(NM_005627.3). 
Also referred to as 












Will amplify 140bp of 
human SGK1 variant 4 
mRNA 
(NM_001143678.1). 
















Will amplify 121bp of 
human SGK1 variant 3 
mRNA(NM_00114367











Will amplify 140bp of 
human SGK1 variant 2 
(NM_001143676.1). 










Will amplify 211bp of 










Will amplify rat 
(NM_019232) Sgk1acDNA 
sequence of 128 bp226 
 
DS GCATGCATAGGAGTTG
TTGG   












Will amplify rat Sgk1b 











Will amplify rat Sgk1c - 
also referred to as variant 2 
(NM_001193569.1) cDNA 
sequence of 143bp 226 
DS GCATGCATAGGAGTTG
TTGG 








Will amplify rat Sgk1 
like loc  cDNA 









Will amplify rat Sgk1 
X2  ( 
XM_006227723.1)  
















Will hybridise to 







amplify fragments all 





















Will amplify fragments 











Appendix B. Rat and human Sgk1 proteins sequences (raw sequence data ) 
Rat Sgk1 protein sequences 










































CLUSTAL O(1.2.4) multiple sequence alignment of rat Sgk1 protein sequences 
 
 
4      MVNKDMNGFPVKKCSAFQFFKKRVRRWIKSPMVSVDKHQSPNLKYTGPAGVHLPPGEPDF 60 
3      ------------------------------------------------------------ 0 
1      ------------------------------------------------------------ 0 
2      ------------------------------------------------------------ 0 
                                                                    
 
4      EPALCQSCLGDHTFQRGMLSPEESRSWEIQPGGEVKEPCNHANILTKPDPRTFWTSDDPA 120 
3      ----------------------------M-----TVKTEAARSTLTYS-RMRGMVAILIA 26 
1      --------MGEM---QGALARAR---LES-----LLRPRHKKRVEAQK-RSESVLLSGLA 40 
2      -----------------------------------------------M-REEALRSPWKA 12 
                                                                  * 
 
4      FMKQRRMGLNDFIQKLANNSYACKHPEVQSYLKISQPQEPELMNANPSPPPSPSQQINLG 180 
3      FMKQRRMGLNDFIQKLANNSYACKHPEVQSYLKISQPQEPELMNANPSPPPSPSQQINLG 86 
1      FMKQRRMGLNDFIQKLANNSYACKHPEVQSYLKISQPQEPELMNANPSPPPSPSQQINLG 100 
2      FMKQRRMGLNDFIQKLANNSYACKHPEVQSYLKISQPQEPELMNANPSPPPSPSQQINLG 72 
       ************************************************************ 
 
4      PSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAEEAFYAVKVLQKKAILKKKEEKHIMSE 240 
3      PSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAEEAFYAVKVLQKKAILKKKEEKHIMSE 146 
1      PSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAEEAFYAVKVLQKKAILKKKEEKHIMSE 160 
2      PSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAEEAFYAVKVLQKKAILKKKEEKHIMSE 132 
       ************************************************************ 
 
4      RNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYINGGELFYHLQRERCFLEPRARFYAAEI 300 
3      RNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYINGGELFYHLQRERCFLEPRARFYAAEI 206 
1      RNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYINGGELFYHLQRERCFLEPRARFYAAEI 220 
2      RNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYINGGELFYHLQRERCFLEPRARFYAAEI 192 
       ************************************************************ 
 
4      ASALGYLHSLNIVYRDLKPENILLDSQGHIVLTDFGLCKENIEHNGTTSTFCGTPEYLAP 360 
3      ASALGYLHSLNIVYRDLKPENILLDSQGHIVLTDFGLCKENIEHNGTTSTFCGTPEYLAP 266 
1      ASALGYLHSLNIVYRDLKPENILLDSQGHIVLTDFGLCKENIEHNGTTSTFCGTPEYLAP 280 
2      ASALGYLHSLNIVYRDLKPENILLDSQGHIVLTDFGLCKENIEHNGTTSTFCGTPEYLAP 252 
       ************************************************************ 
 
4      EVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSRNTAEMYDNILNKPLQLKPNITNSARH 420 
3      EVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSRNTAEMYDNILNKPLQLKPNITNSARH 326 
1      EVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSRNTAEMYDNILNKPLQLKPNITNSARH 340 
2      EVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSRNTAEMYDNILNKPLQLKPNITNSARH 312 
       ************************************************************ 
 
4      LLEGLLQKDRTKRLGAKDDFMEIKSHIFFSLINWDDLINKKITPPFNPNVSGPSDLRHFD 480 
3      LLEGLLQKDRTKRLGAKDDFMEIKSHIFFSLINWDDLINKKITPPFNPNVSGPSDLRHFD 386 
1      LLEGLLQKDRTKRLGAKDDFMEIKSHIFFSLINWDDLINKKITPPFNPNVSGPSDLRHFD 400 
2      LLEGLLQKDRTKRLGAKDDFMEIKSHIFFSLINWDDLINKKITPPFNPNVSGPSDLRHFD 372 
       ************************************************************ 
 
4      PEFTEEPVPSSIGRSPDSILVTASVKEAAEAFLGFSYAPPMDSFL 525 
3      PEFTEEPVPSSIGRSPDSILVTASVKEAAEAFLGFSYAPPMDSFL 431 
1      PEFTEEPVPSSIGRSPDSILVTASVKEAAEAFLGFSYAPPMDSFL 445 
2      PEFTEEPVPSSIGRSPDSILVTASVKEAAEAFLGFSYAPPMDSFL 417 






Human SGK1 protein sequences 
Note: Transcripts from isoform 1 and isoform 5 generate the same N terminus but differ in that 
isoform 5 lacks an internal 44 residues present in all other proteins.  























































2      MVNKDMNGFPVKKCSAFQFFKKRVRRWIKSPMVSVDKHQSPSLKYTGSSMVHIPPGEPDF 60 
4      --------------------------------------------------------MGEM 4 
3      --------------------------------------------------------MSSQ 4 
1      ------------------------------------------------------------ 0 
5      ------------------------------------------------------------ 0 
                                                                    
 
2      ESSLCQTCLGEHAFQRGVLPQENESCSWETQSGCEVREPCNHANILTKPDPRTF------ 114 
4      QGALA----------------------RARL---ESLLR---PRHK-------KRAEAQK 29 
3      SSSLSE------------------ACSREAYSSHNWALP---PASRSNPQPAYPWATRRM 43 
1      -------------------------------------MT----VKTEAAKGTLT----YS 15 
5      -------------------------------------MT----VKTEAAKGTLT----YS 15 
                                                                    
 
2      ----WTNDDPAFMKQRRMGLNDFIQKIANNSYACKHPEVQSILKISQPQEPELMNANPSP 170 
4      RSESFLLSGLAFMKQRRMGLNDFIQKIANNSYACKHPEVQSILKISQPQEPELMNANPSP 89 
3      KEEAIKPPLKAFMKQRRMGLNDFIQKIANNSYACKHPEVQSILKISQPQEPELMNANPSP 103 
1      RMRGMVAILIAFMKQRRMGLNDFIQKIANNSYACKHPEVQSILKISQPQEPELMNANPSP 75 
5      RMRGMVAILIAFMKQRRMGLNDFIQKIANNSYACKHPEVQSILKISQPQEPELMNANPSP 75 
                 ************************************************** 
 
2      PPSPSQQINLGPSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAEEVFYAVKVLQKKAIL 230 
4      PPSPSQQINLGPSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAEEVFYAVKVLQKKAIL 149 
3      PPSPSQQINLGPSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAEEVFYAVKVLQKKAIL 163 
1      PPSPSQQINLGPSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAEEVFYAVKVLQKKAIL 135 
5      PPSPSQQINLGPSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAEEVFYAVKVLQKKAIL 135 
       ************************************************************ 
 
2      KKKEEKHIMSERNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYINGGELFYHLQRERCFL 290 
4      KKKEEKHIMSERNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYINGGELFYHLQRERCFL 209 
3      KKKEEKHIMSERNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYINGGELFYHLQRERCFL 223 
1      KKKEEKHIMSERNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYINGGELFYHLQRERCFL 195 
5      KKK--------------------------------------------ELFYHLQRERCFL 151 
       ***                                            ************* 
 
2      EPRARFYAAEIASALGYLHSLNIVYRDLKPENILLDSQGHIVLTDFGLCKENIEHNSTTS 350 
4      EPRARFYAAEIASALGYLHSLNIVYRDLKPENILLDSQGHIVLTDFGLCKENIEHNSTTS 269 
3      EPRARFYAAEIASALGYLHSLNIVYRDLKPENILLDSQGHIVLTDFGLCKENIEHNSTTS 283 
1      EPRARFYAAEIASALGYLHSLNIVYRDLKPENILLDSQGHIVLTDFGLCKENIEHNSTTS 255 
5      EPRARFYAAEIASALGYLHSLNIVYRDLKPENILLDSQGHIVLTDFGLCKENIEHNSTTS 211 
       ************************************************************ 
 
2      TFCGTPEYLAPEVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSRNTAEMYDNILNKPLQ 410 
4      TFCGTPEYLAPEVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSRNTAEMYDNILNKPLQ 329 
3      TFCGTPEYLAPEVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSRNTAEMYDNILNKPLQ 343 
1      TFCGTPEYLAPEVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSRNTAEMYDNILNKPLQ 315 
5      TFCGTPEYLAPEVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSRNTAEMYDNILNKPLQ 271 
       ************************************************************ 
 
2      LKPNITNSARHLLEGLLQKDRTKRLGAKDDFMEIKSHVFFSLINWDDLINKKITPPFNPN 470 
4      LKPNITNSARHLLEGLLQKDRTKRLGAKDDFMEIKSHVFFSLINWDDLINKKITPPFNPN 389 
3      LKPNITNSARHLLEGLLQKDRTKRLGAKDDFMEIKSHVFFSLINWDDLINKKITPPFNPN 403 
1      LKPNITNSARHLLEGLLQKDRTKRLGAKDDFMEIKSHVFFSLINWDDLINKKITPPFNPN 375 
5      LKPNITNSARHLLEGLLQKDRTKRLGAKDDFMEIKSHVFFSLINWDDLINKKITPPFNPN 331 
       ************************************************************ 
 
2      VSGPNDLRHFDPEFTEEPVPNSIGKSPDSVLVTASVKEAAEAFLGFSYAPPTDSFL 526 
4      VSGPNDLRHFDPEFTEEPVPNSIGKSPDSVLVTASVKEAAEAFLGFSYAPPTDSFL 445 
3      VSGPNDLRHFDPEFTEEPVPNSIGKSPDSVLVTASVKEAAEAFLGFSYAPPTDSFL 459 
1      VSGPNDLRHFDPEFTEEPVPNSIGKSPDSVLVTASVKEAAEAFLGFSYAPPTDSFL 431 
5      VSGPNDLRHFDPEFTEEPVPNSIGKSPDSVLVTASVKEAAEAFLGFSYAPPTDSFL 387 


























CLUSTAL O(1.2.4) multiple sequence alignment of SGK1F (F) with human SGK1 
isoform 1 (1) 
 
 
F      ----------MKPSKRFFISPPSSTAFMKQRRMGLNDFIQKIANNSYACKHPEVQSILKI 50 
1      MTVKTEAAKGTLTYSRMRGMVAILIAFMKQRRMGLNDFIQKIANNSYACKHPEVQSILKI 60 
                     .*:        *********************************** 
 
F      SQPQEPELMNANPSPPPSPSQQINLGPSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAE 110 
1      SQPQEPELMNANPSPPPSPSQQINLGPSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAE 120 
       ************************************************************ 
 
F      EVFYAVKVLQKKAILKKKEEKHIMSERNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYIN 170 
1      EVFYAVKVLQKKAILKKKEEKHIMSERNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYIN 180 
       ************************************************************ 
 
F      GGELFYHLQRERCFLEPRARFYAAEIASALGYLHSLNIVYRDLKPENILLDSQGHIVLTD 230 
1      GGELFYHLQRERCFLEPRARFYAAEIASALGYLHSLNIVYRDLKPENILLDSQGHIVLTD 240 
       ************************************************************ 
 
F      FGLCKENIEHNSTTSTFCGTPEYLAPEVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSR 290 
1      FGLCKENIEHNSTTSTFCGTPEYLAPEVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSR 300 
       ************************************************************ 
 
F      NTAEMYDNILNKPLQLKPNITNSARHLLEGLLQKDRTKRLGAKDDFMEIKSHVFFSLINW 350 
1      NTAEMYDNILNKPLQLKPNITNSARHLLEGLLQKDRTKRLGAKDDFMEIKSHVFFSLINW 360 
       ************************************************************ 
 
F      DDLINKKITPPFNPNVSGPNDLRHFDPEFTEEPVPNSIGKSPDSVLVTASVKEAAEAFLG 410 
1      DDLINKKITPPFNPNVSGPNDLRHFDPEFTEEPVPNSIGKSPDSVLVTASVKEAAEAFLG 420 
       ************************************************************ 
 
F      FSYAPPTDSFL 421 
1      FSYAPPTDSFL 431 






















1. Evans, M.J. and Kaufman, M.H. (1981) 'Establishment in culture of pluripotential cells 
from mouse embryos', Nature, 292(5819), 154-6. 
2. Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., 
Marshall, V.S. and Jones, J.M. (1998) 'Embryonic stem cell lines derived from human 
blastocysts', Science, 282(5391), 1145-7. 
3. Mitalipov, S. and Wolf, D. (2009) 'Totipotency, Pluripotency and Nuclear 
Reprogramming', Adv Biochem Eng Biotechnol, 114, 185-99. 
4. Ulloa-Montoya, F., Verfaillie, C.M. and Hu, W.S. (2005) 'Culture systems for 
pluripotent stem cells', J Biosci Bioeng, 100(1), 12-27. 
5. Pelton, T.A., Bettess, M.D., Lake, J., Rathjen, J. and Rathjen, P.D. (1998) 
'Developmental complexity of early mammalian pluripotent cell populations in vivo and 
in vitro', Reprod Fertil Dev, 10(7-8), 535-49. 
6. Karanes, C., Nelson, G.O., Chitphakdithai, P., Agura, E., Ballen, K.K., Bolan, C.D., 
Porter, D.L., Uberti, J.P., King, R.J. and Confer, D.L. (2008) 'Twenty years of unrelated 
donor hematopoietic cell transplantation for adult recipients facilitated by the National 
Marrow Donor Program', Biol Blood Marrow Transplant, 14(9 Suppl), 8-15. 
7. Tuch, B.E. (2006) 'Stem cells--a clinical update', Aust Fam Physician, 35(9), 719-21. 
8. Robinton, D.A. and Daley, G.Q. (2012) 'The promise of induced pluripotent stem cells 
in research and therapy', Nature, 481(7381), 295-305. 
9.   . Available at: https://vignette.wikia.nocookie.net/mmg-233-2014-genetics-
genomics/images/f/f6/3D-Medical-Illustration-Pluripotent-Stem-
Cells.jpg/revision/latest?cb=20141013062832 (Accessed: 21/02/2019). 
10. Murry, C.E. and Keller, G. (2008) 'Differentiation of embryonic stem cells to clinically 
relevant populations: lessons from embryonic development', Cell, 132(4), 661-80. 
11. Tam, P.P. and Behringer, R.R. (1997) 'Mouse gastrulation: the formation of a 
mammalian body plan', Mech Dev, 68(1-2), 3-25. 
12. Hart, A.H., Hartley, L., Sourris, K., Stadler, E.S., Li, R., Stanley, E.G., Tam, P.P., 
Elefanty, A.G. and Robb, L. (2002) 'Mixl1 is required for axial mesendoderm 
morphogenesis and patterning in the murine embryo', Development, 129(15), 3597-608. 
13. Kispert, A. and Herrmann, B.G. (1994) 'Immunohistochemical analysis of the 
Brachyury protein in wild-type and mutant mouse embryos', Dev Biol, 161(1), 179-93. 
14. Kinder, S.J., Tsang, T.E., Wakamiya, M., Sasaki, H., Behringer, R.R., Nagy, A. and 
Tam, P.P. (2001) 'The organizer of the mouse gastrula is composed of a dynamic 
population of progenitor cells for the axial mesoderm', Development, 128(18), 3623-34. 
15. Dush, M.K. and Martin, G.R. (1992) 'Analysis of mouse Evx genes: Evx-1 displays 
graded expression in the primitive streak', Dev Biol, 151(1), 273-87. 
16. Forlani, S., Lawson, K.A. and Deschamps, J. (2003) 'Acquisition of Hox codes during 
gastrulation and axial elongation in the mouse embryo', Development, 130(16), 3807-
19. 
17. Kinder, S.J., Tsang, T.E., Quinlan, G.A., Hadjantonakis, A.K., Nagy, A. and Tam, P.P. 
(1999) 'The orderly allocation of mesodermal cells to the extraembryonic structures and 
the anteroposterior axis during gastrulation of the mouse embryo', Development, 
126(21), 4691-701. 
18. Yamaguchi, T.P. (2001) 'Heads or tails: Wnts and anterior-posterior patterning', Curr 
Biol, 11(17), R713-24. 
19. Hogan, B.L. (1996) 'Bone morphogenetic proteins in development', Curr Opin Genet 




20. Conlon, F.L., Lyons, K.M., Takaesu, N., Barth, K.S., Kispert, A., Herrmann, B. and 
Robertson, E.J. (1994) 'A primary requirement for nodal in the formation and 
maintenance of the primitive streak in the mouse', Development, 120(7), 1919-28. 
21. Schier, A.F. and Shen, M.M. (2000) 'Nodal signalling in vertebrate development', 
Nature, 403(6768), 385-9. 
22. Gadue, P., Huber, T.L., Nostro, M.C., Kattman, S. and Keller, G.M. (2005) 'Germ layer 
induction from embryonic stem cells', Exp Hematol, 33(9), 955-64. 
23. Keirstead, H.S. (2001) 'Stem cell transplantation into the central nervous system and the 
control of differentiation', Journal of neuroscience research, 63(3), 233-236. 
24. Wagers, A.J. and Weissman, I.L. (2004) 'Plasticity of adult stem cells', Cell, 116(5), 
639-48. 
25. Leblond, C.P. (1964) 'CLASSIFICATION OF CELL POPULATIONS ON THE BASIS 
OF THEIR PROLIFERATIVE BEHAVIOR', Natl Cancer Inst Monogr, 14, 119-50. 
26. health, N.i.o. (2018) Stem Cell Basics IV. Available at: 
https://stemcells.nih.gov/info/basics/4.htm (Accessed: 25sep). 
27. Muller-Sieburg, C.E., Cho, R.H., Thoman, M., Adkins, B. and Sieburg, H.B. (2002) 
'Deterministic regulation of hematopoietic stem cell self-renewal and differentiation', 
Blood, 100(4), 1302-9. 
28. Lewis, P.D. (1968) 'Mitotic activity in the primate subependymal layer and the genesis 
of gliomas', Nature, 217(5132), 974-5. 
29. Bryder, D., Rossi, D.J. and Weissman, I.L. (2006) 'Hematopoietic stem cells: the 
paradigmatic tissue-specific stem cell', Am J Pathol, 169(2), 338-46. 
30. Shi, S., Bartold, P.M., Miura, M., Seo, B.M., Robey, P.G. and Gronthos, S. (2005) 'The 
efficacy of mesenchymal stem cells to regenerate and repair dental structures', Orthod 
Craniofac Res, 8(3), 191-9. 
31. Petersen, B.E., Goff, J.P., Greenberger, J.S. and Michalopoulos, G.K. (1998) 'Hepatic 
oval cells express the hematopoietic stem cell marker Thy-1 in the rat', Hepatology, 
27(2), 433-45. 
32. Liu, S., Dontu, G. and Wicha, M.S. (2005) 'Mammary stem cells, self-renewal 
pathways, and carcinogenesis', Breast Cancer Res, 7(3), 86-95. 
33. Pan, G., Mu, Y., Hou, L. and Liu, J. (2019) Annales d'endocrinologie. Elsevier. 
34. National Institutes of Health, U.S.D.o.H.a.H.S. (2016) NIH Stem Cell Information 
Available at: https://stemcells.nih.gov/info/basics/4.htm (Accessed: 17/04/2019). 
35. Goldthwaite Jr, C.A. (2007) 'Mending a broken heart: Stem cells and cardiac repair', 
NIH report. 
36. Jensen, J.N., Cameron, E., Garay, M.V., Starkey, T.W., Gianani, R. and Jensen, J. 
(2005) 'Recapitulation of elements of embryonic development in adult mouse pancreatic 
regeneration', Gastroenterology, 128(3), 728-41. 
37. Krause, D.S., Theise, N.D., Collector, M.I., Henegariu, O., Hwang, S., Gardner, R., 
Neutzel, S. and Sharkis, S.J. (2001) 'Multi-organ, multi-lineage engraftment by a single 
bone marrow-derived stem cell', Cell, 105(3), 369-77. 
38. Germain, L., Noel, M., Gourdeau, H. and Marceau, N. (1988) 'Promotion of growth and 
differentiation of rat ductular oval cells in primary culture', Cancer Res, 48(2), 368-78. 
39. Sirica, A.E., Mathis, G.A., Sano, N. and Elmore, L.W. (1990) 'Isolation, culture, and 
transplantation of intrahepatic biliary epithelial cells and oval cells', Pathobiology, 
58(1), 44-64. 
40. Dabeva, M.D. and Shafritz, D.A. (1993) 'Activation, proliferation, and differentiation 
of progenitor cells into hepatocytes in the D-galactosamine model of liver regeneration', 
Am J Pathol, 143(6), 1606-20. 
41. Lazaro, C.A., Rhim, J.A., Yamada, Y. and Fausto, N. (1998) 'Generation of hepatocytes 




42. Lagasse, E., Connors, H., Al-Dhalimy, M., Reitsma, M., Dohse, M., Osborne, L., Wang, 
X., Finegold, M., Weissman, I.L. and Grompe, M. (2000) 'Purified hematopoietic stem 
cells can differentiate into hepatocytes in vivo', Nat Med, 6(11), 1229-34. 
43. Smith, A.G., Heath, J.K., Donaldson, D.D., Wong, G.G., Moreau, J., Stahl, M. and 
Rogers, D. (1988) 'Inhibition of pluripotential embryonic stem cell differentiation by 
purified polypeptides', Nature, 336(6200), 688-90. 
44. Wilmut, I., Schnieke, A.E., McWhir, J., Kind, A.J. and Campbell, K.H. (1997) 'Viable 
offspring derived from fetal and adult mammalian cells', Nature, 385(6619), 810-3. 
45. Tada, M., Takahama, Y., Abe, K., Nakatsuji, N. and Tada, T. (2001) 'Nuclear 
reprogramming of somatic cells by in vitro hybridization with ES cells', Curr Biol, 
11(19), 1553-8. 
46. Takahashi, K. and Yamanaka, S. (2006) 'Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors', Cell, 126(4), 663-76. 
47. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. and 
Yamanaka, S. (2007) 'Induction of pluripotent stem cells from adult human fibroblasts 
by defined factors', Cell, 131(5), 861-72. 
48. Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., 
Nie, J., Jonsdottir, G.A., Ruotti, V., Stewart, R., Slukvin, II and Thomson, J.A. (2007) 
'Induced pluripotent stem cell lines derived from human somatic cells', Science, 
318(5858), 1917-20. 
49. Lowry, W.E., Richter, L., Yachechko, R., Pyle, A.D., Tchieu, J., Sridharan, R., Clark, 
A.T. and Plath, K. (2008) 'Generation of human induced pluripotent stem cells from 
dermal fibroblasts', Proc Natl Acad Sci U S A, 105(8), 2883-8. 
50. Vierbuchen, T., Ostermeier, A., Pang, Z.P., Kokubu, Y., Sudhof, T.C. and Wernig, M. 
(2010) 'Direct conversion of fibroblasts to functional neurons by defined factors', 
Nature, 463(7284), 1035-41. 
51. Huang, P., He, Z., Ji, S., Sun, H., Xiang, D., Liu, C., Hu, Y., Wang, X. and Hui, L. 
(2011) 'Induction of functional hepatocyte-like cells from mouse fibroblasts by defined 
factors', Nature, 475(7356), 386-9. 
52. Hannan, N.R.F., Segeritz, C.P., Touboul, T. and Vallier, L. (2013b) 'Production of 
hepatocyte-like cells from human pluripotent stem cells', Nature Protocols, 8(2), 430-
437. 
53. Ieda, M., Fu, J.D., Delgado-Olguin, P., Vedantham, V., Hayashi, Y., Bruneau, B.G. and 
Srivastava, D. (2010) 'Direct reprogramming of fibroblasts into functional 
cardiomyocytes by defined factors', Cell, 142(3), 375-86. 
54. Szabo, E., Rampalli, S., Risueno, R.M., Schnerch, A., Mitchell, R., Fiebig-Comyn, A., 
Levadoux-Martin, M. and Bhatia, M. (2010) 'Direct conversion of human fibroblasts to 
multilineage blood progenitors', Nature, 468(7323), 521-6. 
55. Chun, Y.S., Chaudhari, P. and Jang, Y.Y. (2010) 'Applications of patient-specific 
induced pluripotent stem cells; focused on disease modeling, drug screening and 
therapeutic potentials for liver disease', Int J Biol Sci, 6(7), 796-805. 
56. Sommer, C.A., Stadtfeld, M., Murphy, G.J., Hochedlinger, K., Kotton, D.N. and 
Mostoslavsky, G. (2009) 'Induced pluripotent stem cell generation using a single 
lentiviral stem cell cassette', Stem Cells, 27(3), 543-549. 
57. Yang, Y., Goldstein, B.G., Chao, H.H. and Katz, J.P. (2005) 'KLF4 and KLF5 regulate 
proliferation, apoptosis and invasion in esophageal cancer cells', Cancer Biol Ther, 
4(11), 1216-21. 
58. Ruggero, D. (2009) 'The role of Myc-induced protein synthesis in cancer', Cancer Res, 
69(23), 8839-43. 
59. Wernig, M., Zhao, J.P., Pruszak, J., Hedlund, E., Fu, D., Soldner, F., Broccoli, V., 
Constantine-Paton, M., Isacson, O. and Jaenisch, R. (2008) 'Neurons derived from 




symptoms of rats with Parkinson's disease', Proc Natl Acad Sci U S A, 105(15), 5856-
61. 
60. Ranzani, M., Annunziato, S., Adams, D.J. and Montini, E. (2013) 'Cancer gene 
discovery: exploiting insertional mutagenesis', Mol Cancer Res, 11(10), 1141-58. 
61. Nalla, A.K., Williams, T.F., Collins, C.P., Rae, D.T. and Trobridge, G.D. (2016) 
'Lentiviral vector-mediated insertional mutagenesis screen identifies genes that 
influence androgen independent prostate cancer progression and predict clinical 
outcome', Mol Carcinog, 55(11), 1761-1771. 
62. Huangfu, D., Osafune, K., Maehr, R., Guo, W., Eijkelenboom, A., Chen, S., Muhlestein, 
W. and Melton, D.A. (2008) 'Induction of pluripotent stem cells from primary human 
fibroblasts with only Oct4 and Sox2', Nat Biotechnol, 26(11), 1269-75. 
63. Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., 
Nakagawa, M., Tanabe, K., Tezuka, K., Shibata, T., Kunisada, T., Takahashi, M., 
Takahashi, J., Saji, H. and Yamanaka, S. (2011a) 'A more efficient method to generate 
integration-free human iPS cells', Nat Methods, 8(5), 409-12. 
64. Stadtfeld, M., Nagaya, M., Utikal, J., Weir, G. and Hochedlinger, K. (2008) 'Induced 
pluripotent stem cells generated without viral integration', Science, 322(5903), 945-9. 
65. Fusaki, N., Ban, H., Nishiyama, A., Saeki, K. and Hasegawa, M. (2009) 'Efficient 
induction of transgene-free human pluripotent stem cells using a vector based on Sendai 
virus, an RNA virus that does not integrate into the host genome', Proc Jpn Acad Ser B 
Phys Biol Sci, 85(8), 348-62. 
66. Warren, L., Manos, P.D., Ahfeldt, T., Loh, Y.H., Li, H., Lau, F., Ebina, W., Mandal, 
P.K., Smith, Z.D., Meissner, A., Daley, G.Q., Brack, A.S., Collins, J.J., Cowan, C., 
Schlaeger, T.M. and Rossi, D.J. (2010) 'Highly efficient reprogramming to pluripotency 
and directed differentiation of human cells with synthetic modified mRNA', Cell Stem 
Cell, 7(5), 618-30. 
67. Anokye-Danso, F., Trivedi, C.M., Juhr, D., Gupta, M., Cui, Z., Tian, Y., Zhang, Y., 
Yang, W., Gruber, P.J., Epstein, J.A. and Morrisey, E.E. (2011) 'Highly efficient 
miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency', 
Cell Stem Cell, 8(4), 376-88. 
68. Maury, Y., Gauthier, M., Peschanski, M. and Martinat, C. (2012) 'Human pluripotent 
stem cells for disease modelling and drug screening', Bioessays, 34(1), 61-71. 
69. Dimos, J.T., Rodolfa, K.T., Niakan, K.K., Weisenthal, L.M., Mitsumoto, H., Chung, 
W., Croft, G.F., Saphier, G., Leibel, R., Goland, R., Wichterle, H., Henderson, C.E. and 
Eggan, K. (2008) 'Induced pluripotent stem cells generated from patients with ALS can 
be differentiated into motor neurons', Science, 321(5893), 1218-21. 
70. Ebert, A.D., Yu, J., Rose, F.F., Jr., Mattis, V.B., Lorson, C.L., Thomson, J.A. and 
Svendsen, C.N. (2009) 'Induced pluripotent stem cells from a spinal muscular atrophy 
patient', Nature, 457(7227), 277-80. 
71. Ohuchi, K., Funato, M., Kato, Z., Seki, J., Kawase, C., Tamai, Y., Ono, Y., Nagahara, 
Y., Noda, Y., Kameyama, T., Ando, S., Tsuruma, K., Shimazawa, M., Hara, H. and 
Kaneko, H. (2016) 'Established Stem Cell Model of Spinal Muscular Atrophy Is 
Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone 
Analog', Stem Cells Transl Med, 5(2), 152-63. 
72. Lee, G., Papapetrou, E.P., Kim, H., Chambers, S.M., Tomishima, M.J., Fasano, C.A., 
Ganat, Y.M., Menon, J., Shimizu, F., Viale, A., Tabar, V., Sadelain, M. and Studer, L. 
(2009) 'Modeling Pathogenesis and Treatment of Familial Dysautonomia using Patient 
Specific iPSCs', Nature, 461(7262), 402-406. 
73. Stadtfeld, M. and Hochedlinger, K. (2010) 'Induced pluripotency: history, mechanisms, 




74. de Lazaro, I., Yilmazer, A. and Kostarelos, K. (2014) 'Induced pluripotent stem (iPS) 
cells: a new source for cell-based therapeutics?', Journal of Controlled Release, 185, 
37-44. 
75. Modric, J.  Liver. Available at: https://www.ehealthstar.com/anatomy/liver (Accessed: 
22/02/2019). 
76. Katz, N., Teutsch, H.F., Jungermann, K. and Sasse, D. (1977) 'Heterogeneous reciprocal 
localization of fructose-1,6-bisphosphatase and of glucokinase in microdissected 
periportal and perivenous rat liver tissue', FEBS Lett, 83(2), 272-6. 
77. Rappaport, A.M., Borowy, Z.J., Lougheed, W.M. and Lotto, W.N. (1954) 'Subdivision 
of hexagonal liver lobules into a structural and functional unit; role in hepatic 
physiology and pathology', Anat Rec, 119(1), 11-33. 
78. Blouin, A., Bolender, R.P. and Weibel, E.R. (1977) 'Distribution of organelles and 
membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma. A 
stereological study', J Cell Biol, 72(2), 441-55. 
79. Braet, F. and Wisse, E. (2002) 'Structural and functional aspects of liver sinusoidal 
endothelial cell fenestrae: a review', Comp Hepatol, 1(1), 1. 
80. Godoy, P., Hewitt, N.J., Albrecht, U., Andersen, M.E., Ansari, N., Bhattacharya, S., 
Bode, J.G., Bolleyn, J., Borner, C., Bottger, J., Braeuning, A., Budinsky, R.A., 
Burkhardt, B., Cameron, N.R., Camussi, G., Cho, C.S., Choi, Y.J., Craig Rowlands, J., 
Dahmen, U., Damm, G., Dirsch, O., Donato, M.T., Dong, J., Dooley, S., Drasdo, D., 
Eakins, R., Ferreira, K.S., Fonsato, V., Fraczek, J., Gebhardt, R., Gibson, A., 
Glanemann, M., Goldring, C.E., Gomez-Lechon, M.J., Groothuis, G.M., Gustavsson, 
L., Guyot, C., Hallifax, D., Hammad, S., Hayward, A., Haussinger, D., Hellerbrand, C., 
Hewitt, P., Hoehme, S., Holzhutter, H.G., Houston, J.B., Hrach, J., Ito, K., Jaeschke, 
H., Keitel, V., Kelm, J.M., Kevin Park, B., Kordes, C., Kullak-Ublick, G.A., LeCluyse, 
E.L., Lu, P., Luebke-Wheeler, J., Lutz, A., Maltman, D.J., Matz-Soja, M., McMullen, 
P., Merfort, I., Messner, S., Meyer, C., Mwinyi, J., Naisbitt, D.J., Nussler, A.K., Olinga, 
P., Pampaloni, F., Pi, J., Pluta, L., Przyborski, S.A., Ramachandran, A., Rogiers, V., 
Rowe, C., Schelcher, C., Schmich, K., Schwarz, M., Singh, B., Stelzer, E.H., Stieger, 
B., Stober, R., Sugiyama, Y., Tetta, C., Thasler, W.E., Vanhaecke, T., Vinken, M., 
Weiss, T.S., Widera, A., Woods, C.G., Xu, J.J., Yarborough, K.M. and Hengstler, J.G. 
(2013) 'Recent advances in 2D and 3D in vitro systems using primary hepatocytes, 
alternative hepatocyte sources and non-parenchymal liver cells and their use in 
investigating mechanisms of hepatotoxicity, cell signaling and ADME', Arch Toxicol, 
87(8), 1315-530. 
81. Komal Arora, M.D. (2012) Liver and intrahepatic bile ducts - nontumor General 
Normal histology Available at: 
http://www.pathologyoutlines.com/topic/livernormalhistology.html (Accessed: 
26/02/2019). 
82. Jungermann, K. and Katz, N. (1989) 'Functional specialization of different hepatocyte 
populations', Physiol Rev, 69(3), 708-64. 
83. Jungermann, K. and Kietzmann, T. (2000) 'Oxygen: modulator of metabolic zonation 
and disease of the liver', Hepatology, 31(2), 255-60. 
84. Jungermann, K. (1988) Seminars in liver disease. © 1988 by Thieme Medical 
Publishers, Inc. 
85. Torre, C., Perret, C. and Colnot, S. (2010) 'Molecular determinants of liver zonation', 
Prog Mol Biol Transl Sci, 97, 127-50. 
86. Wallace, K., Burt, A.D. and Wright, M.C. (2008) 'Liver fibrosis', Biochemical Journal, 
411(1), 1-18. 
87. Benhamouche, S., Decaens, T., Godard, C., Chambrey, R., Rickman, D.S., Moinard, C., 
Vasseur-Cognet, M., Kuo, C.J., Kahn, A. and Perret, C. (2006) 'Apc tumor suppressor 




88. Wang, B., Zhao, L., Fish, M., Logan, C.Y. and Nusse, R. (2015) 'Self-renewing diploid 
Axin2(+) cells fuel homeostatic renewal of the liver', Nature, 524(7564), 180-5. 
89. Burke, Z.D., Reed, K.R., Phesse, T.J., Sansom, O.J., Clarke, A.R. and Tosh, D. (2009) 
'Liver zonation occurs through a beta-catenin-dependent, c-Myc-independent 
mechanism', Gastroenterology, 136(7), 2316-2324.e1-3. 
90. McEnerney, L., Duncan, K., Bang, B.-R., Elmasry, S., Li, M., Miki, T., Ramakrishnan, 
S.K., Shah, Y.M. and Saito, T. (2017) 'Dual modulation of human hepatic zonation via 
canonical and non-canonical Wnt pathways', Exp Mol Med, 49(12), e413. 
91. Colnot, S. and Perret, C. (2011) 'Liver Zonation', in Monga, S.P.S. (ed.) Molecular 
Pathology of Liver Diseases. Boston, MA: Springer US, 7-16. 
92. Chiang, J. (2014) 'Liver Physiology: Metabolism and Detoxification'. 
93. Russell, D.W. (2009) 'Fifty years of advances in bile acid synthesis and metabolism', J 
Lipid Res, 50 Suppl, S120-5. 
94. Chiang, J.Y.L. and Ferrell, J.M. (2018) 'Bile Acid Metabolism in Liver Pathobiology', 
Gene Expr, 18(2), 71-87. 
95. Schlichting, I., Berendzen, J., Chu, K., Stock, A.M., Maves, S.A., Benson, D.E., Sweet, 
R.M., Ringe, D., Petsko, G.A. and Sligar, S.G. (2000) 'The catalytic pathway of 
cytochrome p450cam at atomic resolution', Science, 287(5458), 1615-22. 
96. Anzenbacher, P. and Anzenbacherova, E. (2001) 'Cytochromes P450 and metabolism 
of xenobiotics', Cell Mol Life Sci, 58(5-6), 737-47. 
97. Guengerich, F.P. (2008) 'Cytochrome P450 and Chemical Toxicology', Chem Res 
Toxicol, 21(1), 70-83. 
98. Chiang, J. (2014) 'Liver Physiology: MetaboLism and Detoxification', in, 1770-1782. 
99. Siegel, G.J. (1999) Basic neurochemistry: molecular, cellular and medical aspects. 
100. Krishna, M. (2013) 'Microscopic anatomy of the liver', Clinical Liver Disease, 2(S1), 
S4-S7. 
101. Gissen, P. and Arias, I.M. (2015) 'Structural and functional hepatocyte polarity and liver 
disease', J Hepatol, 63(4), 1023-37. 
102. Glaser, S.S., Gaudio, E., Miller, T., Alvaro, D. and Alpini, G. (2009) 'Cholangiocyte 
proliferation and liver fibrosis', Expert Rev Mol Med, 11, e7. 
103. Park, S.M. (2012) 'The crucial role of cholangiocytes in cholangiopathies', Gut Liver, 
6(3), 295-304. 
104. Senoo, H. (2004) 'Structure and function of hepatic stellate cells', Med Electron 
Microsc, 37(1), 3-15. 
105. Sleyster, E.C. and Knook, D.L. (1982) 'Relation between localization and function of 
rat liver Kupffer cells', Lab Invest, 47(5), 484-90. 
106. Ramachandran, P. and Iredale, J.P. (2012) 'Macrophages: central regulators of hepatic 
fibrogenesis and fibrosis resolution', J Hepatol, 56(6), 1417-9. 
107. Ju, C., Reilly, T.P., Bourdi, M., Radonovich, M.F., Brady, J.N., George, J.W. and Pohl, 
L.R. (2002) 'Protective role of Kupffer cells in acetaminophen-induced hepatic injury 
in mice', Chem Res Toxicol, 15(12), 1504-13. 
108. Roberts, R.A., Ganey, P.E., Ju, C., Kamendulis, L.M., Rusyn, I. and Klaunig, J.E. 
(2007) 'Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis', 
Toxicol Sci, 96(1), 2-15. 
109. Fraser, R., Dobbs, B.R. and Rogers, G.W. (1995) 'Lipoproteins and the liver sieve: the 
role of the fenestrated sinusoidal endothelium in lipoprotein metabolism, 
atherosclerosis, and cirrhosis', Hepatology, 21(3), 863-74. 
110. Wisse, E., De Zanger, R.B., Charels, K., Van Der Smissen, P. and McCuskey, R.S. 
(1985) 'The liver sieve: considerations concerning the structure and function of 





111. Sorensen, K.K., McCourt, P., Berg, T., Crossley, C., Le Couteur, D., Wake, K. and 
Smedsrod, B. (2012) 'The scavenger endothelial cell: a new player in homeostasis and 
immunity', Am J Physiol Regul Integr Comp Physiol, 303(12), R1217-30. 
112. Rossant, J. (2004) 'Lineage development and polar asymmetries in the peri-implantation 
mouse blastocyst', Semin Cell Dev Biol, 15(5), 573-81. 
113. Lowe, L.A., Yamada, S. and Kuehn, M.R. (2001) 'Genetic dissection of nodal function 
in patterning the mouse embryo', Development, 128(10), 1831-43. 
114. Zaret, K.S. (2002) 'Regulatory phases of early liver development: paradigms of 
organogenesis', Nat Rev Genet, 3(7), 499-512. 
115. Tam, P.P., Kanai-Azuma, M. and Kanai, Y. (2003) 'Early endoderm development in 
vertebrates: lineage differentiation and morphogenetic function', Curr Opin Genet Dev, 
13(4), 393-400. 
116. Vincent, S.D., Dunn, N.R., Hayashi, S., Norris, D.P. and Robertson, E.J. (2003) 'Cell 
fate decisions within the mouse organizer are governed by graded Nodal signals', Genes 
Dev, 17(13), 1646-62. 
117. Zorn, A.M. and Wells, J.M. (2007) 'Molecular basis of vertebrate endoderm 
development', Int Rev Cytol, 259, 49-111. 
118. Dufort, D., Schwartz, L., Harpal, K. and Rossant, J. (1998) 'The transcription factor 
HNF3beta is required in visceral endoderm for normal primitive streak morphogenesis', 
Development, 125(16), 3015-25. 
119. Moore-Scott, B.A., Opoka, R., Lin, S.C., Kordich, J.J. and Wells, J.M. (2007) 
'Identification of molecular markers that are expressed in discrete anterior-posterior 
domains of the endoderm from the gastrula stage to mid-gestation', Dev Dyn, 236(7), 
1997-2003. 
120. Wells, J.M. and Melton, D.A. (2000) 'Early mouse endoderm is patterned by soluble 
factors from adjacent germ layers', Development, 127(8), 1563-72. 
121. Chalmers, A.D. and Slack, J.M. (2000) 'The Xenopus tadpole gut: fate maps and 
morphogenetic movements', Development, 127(2), 381-92. 
122. Tremblay, K.D. and Zaret, K.S. (2005) 'Distinct populations of endoderm cells converge 
to generate the embryonic liver bud and ventral foregut tissues', Dev Biol, 280(1), 87-
99. 
123. Dessimoz, J., Opoka, R., Kordich, J.J., Grapin-Botton, A. and Wells, J.M. (2006) 'FGF 
signaling is necessary for establishing gut tube domains along the anterior-posterior axis 
in vivo', Mech Dev, 123(1), 42-55. 
124. McLin, V.A., Rankin, S.A. and Zorn, A.M. (2007) 'Repression of Wnt/beta-catenin 
signaling in the anterior endoderm is essential for liver and pancreas development', 
Development, 134(12), 2207-17. 
125. Poulain, M. and Ober, E.A. (2011) 'Interplay between Wnt2 and Wnt2bb controls 
multiple steps of early foregut-derived organ development', Development, 138(16), 
3557-3568. 
126. Zorn, A. (2008) 'Liver development. StemBook', in  Cambridge: The Stem Cell 
Research Community. 
127. Okada, T. (1954) 'Experimental studies on the differentiation of the endodermal organs 
in Amphibia. I. Significance of the mesenchymatous tissue to the differentiation of the 
presumptive endo-derm', Mem Coll Sci Univ Kyoto Ser B, 21, 1-6. 
128. Fukuda-Taira, S. (1981) 'Hepatic induction in the avian embryo: specificity of reactive 
endoderm and inductive mesoderm', J Embryol Exp Morphol, 63, 111-25. 
129. Bossard, P. and Zaret, K.S. (1998) 'GATA transcription factors as potentiators of gut 
endoderm differentiation', Development, 125(24), 4909-17. 
130. Cirillo, L.A., Lin, F.R., Cuesta, I., Friedman, D., Jarnik, M. and Zaret, K.S. (2002) 
'Opening of compacted chromatin by early developmental transcription factors HNF3 




131. Bossard, P. and Zaret, K.S. (2000) 'Repressive and restrictive mesodermal interactions 
with gut endoderm: possible relation to Meckel's Diverticulum', Development, 127(22), 
4915-23. 
132. Shifley, E.T., Kenny, A.P., Rankin, S.A. and Zorn, A.M. (2012) 'Prolonged FGF 
signaling is necessary for lung and liver induction in Xenopus', BMC Dev Biol, 12, 27. 
133. Rossi, J.M., Dunn, N.R., Hogan, B.L. and Zaret, K.S. (2001) 'Distinct mesodermal 
signals, including BMPs from the septum transversum mesenchyme, are required in 
combination for hepatogenesis from the endoderm', Genes Dev, 15(15), 1998-2009. 
134. Calmont, A., Wandzioch, E., Tremblay, K.D., Minowada, G., Kaestner, K.H., Martin, 
G.R. and Zaret, K.S. (2006) 'An FGF response pathway that mediates hepatic gene 
induction in embryonic endoderm cells', Dev Cell, 11(3), 339-48. 
135. Zorn, A.M. and Wells, J.M. (2009) 'Vertebrate endoderm development and organ 
formation', Annu Rev Cell Dev Biol, 25, 221-51. 
136. Asrani, S.K., Devarbhavi, H., Eaton, J. and Kamath, P.S. (2019) 'Burden of liver 
diseases in the world', J Hepatol, 70(1), 151-171. 
137. Anthony, P.P., Ishak, K.G., Nayak, N.C., Poulsen, H.E., Scheuer, P.J. and Sobin, L.H. 
(1977) 'The morphology of cirrhosis: definition, nomenclature, and classification', Bull 
World Health Organ, 55(4), 521-40. 
138. Bilzer, M., Roggel, F. and Gerbes, A.L. (2006) 'Role of Kupffer cells in host defense 
and liver disease', Liver Int, 26(10), 1175-86. 
139. Canbay, A., Feldstein, A.E., Higuchi, H., Werneburg, N., Grambihler, A., Bronk, S.F. 
and Gores, G.J. (2003) 'Kupffer cell engulfment of apoptotic bodies stimulates death 
ligand and cytokine expression', Hepatology, 38(5), 1188-98. 
140. Iredale, J.P., Benyon, R.C., Pickering, J., McCullen, M., Northrop, M., Pawley, S., 
Hovell, C. and Arthur, M.J. (1998) 'Mechanisms of spontaneous resolution of rat liver 
fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of 
metalloproteinase inhibitors', J Clin Invest, 102(3), 538-49. 
141. Xiao, J.C., Ruck, P., Adam, A., Wang, T.X. and Kaiserling, E. (2003) 'Small epithelial 
cells in human liver cirrhosis exhibit features of hepatic stem-like cells: 
immunohistochemical, electron microscopic and immunoelectron microscopic 
findings', Histopathology, 42(2), 141-9. 
142. Santoni-Rugiu, E., Jelnes, P., Thorgeirsson, S.S. and Bisgaard, H.C. (2005) 'Progenitor 
cells in liver regeneration: molecular responses controlling their activation and 
expansion', Apmis, 113(11-12), 876-902. 
143. Falkowski, O., An, H.J., Ianus, I.A., Chiriboga, L., Yee, H., West, A.B. and Theise, 
N.D. (2003) 'Regeneration of hepatocyte 'buds' in cirrhosis from intrabiliary stem cells', 
J Hepatol, 39(3), 357-64. 
144. Kamiya, A., Kakinuma, S., Yamazaki, Y. and Nakauchi, H. (2009) 'Enrichment and 
clonal culture of progenitor cells during mouse postnatal liver development in mice', 
Gastroenterology, 137(3), 1114-26, 1126.e1-14. 
145. Lee, J.S., Heo, J., Libbrecht, L., Chu, I.S., Kaposi-Novak, P., Calvisi, D.F., Mikaelyan, 
A., Roberts, L.R., Demetris, A.J., Sun, Z., Nevens, F., Roskams, T. and Thorgeirsson, 
S.S. (2006) 'A novel prognostic subtype of human hepatocellular carcinoma derived 
from hepatic progenitor cells', Nat Med, 12(4), 410-6. 
146. Fausto, N. (2004) 'Liver regeneration and repair: hepatocytes, progenitor cells, and stem 
cells', Hepatology, 39(6), 1477-87. 
147. Farber, E. (1956) 'Similarities in the sequence of early histological changes induced in 
the liver of the rat by ethionine, 2-acetylamino-fluorene, and 3'-methyl-4-
dimethylaminoazobenzene', Cancer Res, 16(2), 142-8. 
148. Petersen, B.E., Bowen, W.C., Patrene, K.D., Mars, W.M., Sullivan, A.K., Murase, N., 
Boggs, S.S., Greenberger, J.S. and Goff, J.P. (1999) 'Bone marrow as a potential source 




149. Kordes, C., Sawitza, I., Gotze, S., Herebian, D. and Haussinger, D. (2014) 'Hepatic 
stellate cells contribute to progenitor cells and liver regeneration', J Clin Invest, 124(12), 
5503-15. 
150. Tarlow, B.D., Pelz, C., Naugler, W.E., Wakefield, L., Wilson, E.M., Finegold, M.J. and 
Grompe, M. (2014) 'Bipotential adult liver progenitors are derived from chronically 
injured mature hepatocytes', Cell Stem Cell, 15(5), 605-18. 
151. Spee, B., Carpino, G., Schotanus, B.A., Katoonizadeh, A., Vander Borght, S., Gaudio, 
E. and Roskams, T. (2010) 'Characterisation of the liver progenitor cell niche in liver 
diseases: potential involvement of Wnt and Notch signalling', Gut, 59(2), 247-57. 
152. Boulter, L., Govaere, O., Bird, T.G., Radulescu, S., Ramachandran, P., Pellicoro, A., 
Ridgway, R.A., Seo, S.S., Spee, B., Van Rooijen, N., Sansom, O.J., Iredale, J.P., 
Lowell, S., Roskams, T. and Forbes, S.J. (2012) 'Macrophage-derived Wnt opposes 
Notch signaling to specify hepatic progenitor cell fate in chronic liver disease', Nat Med, 
18(4), 572-9. 
153. Scadden, D.T. (2006) 'The stem-cell niche as an entity of action', Nature, 441(7097), 
1075-9. 
154. Miyajima, A., Tanaka, M. and Itoh, T. (2014) 'Stem/progenitor cells in liver 
development, homeostasis, regeneration, and reprogramming', Cell Stem Cell, 14(5), 
561-74. 
155. Ionescu-Tirgoviste, C., Gagniuc, P.A., Gubceac, E., Mardare, L., Popescu, I., Dima, S. 
and Militaru, M. (2015) 'A 3D map of the islet routes throughout the healthy human 
pancreas', Sci Rep, 5, 14634. 
156. Young, B., Lowe, J., Stevens, A. and Heath, J. (2006) 'Wheater’s Functional Histology, 
5 th Edn. Churchill Livingstone', in   Elsevier, Glasgow UK. 
157. Van Nest, G.A., MacDonald, R.J., Raman, R.K. and Rutter, W.J. (1980) 'Proteins 
synthesized and secreted during rat pancreatic development', J Cell Biol, 86(3), 784-94. 
158. Slack, J.M. (1995) 'Developmental biology of the pancreas', Development, 121(6), 
1569-80. 
159. Triplitt, C.L. (2012) 'Examining the mechanisms of glucose regulation', Am J Manag 
Care, 18(1 Suppl), S4-10. 
160. Dimitriadis, G., Mitrou, P., Lambadiari, V., Maratou, E. and Raptis, S.A. (2011) 'Insulin 
effects in muscle and adipose tissue', Diabetes Res Clin Pract, 93 Suppl 1, S52-9. 
161. Human Anatomy & Physiology of Pancreas (2013). Available at: 
http://www.pharmatips.in/Articles/Human-Anatomy/Human-Anatomy-Physiology-
Of-Pancreas.aspx (Accessed: 16/04/2019). 
162. Bort, R., Signore, M., Tremblay, K., Martinez Barbera, J.P. and Zaret, K.S. (2006) 'Hex 
homeobox gene controls the transition of the endoderm to a pseudostratified, cell 
emergent epithelium for liver bud development', Dev Biol, 290(1), 44-56. 
163. Bort, R., Martinez-Barbera, J.P., Beddington, R.S. and Zaret, K.S. (2004) 'Hex 
homeobox gene-dependent tissue positioning is required for organogenesis of the 
ventral pancreas', Development, 131(4), 797-806. 
164. Hebrok, M., Kim, S.K. and Melton, D.A. (1998) 'Notochord repression of endodermal 
Sonic hedgehog permits pancreas development', Genes Dev, 12(11), 1705-13. 
165. Slack, J.M. and Tosh, D. (2001) 'Transdifferentiation and metaplasia--switching cell 
types', Curr Opin Genet Dev, 11(5), 581-6. 
166. Tosh, D. and Slack, J.M. (2002) 'How cells change their phenotype', Nat Rev Mol Cell 
Biol, 3(3), 187-94. 
167. Slack, J.M. (2009) 'Metaplasia and somatic cell reprogramming', J Pathol, 217(2), 161-
8. 





169. Matsukura, N., Suzuki, K., Kawachi, T., Aoyagi, M., Sugimura, T., Kitaoka, H., 
Numajiri, H., Shirota, A., Itabashi, M. and Hirota, T. (1980) 'Distribution of marker 
enzymes and mucin in intestinal metaplasia in human stomach and relation to complete 
and incomplete types of intestinal metaplasia to minute gastric carcinomas', J Natl 
Cancer Inst, 65(2), 231-40. 
170. Eguchi, G. and Kodama, R. (1993) 'Transdifferentiation', Curr Opin Cell Biol, 5(6), 
1023-8. 
171. Selman, K. and Kafatos, F.C. (1974) 'Transdifferentiation in the labial gland of silk 
moths: is DNA required for cellular metamorphosis?', Cell Differ, 3(2), 81-94. 
172. Scarpelli, D.G. and Rao, M.S. (1981) 'Differentiation of regenerating pancreatic cells 
into hepatocyte-like cells', Proc Natl Acad Sci U S A, 78(4), 2577-81. 
173. Rao, M.S., Reddy, M.K., Reddy, J.K. and Scarpelli, D.G. (1982) 'Response of 
chemically induced hepatocytelike cells in hamster pancreas to methyl clofenapate, a 
peroxisome proliferator', J Cell Biol, 95(1), 50-6. 
174. Reddy, J.K., Rao, M.S., Qureshi, S.A., Reddy, M.K., Scarpelli, D.G. and Lalwani, N.D. 
(1984) 'Induction and origin of hepatocytes in rat pancreas', J Cell Biol, 98(6), 2082-90. 
175. Rao, M.S., Subbarao, V. and Reddy, J.K. (1986b) 'Induction of hepatocytes in the 
pancreas of copper-depleted rats following copper repletion', Cell Differ, 18(2), 109-17. 
176. Dabeva, M.D., Hwang, S.G., Vasa, S.R., Hurston, E., Novikoff, P.M., Hixson, D.C., 
Gupta, S. and Shafritz, D.A. (1997) 'Differentiation of pancreatic epithelial progenitor 
cells into hepatocytes following transplantation into rat liver', Proc Natl Acad Sci U S 
A, 94(14), 7356-61. 
177. Rao, M.S., Dwivedi, R.S., Subbarao, V., Usman, M.I., Scarpelli, D.G., Nemali, M.R., 
Yeldandi, A., Thangada, S., Kumar, S. and Reddy, J.K. (1988a) 'Almost total conversion 
of pancreas to liver in the adult rat: a reliable model to study transdifferentiation', 
Biochem Biophys Res Commun, 156(1), 131-6. 
178. Dabeva, M.D., Hurston, E. and Shafritz, D.A. (1995) 'Transcription factor and liver-
specific mRNA expression in facultative epithelial progenitor cells of liver and 
pancreas', Am J Pathol, 147(6), 1633-48. 
179. Rao, M.S., Yukawa, M., Omori, M., Thorgeirsson, S.S. and Reddy, J.K. (1996) 
'Expression of transcription factors and stem cell factor precedes hepatocyte 
differentiation in rat pancreas', Gene Expr, 6(1), 15-22. 
180. Cereghini, S. (1996) 'Liver-enriched transcription factors and hepatocyte 
differentiation', Faseb j, 10(2), 267-82. 
181. Chia-Ning, S., Seckl, J.R., Slack, J.M. and David, T. (2003) 'Glucocorticoids suppress 
β-cell development and induce hepatic metaplasia in embryonic pancreas', Biochemical 
Journal, 375(1), 41-50. 
182. Krakowski, M.L., Kritzik, M.R., Jones, E.M., Krahl, T., Lee, J., Arnush, M., Gu, D. and 
Sarvetnick, N. (1999) 'Pancreatic expression of keratinocyte growth factor leads to 
differentiation of islet hepatocytes and proliferation of duct cells', Am J Pathol, 154(3), 
683-91. 
183. Wells, J.M. and Melton, D.A. (1999) 'Vertebrate endoderm development', Annu Rev 
Cell Dev Biol, 15, 393-410. 
184. Rao, M.S., Bendayan, M., Kimbrough, R.D. and Reddy, J.K. (1986a) 'Characterization 
of pancreatic-type tissue in the liver of rat induced by polychlorinated biphenyls', J 
Histochem Cytochem, 34(2), 197-201. 
185. Lee, B.C., Hendricks, J.D. and Bailey, G.S. (1989) 'Metaplastic pancreatic cells in liver 
tumors induced by diethylnitrosamine', Exp Mol Pathol, 50(1), 104-13. 
186. Paner, G.P., Thompson, K.S. and Reyes, C.V. (2000) 'Hepatoid carcinoma of the 
pancreas', Cancer, 88(7), 1582-9. 
187. Ferber, S., Halkin, A., Cohen, H., Ber, I., Einav, Y., Goldberg, I., Barshack, I., Seijffers, 




gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-
induced hyperglycemia', Nat Med, 6(5), 568-72. 
188. Shternhall-Ron, K., Quintana, F.J., Perl, S., Meivar-Levy, I., Barshack, I., Cohen, I.R. 
and Ferber, S. (2007) 'Ectopic PDX-1 expression in liver ameliorates type 1 diabetes', J 
Autoimmun, 28(2-3), 134-42. 
189. Longnecker, D.S., Lilja, H.S., French, J., Kuhlmann, E. and Noll, W. (1979) 
'Transplantation of azaserine-induced carcinomas of pancreas in rats', Cancer letters, 
7(4), 197-202. 
190. Ehrlich, J., Anderson, L.E., Coffey, G.L., Hillegas, A.B., Knudsen, M.P., Koepsell, H.J., 
Kohberger, D.L. and Oyaas, J.E. (1954) 'Antibiotic studies of azaserine', Nature, 
173(4393), 72. 
191. Loser, C., Stuber, E. and Folsch, U.R. (1995) 'Dissimilar effect of the carcinogenic agent 
azaserine on pancreatic and hepatic polyamine metabolism in rats', Pancreas, 10(1), 44-
52. 
192. Chu, J., Ji, H., Lu, M., Li, Z., Qiao, X., Sun, B., Zhang, W. and Xue, D. (2013) 
'Proteomic analysis of apoptotic and oncotic pancreatic acinar AR42J cells treated with 
caerulein', Mol Cell Biochem, 382(1-2), 1-17. 
193. Jessop, N. (1980) 'Characteristics of two rat pancreatic exocrine cell lines derived from 
transplantable tumors', In vitro, 16, 212-216. 
194. Mashima, H., Ohnishi, H., Wakabayashi, K., Mine, T., Miyagawa, J.-i., Hanafusa, T., 
Seno, M., Yamada, H. and Kojima, I. (1996 a) 'Betacellulin and activin A coordinately 
convert amylase-secreting pancreatic AR42J cells into insulin-secreting cells', J Clin 
Invest, 97(7), 1647-1654. 
195. Mashima, H., Shibata, H., Mine, T. and Kojima, I. (1996 b) 'Formation of insulin-
producing cells from pancreatic acinar AR42J cells by hepatocyte growth factor', 
Endocrinology, 137(9), 3969-3976. 
196. Shen, C.-N., Slack, J.M. and Tosh, D. (2000) 'Molecular basis of transdifferentiation of 
pancreas to liver', Nat Cell Biol, 2(12), 879. 
197. Wallace, K., Marek, C.J., Currie, R.A. and Wright, M.C. (2009) 'Exocrine pancreas 
trans-differentiation to hepatocytes-A physiological response to elevated glucocorticoid 
in vivo', Journal of Steroid Biochemistry and Molecular Biology, 116(1-2), 76-85. 
198. Marek, C.J., Cameron, G.A., Elrick, L.J., Hawksworth, G.M. and Wright, M.C. (2003) 
'Generation of hepatocytes expressing functional cytochromes P450 from a pancreatic 
progenitor cell line in vitro', Biochemical Journal, 370, 763-769. 
199. Burke, Z.D., Shen, C.N., Ralphs, K.L. and Tosh, D. (2006) 'Characterization of liver 
function in transdifferentiated hepatocytes', Journal of cellular physiology, 206(1), 147-
159. 
200. Probert, P.M., Meyer, S.K., Alsaeedi, F., Axon, A.A., Fairhall, E.A., Wallace, K., 
Charles, M., Oakley, F., Jowsey, P.A. and Blain, P.G. (2015) 'An expandable donor-
free supply of functional hepatocytes for Toxicology', Toxicology Research, 4(2), 203-
222. 
201. Al-Adsani, A., Burke, Z.D., Eberhard, D., Lawrence, K.L., Shen, C.-N., Rustgi, A.K., 
Sakaue, H., Farrant, J.M. and Tosh, D. (2010) 'Dexamethasone treatment induces the 
reprogramming of pancreatic acinar cells to hepatocytes and ductal cells', PLoS One, 
5(10), e13650. 
202. Xie, G. and Diehl, A.M. (2013) 'Evidence for and against epithelial-to-mesenchymal 
transition in the liver', American Journal of Physiology-Gastrointestinal and Liver 
Physiology, 305(12), G881-G890. 
203. Shen, C.-N., Horb, M.E., Slack, J.M. and Tosh, D. (2003) 'Transdifferentiation of 




204. Wallace, K., Marek, C.J., Hoppler, S. and Wright, M.C. (2010) 'Glucocorticoid-
dependent transdifferentiation of pancreatic progenitor cells into hepatocytes is 
dependent on transient suppression of WNT signalling', J Cell Sci, 123(12), 2102-2109. 
205. Cadigan, K.M. and Nusse, R. (1997) 'Wnt signaling: a common theme in animal 
development', Genes Dev, 11(24), 3286-305. 
206. Nusse, R. and Varmus, H.E. (1992) 'Wnt genes', Cell, 69(7), 1073-87. 
207. Tolwinski, N.S., Wehrli, M., Rives, A., Erdeniz, N., DiNardo, S. and Wieschaus, E. 
(2003) 'Wg/Wnt signal can be transmitted through arrow/LRP5,6 and Axin 
independently of Zw3/Gsk3beta activity', Dev Cell, 4(3), 407-18. 
208. Pinson, K.I., Brennan, J., Monkley, S., Avery, B.J. and Skarnes, W.C. (2000) 'An LDL-
receptor-related protein mediates Wnt signalling in mice', Nature, 407(6803), 535-8. 
209. Logan, C.Y. and Nusse, R. (2004) 'The Wnt signaling pathway in development and 
disease', Annu Rev Cell Dev Biol, 20, 781-810. 
210. Pai, S.G., Carneiro, B.A., Mota, J.M., Costa, R., Leite, C.A., Barroso-Sousa, R., Kaplan, 
J.B., Chae, Y.K. and Giles, F.J. (2017) 'Wnt/beta-catenin pathway: modulating 
anticancer immune response', J Hematol Oncol, 10(1), 101. 
211. Yanagawa, S., Matsuda, Y., Lee, J.S., Matsubayashi, H., Sese, S., Kadowaki, T. and 
Ishimoto, A. (2002) 'Casein kinase I phosphorylates the Armadillo protein and induces 
its degradation in Drosophila', Embo j, 21(7), 1733-42. 
212. Lustig, B. and Behrens, J. (2003) 'The Wnt signaling pathway and its role in tumor 
development', J Cancer Res Clin Oncol, 129(4), 199-221. 
213. Moon, R.T. (2005) 'Wnt/beta-catenin pathway', Sci STKE, 2005(271), cm1. 
214. van Amerongen, R. and Nusse, R. (2009) 'Towards an integrated view of Wnt signaling 
in development', Development, 136(19), 3205-14. 
215. Zeng, G., Awan, F., Otruba, W., Muller, P., Apte, U., Tan, X., Gandhi, C., Demetris, 
A.J. and Monga, S.P. (2007) 'Wnt'er in liver: expression of Wnt and frizzled genes in 
mouse', Hepatology, 45(1), 195-204. 
216. Burke, Z.D. and Tosh, D. (2006) 'The Wnt/beta-catenin pathway: master regulator of 
liver zonation?', Bioessays, 28(11), 1072-7. 
217. Wallace, K., Marek, C.J., Currie, R.A. and Wright, M.C. (2009) 'Exocrine pancreas 
trans-differentiation to hepatocytes--a physiological response to elevated glucocorticoid 
in vivo', J Steroid Biochem Mol Biol, 116(1-2), 76-85. 
218. Wallace, K., Marek, C.J., Hoppler, S. and Wright, M.C. (2010 b) 'Glucocorticoid-
dependent transdifferentiation of pancreatic progenitor cells into hepatocytes is 
dependent on transient suppression of WNT signalling', J Cell Sci, 123(Pt 12), 2103-10. 
219. Barnes, P.J. (2014) 'Glucocorticoids', Chem Immunol Allergy, 100, 311-6. 
220. Silverman, M.N. and Sternberg, E.M. (2012) 'Glucocorticoid regulation of 
inflammation and its functional correlates: from HPA axis to glucocorticoid receptor 
dysfunction', Ann N Y Acad Sci, 1261, 55-63. 
221. Flammer, J.R. and Rogatsky, I. (2011) 'Minireview: Glucocorticoids in autoimmunity: 
unexpected targets and mechanisms', Mol Endocrinol, 25(7), 1075-86. 
222. Seckl, J.R. and Holmes, M.C. (2007) 'Mechanisms of disease: glucocorticoids, their 
placental metabolism and fetal 'programming' of adult pathophysiology', Nat Clin Pract 
Endocrinol Metab, 3(6), 479-88. 
223. Reynolds, R.M. (2013) 'Glucocorticoid excess and the developmental origins of disease: 
two decades of testing the hypothesis--2012 Curt Richter Award Winner', 
Psychoneuroendocrinology, 38(1), 1-11. 
224. Grier, D.G. and Halliday, H.L. (2004) 'Effects of glucocorticoids on fetal and neonatal 
lung development', Treat Respir Med, 3(5), 295-306. 
225. Munck, A., Guyre, P.M. and Holbrook, N.J. (1984) 'Physiological functions of 





226. Wallace, K., Long, Q.A., Fairhall, E.A., Charlton, K.A. and Wright, M.C. (2011) 
'Serine/threonine protein kinase SGK1 in glucocorticoid-dependent transdifferentiation 
of pancreatic acinar cells to hepatocytes', J Cell Sci, 124(3), 405-413. 
227. Fairhall, E.A., Wallace, K., White, S.A., Huang, G.C., Shaw, J.A., Wright, S.C., 
Charlton, K.A., Burt, A.D. and Wright, M.C. (2013) 'Adult human exocrine pancreas 
differentiation to hepatocytes - potential source of a human hepatocyte progenitor for 
use in toxicology research', Toxicology Research, 2(1), 80-87. 
228. Seckl, J.R. and Walker, B.R. (2001) 'Minireview: 11β-hydroxysteroid dehydrogenase 
type 1—a tissue-specific amplifier of glucocorticoid action', Endocrinology, 142(4), 
1371-1376. 
229. Sumitran-Holgersson, S., Nowak, G., Thowfeequ, S., Begum, S., Joshi, M., Jaksch, M., 
Kjaeldgaard, A., Jorns, C., Ericzon, B.-G. and Tosh, D. (2009) 'Generation of 
hepatocyte-like cells from in vitro transdifferentiated human fetal pancreas', Cell 
Transplant, 18(2), 183-193. 
230. Lonser, R.R., Nieman, L. and Oldfield, E.H. (2017) 'Cushing's disease: pathobiology, 
diagnosis, and management', J Neurosurg, 126(2), 404-417. 
231. Wallace, K., Flecknell, P.A., Burt, A.D. and Wright, M.C. (2010 c) 'Disrupted 
Pancreatic Exocrine Differentiation and Malabsorption in Response to Chronic Elevated 
Systemic Glucocorticoid', American Journal of Pathology, 177(3), 1225-1232. 
232. Pearce, L.R., Komander, D. and Alessi, D.R. (2010) 'The nuts and bolts of AGC protein 
kinases', Nat Rev Mol Cell Biol, 11(1), 9-22. 
233. Lang, F. and Shumilina, E. (2013) 'Regulation of ion channels by the serum-and 
glucocorticoid-inducible kinase SGK1', The FASEB Journal, 27(1), 3-12. 
234. Waerntges, S., Klingel, K., Weigert, C., Fillon, S., Buck, M., Schleicher, E., Rodemann, 
H.P., Knabbe, C., Kandolf, R. and Lang, F. (2002) 'Excessive transcription of the human 
serum and glucocorticoid dependent kinase hSGK1 in lung fibrosis', Cell Physiol 
Biochem, 12(2-3), 135-42. 
235. Rauz, S., Walker, E.A., Hughes, S.V., Coca-Prados, M., Hewison, M., Murray, P.I. and 
Stewart, P.M. (2003) 'Serum- and glucocorticoid-regulated kinase isoform-1 and 
epithelial sodium channel subunits in human ocular ciliary epithelium', Invest 
Ophthalmol Vis Sci, 44(4), 1643-51. 
236. Fillon, S., Klingel, K., Warntges, S., Sauter, M., Gabrysch, S., Pestel, S., Tanneur, V., 
Waldegger, S., Zipfel, A., Viebahn, R., Haussinger, D., Broer, S., Kandolf, R. and Lang, 
F. (2002) 'Expression of the serine/threonine kinase hSGK1 in chronic viral hepatitis', 
Cell Physiol Biochem, 12(1), 47-54. 
237. Alliston, T.N., Gonzalez-Robayna, I.J., Buse, P., Firestone, G.L. and Richards, J.S. 
(2000) 'Expression and localization of serum/glucocorticoid-induced kinase in the rat 
ovary: relation to follicular growth and differentiation', Endocrinology, 141(1), 385-95. 
238. Klingel, K., Warntges, S., Bock, J., Wagner, C.A., Sauter, M., Waldegger, S., Kandolf, 
R. and Lang, F. (2000) 'Expression of cell volume-regulated kinase h-sgk in pancreatic 
tissue', Am J Physiol Gastrointest Liver Physiol, 279(5), G998-g1002. 
239. Friedrich, B., Warntges, S., Klingel, K., Sauter, M., Kandolf, R., Risler, T., Muller, 
G.A., Witzgall, R., Kriz, W., Grone, H.J. and Lang, F. (2002) 'Up-regulation of the 
human serum and glucocorticoid-dependent kinase 1 in glomerulonephritis', Kidney 
Blood Press Res, 25(5), 303-7. 
240. Brickley, D.R., Mikosz, C.A., Hagan, C.R. and Conzen, S.D. (2002) 'Ubiquitin 
modification of serum and glucocorticoid-induced protein kinase-1 (SGK-1)', J Biol 
Chem, 277(45), 43064-70. 
241. Loffing, J., Flores, S.Y. and Staub, O. (2006) 'Sgk kinases and their role in epithelial 
transport', Annu Rev Physiol, 68, 461-90. 
242. Boyd, C. and Naray-Fejes-Toth, A. (2005) 'Gene regulation of ENaC subunits by serum- 




243. Diakov, A. and Korbmacher, C. (2004) 'A novel pathway of epithelial sodium channel 
activation involves a serum- and glucocorticoid-inducible kinase consensus motif in the 
C terminus of the channel's alpha-subunit', J Biol Chem, 279(37), 38134-42. 
244. Seckl, J.R. and Walker, B.R. (2001) 'Minireview: 11beta-hydroxysteroid 
dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action', 
Endocrinology, 142(4), 1371-6. 
245. Chen, S.Y., Bhargava, A., Mastroberardino, L., Meijer, O.C., Wang, J., Buse, P., 
Firestone, G.L., Verrey, F. and Pearce, D. (1999) 'Epithelial sodium channel regulated 
by aldosterone-induced protein sgk', Proc Natl Acad Sci U S A, 96(5), 2514-9. 
246. Waldegger, S., Barth, P., Raber, G. and Lang, F. (1997) 'Cloning and characterization 
of a putative human serine/threonine protein kinase transcriptionally modified during 
anisotonic and isotonic alterations of cell volume', Proceedings of the National 
Academy of Sciences, 94(9), 4440-4445. 
247. Waldegger, S., Klingel, K., Barth, P., Sauter, M., Rfer, M.L., Kandolf, R. and Lang, F. 
(1999) 'h-sgk serine-threonine protein kinase gene as transcriptional target of 
transforming growth factor beta in human intestine', Gastroenterology, 116(5), 1081-8. 
248. Akutsu, N., Lin, R., Bastien, Y., Bestawros, A., Enepekides, D.J., Black, M.J. and 
White, J.H. (2001) 'Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 
and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma 
Cells', Mol Endocrinol, 15(7), 1127-39. 
249. Khan, Z.A., Barbin, Y.P., Farhangkhoee, H., Beier, N., Scholz, W. and Chakrabarti, S. 
(2005) 'Glucose-induced serum- and glucocorticoid-regulated kinase activation in 
oncofetal fibronectin expression', Biochem Biophys Res Commun, 329(1), 275-80. 
250. Mizuno, H. and Nishida, E. (2001) 'The ERK MAP kinase pathway mediates induction 
of SGK (serum- and glucocorticoid-inducible kinase) by growth factors', Genes Cells, 
6(3), 261-8. 
251. You, H., Jang, Y., You-Ten, A.I., Okada, H., Liepa, J., Wakeham, A., Zaugg, K. and 
Mak, T.W. (2004) 'p53-dependent inhibition of FKHRL1 in response to DNA damage 
through protein kinase SGK1', Proc Natl Acad Sci U S A, 101(39), 14057-62. 
252. Wulff, P., Vallon, V., Huang, D.Y., Volkl, H., Yu, F., Richter, K., Jansen, M., Schlunz, 
M., Klingel, K., Loffing, J., Kauselmann, G., Bosl, M.R., Lang, F. and Kuhl, D. (2002) 
'Impaired renal Na(+) retention in the sgk1-knockout mouse', J Clin Invest, 110(9), 
1263-8. 
253. Sobiesiak, M., Shumilina, E., Lam, R.S., Wolbing, F., Matzner, N., Kaesler, S., 
Zemtsova, I.M., Lupescu, A., Zahir, N., Kuhl, D., Schaller, M., Biedermann, T. and 
Lang, F. (2009) 'Impaired mast cell activation in gene-targeted mice lacking the serum- 
and glucocorticoid-inducible kinase SGK1', J Immunol, 183(7), 4395-402. 
254. Wu, C., Yosef, N., Thalhamer, T., Zhu, C., Xiao, S., Kishi, Y., Regev, A. and Kuchroo, 
V.K. (2013) 'Induction of pathogenic TH17 cells by inducible salt-sensing kinase 
SGK1', Nature, 496(7446), 513-7. 
255. Heikamp, E.B., Patel, C.H., Collins, S., Waickman, A., Oh, M.H., Sun, I.H., Illei, P., 
Sharma, A., Naray-Fejes-Toth, A., Fejes-Toth, G., Misra-Sen, J., Horton, M.R. and 
Powell, J.D. (2014) 'The AGC kinase SGK1 regulates TH1 and TH2 differentiation 
downstream of the mTORC2 complex', Nat Immunol, 15(5), 457-64. 
256. Wallace, K., Long, Q., Fairhall, E.A., Charlton, K.A. and Wright, M.C. (2011) 
'Serine/threonine protein kinase SGK1 in glucocorticoid-dependent transdifferentiation 
of pancreatic acinar cells to hepatocytes', J Cell Sci, 124(Pt 3), 405-13. 
257. Fairhall, E.A., Charles, M.A., Probert, P.M., Wallace, K., Gibb, J., Ravindan, C., 
Soloman, M. and Wright, M.C. (2016) 'Pancreatic B-13 Cell Trans-Differentiation to 
Hepatocytes Is Dependent on Epigenetic-Regulated Changes in Gene Expression', PLoS 




258. Puppi, J. and Dhawan, A. (2009) 'Human hepatocyte transplantation overview', Methods 
Mol Biol, 481, 1-16. 
259. Strain, A.J. (1994) 'Isolated hepatocytes: use in experimental and clinical hepatology', 
Gut, 35(4), 433-6. 
260. Terry, C., Hughes, R.D., Mitry, R.R., Lehec, S.C. and Dhawan, A. (2007) 
'Cryopreservation-induced nonattachment of human hepatocytes: role of adhesion 
molecules', Cell Transplant, 16(6), 639-47. 
261. Padgham, C.R., Boyle, C.C., Wang, X.J., Raleigh, S.M., Wright, M.C. and Paine, A.J. 
(1993) 'Alteration of transcription factor mRNAs during the isolation and culture of rat 
hepatocytes suggests the activation of a proliferative mode underlies their de-
differentiation', Biochem Biophys Res Commun, 197(2), 599-605. 
262. Rodriguez-Ariza, A. and Paine, A.J. (1999) 'Rapid induction of NF-kappaB binding 
during liver cell isolation and culture: inhibition by L-NAME indicates a role for nitric 
oxide synthase', Biochem Biophys Res Commun, 257(1), 145-8. 
263. Heslop, J.A., Rowe, C., Walsh, J., Sison-Young, R., Jenkins, R., Kamalian, L., Kia, R., 
Hay, D., Jones, R.P., Malik, H.Z., Fenwick, S., Chadwick, A.E., Mills, J., Kitteringham, 
N.R., Goldring, C.E. and Kevin Park, B. (2017) 'Mechanistic evaluation of primary 
human hepatocyte culture using global proteomic analysis reveals a selective 
dedifferentiation profile', Arch Toxicol, 91(1), 439-452. 
264. Schmelzer, E., Zhang, L., Bruce, A., Wauthier, E., Ludlow, J., Yao, H.L., Moss, N., 
Melhem, A., McClelland, R., Turner, W., Kulik, M., Sherwood, S., Tallheden, T., 
Cheng, N., Furth, M.E. and Reid, L.M. (2007) 'Human hepatic stem cells from fetal and 
postnatal donors', J Exp Med, 204(8), 1973-87. 
265. Aurich, H., Sgodda, M., Kaltwasser, P., Vetter, M., Weise, A., Liehr, T., Brulport, M., 
Hengstler, J.G., Dollinger, M.M., Fleig, W.E. and Christ, B. (2009) 'Hepatocyte 
differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes 
hepatic integration in vivo', Gut, 58(4), 570-81. 
266. Palakkan, A.A., Nanda, J. and Ross, J.A. (2017) 'Pluripotent stem cells to hepatocytes, 
the journey so far', Biomed Rep, 6(4), 367-373. 
267. Si-Tayeb, K., Noto, F.K., Nagaoka, M., Li, J., Battle, M.A., Duris, C., North, P.E., 
Dalton, S. and Duncan, S.A. (2010) 'Highly efficient generation of human hepatocyte-
like cells from induced pluripotent stem cells', Hepatology, 51(1), 297-305. 
268. Yiangou, L., Ross, A.D.B., Goh, K.J. and Vallier, L. (2018) 'Human Pluripotent Stem 
Cell-Derived Endoderm for Modeling Development and Clinical Applications', Cell 
Stem Cell, 22(4), 485-499. 
269. Touboul, T., Hannan, N.R., Corbineau, S., Martinez, A., Martinet, C., Branchereau, S., 
Mainot, S., Strick‐Marchand, H., Pedersen, R. and Di Santo, J. (2010) 'Generation of 
functional hepatocytes from human embryonic stem cells under chemically defined 
conditions that recapitulate liver development', Hepatology, 51(5), 1754-1765. 
270. Yamanaka, Y. and Ralston, A. (2010) 'Early embryonic cell fate decisions in the mouse', 
Adv Exp Med Biol, 695, 1-13. 
271. Vallier, L., Touboul, T., Chng, Z., Brimpari, M., Hannan, N., Millan, E., Smithers, L.E., 
Trotter, M., Rugg-Gunn, P., Weber, A. and Pedersen, R.A. (2009) 'Early cell fate 
decisions of human embryonic stem cells and mouse epiblast stem cells are controlled 
by the same signalling pathways', PLoS One, 4(6), e6082. 
272. Teo, A.K., Ali, Y., Wong, K.Y., Chipperfield, H., Sadasivam, A., Poobalan, Y., Tan, 
E.K., Wang, S.T., Abraham, S., Tsuneyoshi, N., Stanton, L.W. and Dunn, N.R. (2012) 
'Activin and BMP4 synergistically promote formation of definitive endoderm in human 
embryonic stem cells', Stem Cells, 30(4), 631-42. 
273. McLean, A.B., D'Amour, K.A., Jones, K.L., Krishnamoorthy, M., Kulik, M.J., 
Reynolds, D.M., Sheppard, A.M., Liu, H., Xu, Y., Baetge, E.E. and Dalton, S. (2007) 




only when phosphatidylinositol 3-kinase signaling is suppressed', Stem Cells, 25(1), 29-
38. 
274. Sakaki-Yumoto, M., Liu, J., Ramalho-Santos, M., Yoshida, N. and Derynck, R. (2013) 
'Smad2 is essential for maintenance of the human and mouse primed pluripotent stem 
cell state', J Biol Chem, 288(25), 18546-60. 
275. Loh, K.M., Ang, L.T., Zhang, J., Kumar, V., Ang, J., Auyeong, J.Q., Lee, K.L., Choo, 
S.H., Lim, C.Y., Nichane, M., Tan, J., Noghabi, M.S., Azzola, L., Ng, E.S., Durruthy-
Durruthy, J., Sebastiano, V., Poellinger, L., Elefanty, A.G., Stanley, E.G., Chen, Q., 
Prabhakar, S., Weissman, I.L. and Lim, B. (2014) 'Efficient endoderm induction from 
human pluripotent stem cells by logically directing signals controlling lineage 
bifurcations', Cell Stem Cell, 14(2), 237-52. 
276. Tam, P.P. and Loebel, D.A. (2007) 'Gene function in mouse embryogenesis: get set for 
gastrulation', Nat Rev Genet, 8(5), 368-81. 
277. Toivonen, S., Lundin, K., Balboa, D., Ustinov, J., Tamminen, K., Palgi, J., Trokovic, 
R., Tuuri, T. and Otonkoski, T. (2013) 'Activin A and Wnt-dependent specification of 
human definitive endoderm cells', Exp Cell Res, 319(17), 2535-44. 
278. Touboul, T., Chen, S., To, C.C., Mora-Castilla, S., Sabatini, K., Tukey, R.H. and 
Laurent, L.C. (2016) 'Stage-specific regulation of the WNT/beta-catenin pathway 
enhances differentiation of hESCs into hepatocytes', J Hepatol, 64(6), 1315-26. 
279. Hengstler, J.G., Brulport, M., Schormann, W., Bauer, A., Hermes, M., Nussler, A.K., 
Fandrich, F., Ruhnke, M., Ungefroren, H., Griffin, L., Bockamp, E., Oesch, F. and von 
Mach, M.A. (2005) 'Generation of human hepatocytes by stem cell technology: 
definition of the hepatocyte', Expert Opin Drug Metab Toxicol, 1(1), 61-74. 
280. Hannan, N.R., Fordham, R.P., Syed, Y.A., Moignard, V., Berry, A., Bautista, R., 
Hanley, N.A., Jensen, K.B. and Vallier, L. (2013a) 'Generation of multipotent foregut 
stem cells from human pluripotent stem cells', Stem Cell Reports, 1(4), 293-306. 
281. Pagliuca, F.W., Millman, J.R., Gurtler, M., Segel, M., Van Dervort, A., Ryu, J.H., 
Peterson, Q.P., Greiner, D. and Melton, D.A. (2014) 'Generation of functional human 
pancreatic beta cells in vitro', Cell, 159(2), 428-39. 
282. Cai, J., Zhao, Y., Liu, Y., Ye, F., Song, Z., Qin, H., Meng, S., Chen, Y., Zhou, R., Song, 
X., Guo, Y., Ding, M. and Deng, H. (2007) 'Directed differentiation of human 
embryonic stem cells into functional hepatic cells', Hepatology, 45(5), 1229-39. 
283. Brolen, G., Sivertsson, L., Bjorquist, P., Eriksson, G., Ek, M., Semb, H., Johansson, I., 
Andersson, T.B., Ingelman-Sundberg, M. and Heins, N. (2010) 'Hepatocyte-like cells 
derived from human embryonic stem cells specifically via definitive endoderm and a 
progenitor stage', J Biotechnol, 145(3), 284-94. 
284. Ameri, J., Stahlberg, A., Pedersen, J., Johansson, J.K., Johannesson, M.M., Artner, I. 
and Semb, H. (2010) 'FGF2 specifies hESC-derived definitive endoderm into 
foregut/midgut cell lineages in a concentration-dependent manner', Stem Cells, 28(1), 
45-56. 
285. Hannoun, Z., Steichen, C., Dianat, N., Weber, A. and Dubart-Kupperschmitt, A. (2016) 
'The potential of induced pluripotent stem cell derived hepatocytes', J Hepatol, 65(1), 
182-199. 
286. Agarwal, S., Holton, K.L. and Lanza, R. (2008) 'Efficient differentiation of functional 
hepatocytes from human embryonic stem cells', Stem Cells, 26(5), 1117-27. 
287. Heslop, J.A. and Duncan, S.A. (2018) 'The use of human pluripotent stem cells for 
modelling liver development and disease', Hepatology. 
288. Yu, Y., Liu, H., Ikeda, Y., Amiot, B.P., Rinaldo, P., Duncan, S.A. and Nyberg, S.L. 
(2012) 'Hepatocyte-like cells differentiated from human induced pluripotent stem cells: 
relevance to cellular therapies', Stem Cell Res, 9(3), 196-207. 
289. Baxter, M., Withey, S., Harrison, S., Segeritz, C.P., Zhang, F., Atkinson-Dell, R., Rowe, 




Best, M., Fenwick, S.W., Malik, H., Kitteringham, N.R., Goldring, C.E., Piper Hanley, 
K., Vallier, L. and Hanley, N.A. (2015) 'Phenotypic and functional analyses show stem 
cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes', J 
Hepatol, 62(3), 581-9. 
290. Kia, R., Sison, R.L., Heslop, J., Kitteringham, N.R., Hanley, N., Mills, J.S., Park, B.K. 
and Goldring, C.E. (2013) 'Stem cell-derived hepatocytes as a predictive model for 
drug-induced liver injury: are we there yet?', Br J Clin Pharmacol, 75(4), 885-96. 
291. Pettinato, G., Ramanathan, R., Fisher, R.A., Mangino, M.J., Zhang, N. and Wen, X. 
(2016) 'Scalable differentiation of human iPSCs in a multicellular spheroid-based 3D 
culture into hepatocyte-like cells through direct Wnt/β-catenin pathway inhibition', Sci 
Rep, 6, 32888. 
292. Yamashita, T., Takayama, K., Sakurai, F. and Mizuguchi, H. (2018) 'Billion-scale 
production of hepatocyte-like cells from human induced pluripotent stem cells', 
Biochem Biophys Res Commun, 496(4), 1269-1275. 
293. Dash, A., Simmers, M.B., Deering, T.G., Berry, D.J., Feaver, R.E., Hastings, N.E., 
Pruett, T.L., LeCluyse, E.L., Blackman, B.R. and Wamhoff, B.R. (2013) 'Hemodynamic 
flow improves rat hepatocyte morphology, function, and metabolic activity in vitro', 
American Journal of Physiology-Cell Physiology, 304(11), C1053-C1063. 
294. Takayama, K., Inamura, M., Kawabata, K., Tashiro, K., Katayama, K., Sakurai, F., 
Hayakawa, T., Furue, M.K. and Mizuguchi, H. (2011) 'Efficient and directive 
generation of two distinct endoderm lineages from human ESCs and iPSCs by 
differentiation stage-specific SOX17 transduction', PLoS One, 6(7), e21780. 
295. Inamura, M., Kawabata, K., Takayama, K., Tashiro, K., Sakurai, F., Katayama, K., 
Toyoda, M., Akutsu, H., Miyagawa, Y., Okita, H., Kiyokawa, N., Umezawa, A., 
Hayakawa, T., Furue, M.K. and Mizuguchi, H. (2011) 'Efficient generation of 
hepatoblasts from human ES cells and iPS cells by transient overexpression of 
homeobox gene HEX', Mol Ther, 19(2), 400-7. 
296. Takayama, K., Inamura, M., Kawabata, K., Katayama, K., Higuchi, M., Tashiro, K., 
Nonaka, A., Sakurai, F., Hayakawa, T., Furue, M.K. and Mizuguchi, H. (2012) 
'Efficient generation of functional hepatocytes from human embryonic stem cells and 
induced pluripotent stem cells by HNF4alpha transduction', Mol Ther, 20(1), 127-37. 
297. Breyer, B., Jiang, W., Cheng, H., Zhou, L., Paul, R., Feng, T. and He, T.C. (2001) 
'Adenoviral vector-mediated gene transfer for human gene therapy', Curr Gene Ther, 
1(2), 149-62. 
298. 'Assessment of adenoviral vector safety and toxicity: report of the National Institutes of 
Health Recombinant DNA Advisory Committee',  (2002) Hum Gene Ther, 13(1), 3-13. 
299. Rowe, W.P., Huebner, R.J., Gilmore, L.K., Parrott, R.H. and Ward, T.G. (1953) 
'Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous 
degeneration in tissue culture', Proceedings of the Society for Experimental Biology and 
Medicine, 84(3), 570-573. 
300. Ginsberg, H.S. (2013) The adenoviruses. Springer Science & Business Media. 
301. Wold, W.S. and Toth, K. (2013) 'Adenovirus vectors for gene therapy, vaccination and 
cancer gene therapy', Curr Gene Ther, 13(6), 421-33. 
302. Tomko, R.P., Xu, R. and Philipson, L. (1997) 'HCAR and MCAR: the human and mouse 
cellular receptors for subgroup C adenoviruses and group B coxsackieviruses', Proc 
Natl Acad Sci U S A, 94(7), 3352-6. 
303. Wickham, T.J., Mathias, P., Cheresh, D.A. and Nemerow, G.R. (1993) 'Integrins αvβ3 
and αvβ5 promote adenovirus internalization but not virus attachment', Cell, 73(2), 309-
319. 
304. Greber, U.F., Willetts, M., Webster, P. and Helenius, A. (1993) 'Stepwise dismantling 




305. Gao, G.P., Yang, Y. and Wilson, J.M. (1996) 'Biology of adenovirus vectors with E1 
and E4 deletions for liver-directed gene therapy', J Virol, 70(12), 8934-43. 
306. Colosimo, A., Goncz, K.K., Holmes, A.R., Kunzelmann, K., Novelli, G., Malone, R.W., 
Bennett, M.J. and Gruenert, D.C. (2000) 'Transfer and expression of foreign genes in 
mammalian cells', Biotechniques, 29(2), 314-8, 320-2, 324 passim. 
307. Volpers, C. and Kochanek, S. (2004) 'Adenoviral vectors for gene transfer and therapy', 
J Gene Med, 6 Suppl 1, S164-71. 
308. abm  Cell Culture - Adenovirus Techniques. Available at: 
https://www.abmgood.com/marketing/knowledge_base/cell_culture_adenovirus_techn
iques.php#advantdiadvant (Accessed: 17/04/2019). 
309. Graham, F.L., Smiley, J., Russell, W.C. and Nairn, R. (1977) 'Characteristics of a human 
cell line transformed by DNA from human adenovirus type 5', J Gen Virol, 36(1), 59-
74. 
310. Engelhardt, J.F., Ye, X., Doranz, B. and Wilson, J.M. (1994) 'Ablation of E2A in 
recombinant adenoviruses improves transgene persistence and decreases inflammatory 
response in mouse liver', Proc Natl Acad Sci U S A, 91(13), 6196-200. 
311. Armentano, D., Sookdeo, C.C., Hehir, K.M., Gregory, R.J., St George, J.A., Prince, 
G.A., Wadsworth, S.C. and Smith, A.E. (1995) 'Characterization of an adenovirus gene 
transfer vector containing an E4 deletion', Hum Gene Ther, 6(10), 1343-53. 
312. Knowles, B.B. and Aden, D.P. (1983) 'Human hepatoma derived cell line, process for 
preparation thereof, and uses therefor'. Google Patents. 
313. Neganova, I., Zhang, X., Atkinson, S. and Lako, M. (2009) 'Expression and functional 
analysis of G1 to S regulatory components reveals an important role for CDK2 in cell 
cycle regulation in human embryonic stem cells', Oncogene, 28(1), 20. 
314. Neganova, I., Shmeleva, E., Munkley, J., Chichagova, V., Anyfantis, G., Anderson, R., 
Passos, J., Elliott, D.J., Armstrong, L. and Lako, M. (2016) 'JNK/SAPK signaling is 
essential for efficient reprogramming of human fibroblasts to induced pluripotent stem 
cells', Stem Cells, 34(5), 1198-1212. 
315. Diaz, D., Fabre, I., Daujat, M., Saint Aubert, B., Bories, P., Michel, H. and Maurel, P. 
(1990) 'Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome 
P450', Gastroenterology, 99(3), 737-47. 
316. Vogelstein, B. and Gillespie, D. (1979) 'Preparative and analytical purification of DNA 
from agarose', Proceedings of the National Academy of Sciences, 76(2), 615-619. 
317. Addgene  M50 Super 8x TOPFlash. Available at: http://n2t.net/addgene:12456  
318. addgene  M51 Super 8x FOPFlash (TOPFlash mutant). Available at: 
http://www.addgene.org/12457/ (Accessed: 17/04/2019). 
319. Medhurst, A.D., Harrison, D.C., Read, S.J., Campbell, C.A., Robbins, M.J. and 
Pangalos, M.N. (2000) 'The use of TaqMan RT-PCR assays for semiquantitative 
analysis of gene expression in CNS tissues and disease models', Journal of neuroscience 
methods, 98(1), 9-20. 
320. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. (1951) 'Protein 
measurement with the Folin phenol reagent', Journal of biological chemistry, 193, 265-
275. 
321. Laemmli, U.K. (1970) 'Cleavage of structural proteins during the assembly of the head 
of bacteriophage T4', Nature, 227(5259), 680. 
322. Promega  Kinase Enzyme System Protocol. Available at: https://www.promega.com/-
/media/files/resources/protocols/technical-bulletins/kinase-enzyme-system-
protocol.pdf (Accessed: 6/03/2019). 
323. Shen, C.N., Slack, J.M. and Tosh, D. (2000) 'Molecular basis of transdifferentiation of 




324. Dingemanse, M.A., de Boer, P.A., Moorman, A.F., Charles, R. and Lamers, W.H. 
(1994) 'The expression of liver-specific genes within rat embryonic hepatocytes is a 
discontinuous process', Differentiation, 56(3), 153-162. 
325. Kamiya, A., Kinoshita, T., Ito, Y., Matsui, T., Morikawa, Y., Senba, E., Nakashima, K., 
Taga, T., Yoshida, K., Kishimoto, T. and Miyajima, A. (1999) 'Fetal liver development 
requires a paracrine action of oncostatin M through the gp130 signal transducer', Embo 
Journal, 18(8), 2127-2136. 
326. Fairhall, E.A., Charles, M.A., Probert, P.M.E., Wallace, K., Gibb, J., Ravindan, C., 
Soloman, M. and Wright, M.C. (2016) 'Pancreatic B-13 Cell Trans-Differentiation to 
Hepatocytes Is Dependent on Epigenetic-Regulated Changes in Gene Expression', PLoS 
One, 11(3). 
327. Russell, D.W. and Hirata, R.K. (1998) 'Human gene targeting by viral vectors', Nature 
genetics, 18(4), 325. 
328. Monga, S.P., Monga, H.K., Tan, X., Mule, K., Pediaditakis, P. and Michalopoulos, G.K. 
(2003) 'Beta-catenin antisense studies in embryonic liver cultures: role in proliferation, 
apoptosis, and lineage specification', Gastroenterology, 124(1), 202-16. 
329. Micsenyi, A., Tan, X., Sneddon, T., Luo, J.H., Michalopoulos, G.K. and Monga, S.P. 
(2004) 'Beta-catenin is temporally regulated during normal liver development', 
Gastroenterology, 126(4), 1134-46. 
330. Tan, X., Behari, J., Cieply, B., Michalopoulos, G.K. and Monga, S.P. (2006) 
'Conditional deletion of beta-catenin reveals its role in liver growth and regeneration', 
Gastroenterology, 131(5), 1561-72. 
331. Thompson, M.D. and Monga, S.P. (2007) 'WNT/beta-catenin signaling in liver health 
and disease', Hepatology, 45(5), 1298-305. 
332. Benhamouche, S., Decaens, T., Godard, C., Chambrey, R., Rickman, D.S., Moinard, C., 
Vasseur-Cognet, M., Kuo, C.J., Kahn, A., Perret, C. and Colnot, S. (2006) 'Apc tumor 
suppressor gene is the "zonation-keeper" of mouse liver', Dev Cell, 10(6), 759-70. 
333. Spangler, P.R. and Delidow, B.C. (1998) 'Co-regulation of pituitary tumor cell adhesion 
and prolactin gene expression by glucocorticoid', J Cell Physiol, 174(1), 115-24. 
334. Naito, M., Omoteyama, K., Mikami, Y., Takahashi, T. and Takagi, M. (2012) 'Inhibition 
of Wnt/beta-catenin signaling by dexamethasone promotes adipocyte differentiation in 
mesenchymal progenitor cells, ROB-C26', Histochemistry and Cell Biology, 138(6), 
833-845. 
335. Smith, E., Coetzee, G.A. and Frenkel, B. (2002) 'Glucocorticoids inhibit cell cycle 
progression in differentiating osteoblasts via glycogen synthase kinase-3 beta', Journal 
of biological chemistry, 277(20), 18191-18197. 
336. Iansante, V., Mitry, R.R., Filippi, C., Fitzpatrick, E. and Dhawan, A. (2018) 'Human 
hepatocyte transplantation for liver disease: current status and future perspectives', 
Pediatr Res, 83(1-2), 232-240. 
337. Guillouzo, A. (1998) 'Liver cell models in in vitro toxicology', Environ Health Perspect, 
106 Suppl 2, 511-32. 
338. Brandon, E.F., Raap, C.D., Meijerman, I., Beijnen, J.H. and Schellens, J.H. (2003) 'An 
update on in vitro test methods in human hepatic drug biotransformation research: pros 
and cons', Toxicol Appl Pharmacol, 189(3), 233-46. 
339. Gebhardt, R., Hengstler, J.G., Muller, D., Glockner, R., Buenning, P., Laube, B., 
Schmelzer, E., Ullrich, M., Utesch, D., Hewitt, N., Ringel, M., Hilz, B.R., Bader, A., 
Langsch, A., Koose, T., Burger, H.J., Maas, J. and Oesch, F. (2003) 'New hepatocyte in 
vitro systems for drug metabolism: metabolic capacity and recommendations for 
application in basic research and drug development, standard operation procedures', 




340. Miranda, J.P., Leite, S.B., Muller-Vieira, U., Rodrigues, A., Carrondo, M.J. and Alves, 
P.M. (2009) 'Towards an extended functional hepatocyte in vitro culture', Tissue Eng 
Part C Methods, 15(2), 157-67. 
341. Cheng, N., Wauthier, E. and Reid, L.M. (2008) 'Mature human hepatocytes from ex 
vivo differentiation of alginate-encapsulated hepatoblasts', Tissue Eng Part A, 14(1), 1-
7. 
342. Fox, I.J. and Strom, S.C. (2008) 'To be or not to be: generation of hepatocytes from cells 
outside the liver', Gastroenterology, 134(3), 878-81. 
343. Wong, N., Lai, P., Pang, E., Leung, T.W., Lau, J.W. and Johnson, P.J. (2000) 'A 
comprehensive karyotypic study on human hepatocellular carcinoma by spectral 
karyotyping', Hepatology, 32(5), 1060-8. 
344. Lake, B.G. (2009) 'Species differences in the hepatic effects of inducers of CYP2B and 
CYP4A subfamily forms: relationship to rodent liver tumour formation', Xenobiotica, 
39(8), 582-96. 
345. Pan, X.P., Wang, Y.N., Yu, X.P., Zhu, C.X., Li, J.Z., Du, W.B., Zhang, Y.M., Cao, 
H.C., Zhang, Y.H., Zhu, D.H., Yeoh, G.C. and Li, L.J. (2016) 'Efficient generation of 
functional hepatocyte-like cells from mouse liver progenitor cells via indirect co-culture 
with immortalized human hepatic stellate cells', Hepatobiliary Pancreat Dis Int, 15(2), 
173-9. 
346. Heslop, J.A. and Duncan, S.A. (2019) 'The Use of Human Pluripotent Stem Cells for 
Modeling Liver Development and Disease', Hepatology, 69(3), 1306-1316. 
347. Fejes-Tóth, G., Frindt, G., Náray-Fejes-Tóth, A. and Palmer, L.G. (2008) 'Epithelial 
Na+ channel activation and processing in mice lacking SGK1', American Journal of 
Physiology-Renal Physiology, 294(6), F1298-F1305. 
348. Mitsui, K., Suzuki, K., Aizawa, E., Kawase, E., Suemori, H., Nakatsuji, N. and Mitani, 
K. (2009) 'Gene targeting in human pluripotent stem cells with adeno-associated virus 
vectors', Biochem Biophys Res Commun, 388(4), 711-717. 
349. Leong, M.L., Maiyar, A.C., Kim, B., O'Keeffe, B.A. and Firestone, G.L. (2003) 
'Expression of the serum- and glucocorticoid-inducible protein kinase, Sgk, is a cell 
survival response to multiple types of environmental stress stimuli in mammary 
epithelial cells', J Biol Chem, 278(8), 5871-82. 
350. Clotman, F., Jacquemin, P., Plumb-Rudewiez, N., Pierreux, C.E., Van der Smissen, P., 
Dietz, H.C., Courtoy, P.J., Rousseau, G.G. and Lemaigre, F.P. (2005) 'Control of liver 
cell fate decision by a gradient of TGF beta signaling modulated by Onecut transcription 
factors', Genes Dev, 19(16), 1849-54. 
351. Carpentier, A., Nimgaonkar, I., Chu, V., Xia, Y.C., Hu, Z.Y. and Liang, T.J. (2016) 
'Hepatic differentiation of human pluripotent stem cells in miniaturized format suitable 
for high-throughput screen', Stem Cell Res, 16(3), 640-650. 
352. Chen, C., Soto-Gutierrez, A., Baptista, P.M. and Spee, B. (2018) 'Biotechnology 
Challenges to In Vitro Maturation of Hepatic Stem Cells', Gastroenterology, 154(5), 
1258-1272. 
353. Godoy, P., Schmidt-Heck, W., Hellwig, B., Nell, P., Feuerborn, D., Rahnenfuhrer, J., 
Kattler, K., Walter, J., Bluthgen, N. and Hengstler, J.G. (2018) 'Assessment of stem cell 
differentiation based on genome-wide expression profiles', Philos Trans R Soc Lond B 
Biol Sci, 373(1750). 
354. Williams, D.P. (2018) 'Application of hepatocyte-like cells to enhance hepatic safety 
risk assessment in drug discovery', Philos Trans R Soc Lond B Biol Sci, 373(1750). 
355. Wallace, K., Fairhall, E.A., Charlton, K.A. and Wright, M.C. (2010 a) 'AR42J-B-13 
cell: An expandable progenitor to generate an unlimited supply of functional 




356. Wang, X., Foster, M., Al-Dhalimy, M., Lagasse, E., Finegold, M. and Grompe, M. 
(2003) 'The origin and liver repopulating capacity of murine oval cells', Proc Natl Acad 
Sci U S A, 100 Suppl 1, 11881-8. 
357. Zhu, S., Rezvani, M., Harbell, J., Mattis, A.N., Wolfe, A.R., Benet, L.Z., Willenbring, 
H. and Ding, S. (2014) 'Mouse liver repopulation with hepatocytes generated from 
human fibroblasts', Nature, 508(7494), 93-7. 
358. Nagamoto, Y., Takayama, K., Tashiro, K., Tateno, C., Sakurai, F., Tachibana, M., 
Kawabata, K., Ikeda, K., Tanaka, Y. and Mizuguchi, H. (2015) 'Efficient Engraftment 
of Human Induced Pluripotent Stem Cell-Derived Hepatocyte-Like Cells in uPA/SCID 
Mice by Overexpression of FNK, a Bcl-xL Mutant Gene', Cell Transplant, 24(6), 1127-
38. 
359. Richter, M., Fairhall, E.A., Hoffmann, S.A., Trobs, S., Knospel, F., Probert, P.M.E., 
Oakley, F., Stroux, A., Wright, M.C. and Zeilinger, K. (2016) 'Pancreatic progenitor-
derived hepatocytes are viable and functional in a 3D high density bioreactor culture 
system', Toxicol Res (Camb), 5(1), 278-290. 
360. Meyer, J.S., Shearer, R.L., Capowski, E.E., Wright, L.S., Wallace, K.A., McMillan, 
E.L., Zhang, S.-C. and Gamm, D.M. (2009) 'Modeling early retinal development with 
human embryonic and induced pluripotent stem cells', Proceedings of the National 
Academy of Sciences, 106(39), 16698-16703. 
361. Kamiyama, T., Takahashi, M., Nakagawa, T., Nakanishi, K., Kamachi, H., Suzuki, T., 
Shimamura, T., Taniguchi, M., Ozaki, M. and Matsushita, M. (2006) 'AFP mRNA 
detected in bone marrow by real-time quantitative RT-PCR analysis predicts survival 
and recurrence after curative hepatectomy for hepatocellular carcinoma', Annals of 
surgery, 244(3), 451. 
362. Sirico, M.L., Guida, B., Procino, A., Pota, A., Sodo, M., Grandaliano, G., Simone, S., 
Pertosa, G., Riccio, E. and Memoli, B. (2012) 'Human mature adipocytes express 
albumin and this expression is not regulated by inflammation', Mediators of 
inflammation, 2012. 
363. Bowen, W.P., Carey, J.E., Miah, A., McMurray, H.F., Munday, P.W., James, R.S., 
Coleman, R.A. and Brown, A.M. (2000) 'Measurement of cytochrome P450 gene 
induction in human hepatocytes using quantitative real-time reverse transcriptase-
polymerase chain reaction', Drug Metabolism and Disposition, 28(7), 781-788. 
364. Fairhall, E.A., Wallace, K., White, S.A., Huang, G.C., Shaw, J.A., Wright, S.C., 
Charlton, K.A., Burt, A.D. and Wright, M.C. (2013) 'Adult human exocrine pancreas 
differentiation to hepatocytes–potential source of a human hepatocyte progenitor for use 
in toxicology research', Toxicology Research, 2(1), 80-87. 
 
